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CHAPTER I 
GENERAL INTRODUCTION 
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CEREBRAL PALSY 
Cerebral palsy (CP) is defined as a static, but often changing disorder of move-
ment and posture due to a defect or lesion to the developing fetal or infant 
brain.1 It is a major health problem as it affects 1 in 400 children making it the 
most common developmental disorder associated with lifelong disability.2 The 
disorder can result from various insults to different areas within the developing 
central nervous system (CNS), partially explaining the variety in its clinical 
presentation.3 Causes of CP differ to some degree according to their time of on-
set (in utero, during delivery, during the first two years of life) and their clinical 
subtype. Although CP can be caused by a single causative factor (e.g. intracranial 
bleeding, perinatal stroke, congenital malformations, intrauterine infection, 
extreme prematurity, traumatic brain injury), it is most often caused by the 
interaction of genetic values and multiple environmental stressors.4 A specific 
hypoxic event associated with immediate and irreversible cell death explains 
the etiology of CP in less than 50%.5, 6 
Children usually present with slow motor development, abnormal muscle 
tone, muscle weakness, and disturbances in posture, although difficulties in 
swallowing and poor oromotor skills often precede these more noticeable ab-
normalities.7 Diagnosis is based on a complete history, thorough physical ex-
amination and additional investigations.3 Ultrasound (US), magnetic resonance 
imaging (MRI), computed tomography (CT), and diffusion tensor imaging (DTI) 
can be used to assess the extent of CNS damage as more than 80% of the chil-
dren with CP have neuroimaging abnormalities, most often isolated white-
matter damage.8, 9 The Surveillance of Cerebral Palsy in Europe (SCPE) has clas-
sified CP into three main groups: dyskinetic, ataxic, and spastic (table 1.1).10 The 
latter is the most common as 70–80% of the children with CP have spastic clini-
cal features.11 The SCPE states that at least two of the following clinical signs 
have to be present in spastic CP: abnormal pattern of posture and/or movement, 
increased tone, and pathological reflexes. The spastic CP syndromes can be fur-
ther classified according to their topographic distribution. In bilateral spastic CP 
both sides of the body are involved whereas in unilateral CP only one side of the 
body is involved.10 
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Table 1.1 Classifcation of CP subtypes according to the SCPE10 
Spastic CP is characterized by at least two of the following: 
• Abnormal pattern of posture and/or movement 
• Increased tone (not necessarily constant) 
• Pathological reflexes (increased reflexes: hyperreflexia and/or pyramidal signs e.g. Babinski 
response) 
 
Spastic CP may be either bilateral or unilateral: 
• Spastic bilateral CP: Limbs on both sides of the body are involved 
• Spastic unilateral CP: Limbs on one side of the body are involved 
 
Ataxic CP is characterized by both: 
• Abnormal pattern of posture and/or movement 
• Loss of orderly muscular coordination so that movements are performed with abnormal force, 
rhythm, and accuracy 
 
Dyskinetic CP is dominated by both: 
• Abnormal pattern of posture and/or movement 
• Involuntary, uncontrolled, recurring, occasionally stereotyped movements 
 
Dyskinetic CP may be either dystonic or choreo-athetotic: 
• Dystonic CP is dominated by both: Hypokinesia (reduced activity, i.e. stiff movement) and hyper-
tonia (tone usually increased) 
• Choreo-athetotic CP is dominated by both: Hyperkinesia (increased activity, i.e. stormy move-
ment) and hypotonia (tone usually decreased) 
SPASTICITY 
Definition 
Before considering the definitions of spasticity the concept of the upper motor 
neuron (UMN) is discussed. An UMN is a neuron of any long descending tract 
that controls movement and muscle tone, i.e. the pyramidal and parapyramidal 
tracts. Damage to these tracts leads to a so called UMN syndrome, which can 
include both negative phenomena, like weakness, impaired fine-motor function, 
and difficulty in isolating individual movements and positive phenomena, like 
hyperreflexia, clonus, and spasticity. 
The most often cited definition of spasticity is the one by Lance who defined 
spasticity in 1980 as a motor disorder characterized by a velocity dependent 
increase in the tonic stretch reflex (muscle tone) with exaggerated tendon jerks, 
resulting from hyper excitability of the stretch reflex, as one component of the 
upper motor neuron syndrome.12 
However, in 2005 the Support Programme for Assembly of a database for 
Spasticity Measurement (SPASM) project came to the conclusion that the evi-
dence generated since 1980 justified an update of the definition by Lance.13 
Recent research suggests that spasticity is not a pure motor disorder and does 
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not exclusively result from hyper excitability of the stretch reflex. Furthermore, 
the phenomenon of velocity dependence is not exclusive to stretch reflex hyper 
excitability. Therefore, the SPASM project proposed the following definition: a 
disordered sensori-motor control, resulting from an upper motor neuron lesion, 
presenting as intermittent of sustained involuntary activation of muscles. 
However, several more definitions of spasticity are used and debate contin-
ues on which one is most correct. An important contributing factor to the lack of 
an universal and more precise definition of spasticity is the fact that its patho-
physiology remains not fully elucidated. 
Etiology 
Again, an UMN is a neuron of any long descending tract that controls movement 
and muscle tone, i.e. the pyramidal and parapyramidal tracts. A lesion of the 
pyramidal tracts (the corticospinal tracts) results in clumsiness, modest weak-
ness, some exaggeration of deep tendon reflexes, and a Babinksi sign, but does 
not result in spasticity. Lesions of the parapyramidal tracts however do result in 
spasticity. The parapyramidal tracts consist of the medial and dorsal reticu-
lospinal, the rubrospinal, the vestibulospinal, and the tectospinal tracts. These 
descending pathways synapse upon interneural networks within the spinal cord 
that control spinal stretch, flexor, and extensor reflexes. Normally, the supraspi-
nal inhibitory and excitatory inputs are balanced. However, in case of a lesion of 
these tracts a state of net disinhibtion of spinal reflexes develops, which can 
cause spasticity. 
When studying the anatomy of the parapyramidal tracts, one very rapidly 
realizes that there are significant differences in localizations of these fiber tracts 
in the different atlases.14 This is mainly due to the fact that findings in animals 
(cats, macaques) were extrapolated to humans. Before the introduction of ad-
vanced MRI techniques, studying white matter anatomy was limited to the dis-
section of formalin-fixed parts of the CNS. Large fiber tracts, like the pyramidal 
tracts, are therefore well studied in man, but the smaller and not neatly organ-
ized tracts, like the parapyramidal tracts, are not. However, with the introduc-
tion of DTI the direction of white matter fibers can now be shown. Using this 
technique Mamata et al were able to provide us with a detailed map of these 
structures in man.15 Studying small parapyramidal tract traumas in humans by 
means of DTI should provide further insight in the etiology of spasticity. 
Signs and symptoms 
Spasticity can cause pain, sleeping disorders, and increased energy require-
ments.16 Furthermore, ease of care is impeded as spasticity can interfere with 
positioning, transfers, dressing, and body hygiene. Additionally, spasticity can 
lead to contractures, subluxations, pressure sores, and heterotopic calcifica-
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tions.17 There is an implicit, but yet not fully established causal relationship 
between spasticity and activity limitations and participation restrictions.13, 18 
MANAGEMENT OF SPASTICITY 
Background 
Management of spasticity begins with the evaluation of the necessity to treat. 
This is done by a multidisciplinary management team, which includes the pa-
tient and the caregivers. There are two scenarios in which spasticity should not 
be treated. First, when there is no interference with function, comfort, or care. 
Second and perhaps seemingly illogical, when “useful spasticity” is adding func-
tion in stead of restricting it. However, when spasticity, along with other posi-
tive motor phenomena of the UMN syndrome, has a significant negative impact 
on the functioning of a child, it represents an important therapeutic target. Re-
gardless of the selected management option, the goal is to optimize function, 
ease care giving, alleviate pain, and prevent secondary problems like contrac-
tures and subluxations. It is important to set realistic, attainable goals desired 
by both the child and his care-givers. At each stage of goal setting, treatment 
planning, and plan modification, it is necessary to obtain information not only 
about the clinical aspects of spasticity, but also about psychosocial factors, such 
as participation of the child in daily life, his coping strategies, and the stress 
handling capacity of his family. Only then will the chance of treating every 
unique case successfully be highest. 
Common treatment options in the management of spasticity are orally ad-
ministered drugs (Baclofen, Diazepam, Dantrolene, and Tizanidine), intramuscu-
lar chemodenervation agents (alcohol, phenol, and Botulinum Toxin A), in-
trathecally administered drugs (Baclofen), and neurosurgery (selective dorsal 
rhizotomy).3 
Orally administered drugs 
Several orally administered drugs with various mechanisms of action are avail-
able for the management of spasticity in children with CP, i.e. Diazepam, Ba-
clofen, Dantrolene, and Tizanidine. Diazepam, a post-synaptic GABA-a receptor 
agonist, is considered the most useful oral anti-spasticity agent in CP.19, 20 It 
helps against muscle stiffness, flexor and extensor spasms, pain, and insomnia. 
Oral Baclofen, a pre-synaptic GABA-b receptor agonist, is more suited to treat 
spasticity related to spinal dysfunction and is therefore less useful in children 
with CP.21, 22 The evidence on the efficacy of these drugs remains scarce and 
weak, and adverse drug reactions (like drowsiness, sedation, and muscle weak-
ness) are common.23–25 
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Injectable chemodenervation agents 
Two strategies of injecting anti-spasticity agents are presently used, both caus-
ing temporary chemodenervation, i.e. the blockage of nerve-muscle transmis-
sion. Ethyl alcohol or phenol can be injected perineurally where they promote 
axonal degeneration.3, 26 Benefits can last for a few weeks up to over two 
years.27–29 The main drawbacks of this method are the necessity to identify the 
nerve using electrical stimulating and the significant risk of permanent post-
procedure pain or paresthesia.22 Botulinum toxine A and B (BTX-A and B) are 
injected intramuscularly. They disable the sensitive factor attachment protein-
25 (SNAP-25) and thereby prevent the release of acetycholine from the pre-
synaptic vesicle at the neuromuscular junction.30 Clinical effects are usually 
observed after 2–5 days, last for 16–24 weeks, and are more noticeable in lower 
extremities than upper extremities.31–35 Although the functional improvements 
seen in randomized controlled trials are modest, this is most likely due to limita-
tions of study design rather than by the effectiveness of the therapy itself.22 An 
easily administrable outcome instrument capable of measuring change on do-
mains of interest is still lacking. Furthermore, BTX-A therapy is not without 
risks. A recent and large study found that 6% of the children treated with BTX-A 
develop systemic adverse events, mainly respiratory complications and bowel 
and bladder incontinence.36 
Intrathecally administered drugs 
In case of intrathecal Baclofen (ITB) therapy a pump is implanted subcutane-
ously or subfacially in the abdomen which delivers Baclofen directly to the in-
trathecal space via a catheter. This has the large advantage of by-passing the 
blood-brain-barrier (BBB). Orally administered Baclofen passes the BBB poorly 
and results in high blood levels (hence side-effects) and almost undetectable 
cerebrospinal fluid levels of Baclofen (hence low treatment effects).37 In ITB, 
administration of a hundredth part of the dose of oral Baclofen is sufficient to 
relieve spasticity and therefore the side-effects seen when Baclofen is adminis-
tered orally are prevented.38 Children with intractable lower extremity spastic-
ity who show significant response to a test treatment are considered candidates. 
Nevertheless, criteria describing the ideal candidate are still lacking.39 Several 
large trials have shown that ITB is able to reduce spasticity.40–42 Furthermore, in 
a prospective, randomized controlled trial by the Dutch study group on spastic-
ity functional benefits of ITB were shown.43–45 It was found that ITB reduces 
individually formulated problems, relieves pain, and improves ease of care and 
certain domains of health related quality of life. However, as recently stated by 
Miller, the follow-up on ITB treatment so far has been relatively short-term 
regarding that this is a treatment probably going to be continued for a 50–60 
year period.46 It is not clear whether or not benefits of therapy are still present 
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at the very long-term nor is the course over time. Also, the impact of accumula-
tion of more and less severe complications, hospital visits, and hospitalizations 
on the enthusiasm of the caregivers for ITB treatment remains uncertain. 
Furthermore, ITB caries a small but clinically significant risk of complica-
tions. Frequencies and severities of surgical complications, drug adverse events, 
and drug-delivery system-related complications vary significantly between 
studies.47 In general, ITB is generally considered a high risk/high gain treat-
ment.48 
Neurosurgery 
Since its first description by Foerster in 1913, selective dorsal rhizotomy (SDR) 
has been modified by various surgeons and has become a standard neurosurgi-
cal procedure to treat spasticity in children with CP.49, 50 SDR is mainly per-
formed at the lumbar level to reduce spasticity in patients with bilateral spas-
ticy. A multilevel laminotomy/laminectomy exposes the dorsal roots (L2-S2) 
which are then separated into different rootlets. Those eliciting excessive EMG 
activity are incompletely transsected, hereby reducing the excitatory input to 
the spinal cord. SDR reduces spasticity and improves gait pattern, range of mo-
tion, and gross motor function.51 It must be noted that considerable cooperation 
of the patient is required to successfully complete the postoperative rehabilita-
tion program. A recent review found a significant amount of spinal abnormali-
ties and back-pain in children who have undergone SDR.52 However, the rela-
tionship between the two remains unclear. 
In chronic pain medicine, a radiofrequency lesion of the dorsal root ganglion 
(RF-DRG) is considered an alternative to SDR. RF-DRG has been used to treat 
chronic pain for over 30 years.53 The RF-DRG is a simple and safe treatment 
option with little side-effects.54 In the 1980’s several authors reported that the 
same procedure might be able to treat spasticity in adult patients.55, 56 More 
recently, RF-DRG showed to alleviate hip flexor spasms in 2 children with CP.57 
Further research with regard to the role of RF-DRG in the treatment of spasticity 
is required. 
EVALUATION OF SPASTICITY MANAGEMENT 
If you cannot measure it, you cannot control it. (John Grebe, 1990) 
 
Evaluating interventions in children with CP, poses somewhat of a challenge as 
many health-care disciplines are involved and effects can appear at physiologi-
cal, functional, social, and / or behavioral levels. With regard to spasticity, we 
are not absolutely sure what we are dealing with, let alone how we should 
measure it. This is probably best illustrated by the plethora of scales developed 
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to assess spasticity. A recent review found 37 clinical scales claiming to assess 
spasticity or spasticity associated functions.58 However, these scales have not 
been evaluated to a sufficient extent and for many scales reliability data is miss-
ing, especially concerning test-retest reliability. One can understand this to be a 
huge problem when using these scales as an outcome measure for spasticity 
management in children with CP. 
In accordance with the currently often used WHO international classifica-
tion of functioning, disability and health (ICF), the scales are classified into those 
assessing tone (ICF body functions and structure) and those assessing function-
ing (ICF activity and participation). Recently, a modified ICF model has been 
proposed which also incorporates quality of life (fig I.I).59 Quality of life of chil-
dren with CP will be discussed later on. 
 
 
Figure 1.1 The WHO ICF including human development and QoL 
Assessment of tone 
The most often used scales concentrate on assessing tone, i.e. the Ashworth 
Scale, the Modified Ashworth Scale (MAS) and the Tardieu Scale (TS). The Ash-
worth Scale is a 5-point rating scale (0–4), which measures resistance to passive 
movement. Although the most commonly used, the methodological quality of the 
Ashworth Scale is doubtful. It does not measure spasticity exclusively, it has low 
interrater reliability, and it lacks precision and sensitivity for measuring smaller 
changes in spasticity.60–62 A recent study showed both the Ashworth Scale and 
the MAS to not be very reliable and therefore assessment of spasticity using 
these ordinal rating scales should be interpreted with great caution.63 The TS is 
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a 6-point rating scale which describes the muscle reaction to passive stretch at 
different speeds. Recently, it has been shown to be more effective than the Ash-
worth scale in identifying the presence of spasticity, but again is not capable of 
measuring the severity of spasticity.64 Furthermore, it is a very time-consuming 
method and therefore its feasibility is questioned, especially when applied to 
children.62 
Assessment of functioning 
Several other scales focus on functioning after spasticity treatment. The ones 
most often used in children with CP are the Gross Motor Function Measurement 
(GMFM) and the Pediatric Evaluation of Disability Inventory (PEDI). The GMFM 
is widely accepted as the best available quantitative method. However, in infants 
with CP it was shown that spasticity is only marginally related to gross motor 
function development.65 Especially in severely affected children the GMFM is of 
limited value.66 The PEDI is a generic questionnaire which measures the func-
tioning, health, and self care in chronically ill children with disabilities. It is ad-
ministered through a structured interview with a parent. A recent review found 
the PEDI to be valid, reliable and responsive to change.67 The main drawback of 
the PEDI is that it takes over 45 minutes to complete, making it not very suitable 
in a busy outpatient clinic. 
Assessment of side-effects 
Besides evaluating the effect of treatment, the physician has to be aware of pos-
sible side-effects. These are not uncommon after routine treatments of spastic-
ity as mentioned before. 
MORE THAN MOTOR PROBLEMS ALONE 
In addition to their motor problems, children with CP often have a spectrum of 
accompanying problems for which a multidisciplinary approach is needed. Epi-
lepsy in children with CP is common (up to one third), has an early onset, and 
requires prolonged and intense pharmaceutical treatment.68 Recent studies 
have established the relationships between CP and impaired non-verbal intelli-
gence, learning disabilities, impaired memory and language functioning, and 
disturbed executive functions.69 Feeding problems are widespread in children 
with CP; more than 1 out of 10 depends on gastrostomy tube feeding and 
around 40 percent has an abnormal body mass index (BMI).70 Orthopaedic 
problems are highly prevalent amongst children with CP. The most common 
deformity is the equinus, but hip deformities and spastic scoliosis are far from 
rare either.71 It is now recognized that 4 out of 10 children with CP have at least 
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one clinically significant sleeping disorder.72 A recent Dutch study investigated 
sexuality in young adults with CP and found 80% to report physical problems 
with sex and 45% to report emotional inhibition to initiate sexual contact.73 
There is increasing interest in the consequences of the combination of these 
accompanying problems and the previous discussed motor problems on the 
quality of life (QoL) of children with CP. 
QUALITY OF LIFE 
The WHO defines QoL as “an individual’s perception of their position in life in 
the context of culture and value systems in which they live, and in relation to 
their goals, expectations, standards and concerns”.74 Technically speaking QoL is 
not a definition; it is a concept, an invention of the human mind to construct a 
model of the world. As with all human inventions, it is not perfect and therefore 
QoL does not represent one single truth. Nevertheless, attempts should be made 
to capture and analyse this QoL in the best way possible as it may expose prob-
lem areas in chronically ill children and lead to treatment opportunities. 
There are several instruments available to assess QoL of children with CP. 
Two well established and often used instruments are the Child Health Question-
naire (CHQ) and the KIDSCREEN. The CHQ is a generic QoL instrument which 
measures 14 unique physical and psychosocial concepts.75 All concepts are 
scored on a 0–100 scale with higher scores reflecting better QoL. Physical and 
psychosocial summary scores can be derived from the separate CHQ profile 
scores which have a mean of 50 and a standard deviation of 10 in the general 
population. The KIDSCREEN is a modern, generic QoL instrument, which uses 
questions based on focus-groups with children and adolescents held all over 
Europe.76–78 It focuses entirely on subjective perceptions, has shown to possess 
excellent psychometric properties, can be used for both disabled and non-
disabled children, and can be reported by both the children themselves and 
their caregivers.76–79 
Previous studies have assessed QoL of children with CP. Several smaller 
studies found contradicting results.80–83 The largest study so far (SPARCLE 
study, 7 European countries, KIDSCREEN-52) found that QoL of children with CP 
aged 8–12 years is, on average, similar to that of children in the general popula-
tion on practically all domains.84 This study provided clues that children with CP 
might have a slightly better school environment, but experience lower auton-
omy. Specific factors were found to be associated with lower QoL in certain do-
mains, e.g. pain is associated with less QoL in the physical and psychological 
well-being and self-perception domains.85 Greater limitations, on the other 
hand, lead to higher or lower QoL depending on the domain. However, impair-
ment and pain can only explain a small amount of variance in QoL, which is 
therefore likely to be largely determined by social and environmental factors. 
C H A P T E R  I  
 22 
Unfortunately social and environmental factors can differ significantly between 
countries and even regions and KIDSCREEN QoL results for Dutch children with 
CP are still lacking. 
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AIM AND OUTLINE OF THE THESIS 
In the general introduction a brief overview of clinical and therapeutic aspects 
of CP has been provided. Furthermore, gaps, concerns, and controversies in 
current knowledge were highlighted. The aim of this thesis was to address and 
study some of these issues in the population of approximately 100 children with 
CP who are seen at the outpatient clinic of the Maastricht University Medical 
Centre (MUMC). 
As a first step of this thesis the basic characteristics of these children were 
collected, which was followed by a study to see how these children cope with 
their often severe disabilities and limitations. Therefore, in chapter II1 the psy-
chosocial adjustment of the Dutch sample of children with CP is described. 
Chapter IV and V concentrate on the management of spasticity in CP. In 
chapter IV the effects of a percutaneous radiofrequency lesion adjacent to the 
dorsal root ganglion on spasticity and pain is investigated as it was hypothe-
sized that this could serve as an alternative to the conventional SDR. The results 
of a pilot study in 17 children with CP are described. In chapter V two cases of 
dyskinetic CP are reported on in which an anti-convulsant drug (Levetiracetam) 
led to an impressive improvement of balance control and fine motor skills. 
Chapter VI to VIII focus on the evaluation of spasticity management. In chap-
ter VI the usefulness of a simple visual analogue scale to evaluate the effects of 
BTX-A treatment on spasticity is demonstrated. In chapter VII three cases of a 
never before reported side-effect of BTX-A treatment are described. Chapter VIII 
reports on the long-term follow-up on the beneficial effects of ITB treatment in 
children with intractable spastic CP. 
In chapter IX the QoL of children with CP living in the Southern part of the 
Netherlands is described, as the Netherlands did not participate in the SPARCLE 
study. 
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ABSTRACT 
Background 
Over the last couple of years, there has been increasing interest for QoL of chil-
dren with CP. Psychosocial adjustment in these children remains underrepre-
sented in current literature. 
 
Aims 
To describe psychosocial adjustment in children with CP by means of the Psy-
chosocial Adjustment and Role Skills Scale - III (PARS-III), to describe the psy-
chometric properties of this questionnaire, to identify a cut-off score for psycho-
social maladjustment, and to investigate the relationship between patient char-
acteristics (i.e. predictive factors) and psychosocial adjustment. 
 
Methods 
The parents of 93 children with CP (59 boys, 34 girls; mean age 12.3 years, SD 
3.8, 4–18; GMFCS 1: 28, 2: 5, 3: 19, 4: 18, 5: 23) completed the PARS-III and the 
Child Behavior Checklist (CBCL) concerning the psychosocial and behavioral 
functioning of their child. 
 
Results 
Cronbachs alpha-coefficient for the PARS-III was 0.89 indicating good internal 
consistency. High correlation with the CBCL was found. Confirmatory factor 
analysis confirmed the 6 domain structure of the PARS-III. Overall, children with 
CP achieved lower psychosocial adjustment scores compared to healthy chil-
dren. A cut-off score (1 SD below the mean) of 78 was found. When predicting 
psychosocial maladjustment in children with CP, less gross motor function, hand 
function, communication skills, and bilateral involvement of CP are the most 
important factors, but these can only explain 36% of variation in psychosocial 
adjustment. 
 
Conclusion 
Using the by-proxy version of the PARS-III it was found that children with CP are 
reported to achieve lower psychosocial adjustment scores than healthy children. 
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INTRODUCTION 
Over the last couple of years, there has been increasing interest for health out-
comes in children with cerebral palsy (CP).1 More and more, treatments are 
evaluated in terms of health, Quality of Life (QoL) and health related QoL. The 
World Health Organization (WHO) defines QoL as “an individual’s perception of 
their position in life in the context of culture and value systems in which they 
live, and in relation to their goals, expectations, standards and concerns”.2 Ex-
tensive research concerning QoL of children with CP has been done. The largest 
study so far (SPARCLE study, 7 European countries, KIDSCREEN-52) found that 
QoL of children with CP aged 8–12 years is, on average, similar to that of chil-
dren in the general population on practically all domains.3 
Another important concept is psychosocial adjustment, defined as the adap-
tive task of coping with upsetting feelings and frustrations aroused by the ill-
ness.4 Contrary to QoL, psychosocial adjustment remains underrepresented in 
current literature. Although strongly related, psychosocial adjustment and QoL 
are distinct entities, which will hopefully be illustrated by the following exam-
ple. Children with CP frequently have hip deformities which may cause pain.5 
The way of coping with this pain is different for every child. Some children with 
little hip deformity will become very anxious when they have to put weight on 
their hip joint and will therefore not participate in playing outdoors, while oth-
ers with severe hip deformity will ignore the pain, play outside and establish 
new friendships (the so called “disability paradox”).6 Hence, psychosocial ad-
justment determines whether and to what extent pain influences QoL. It is the 
result of a complex process in which children attempt to meet the demands of 
their illness with their emotional/social resources and coping strategies. In oth-
er words, better coping strategies will lead to higher QoL. Thus, in order to un-
derstand a child’s QoL and to eventually be able to improve it, one must under-
stand why and when children will apply appropriate psychosocial adjustment. 
The main problem in this research area is that there are few standardized 
instruments specifically developed for these children with a chronic illness. 
Using the Child Behavior Checklist (CBCL) Sigurdardottir et al found a preva-
lence of 40 to 50% of substantial behavioural or emotional difficulties in pre-
school children with CP.7 However, the primary aim of the CBCL is to identify 
and diagnose psychopathological behaviour.8 It does not take into account the 
stress and emotional reactions part of normal adjustment to a chronic illness.9, 10 
As such, the CBCL is prone to over identify pathological behaviour. Using the 
Strengths and Difficulties Questionnaire (SDQ) Parkes et al found that over a 
quarter of children with CP aged 8–12 years experience significant psychologi-
cal problems, mainly peer problems, hyperactivity, and emotional problems.11 
The major drawback of the SDQ is that it measures general behaviour problems 
without special consideration of illness-related factors. 12 As the CBCL, it may 
over identify pathological behaviour. 
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A questionnaire specifically developed to measure psychosocial adjustment in 
children with a chronic illness is the Psychosocial Adjustment and Role Skills 
Scale - III (PARS-III).13 Its main strength is that it includes domains important to 
the psychosocial adjustment of children with a chronic illness and leaves out 
items based on physical symptoms like pain, fatigue, and headaches.14 
Recently, Hendriksen et al found the PARS-III to be a reliable and valid index 
of psychosocial adjustment in boys with Duchenne Muscular Dystrophy (DMD), 
a fatal, X-linked, muscle disorder, which affects approximately 1 in 3,500 chil-
dren, almost all boys.15 On the basis of this result the current study was con-
ducted with the following aims. The first aim is to describe psychosocial adjust-
ment in a Dutch sample of children with CP using the PARS-III questionnaire 
and to describe its psychometric properties. Secondly, in order to provide a first 
step towards identifying psychosocial adjustment profiles in different patient 
populations, a brief comparison to boys with DMD will be made. Thirdly, a clini-
cal useful cut-off score for psychosocial maladjustment in children with CP will 
be identified. Finally, the relationship between patient charateristics (i.e. predic-
tive factors) and psychosocial adjustment will be investigated. 
METHODS 
Design 
This cross-sectional study was approved by the Medical Ethics Committee 
(MEC) of the Maastricht University Medical Centre (MUMC) according to Dutch 
governmental guidelines. 
The parents of all 94 children with CP (aged 4–18 years) seen at the outpa-
tient clinic of the MUMC were informed about the study and asked to partici-
pate. All except one agreed and were sent the PARS-III and the CBCL question-
naires. 
Data concerning the psychosocial adjustment of 63 Dutch boys with DMD 
and 95 healthy children were collected at an earlier stage.15 
Measures 
Psychosocial Adjustment and Role Skills Scale - III 
The PARS-III was specifically developed to measure psychosocial adjustment in 
children (aged 5 to 18 years) with a variety of chronic physical illnesses.13, 14 It is 
a brief - 28-item - parent-completed questionnaire of which all items use a four-
point ordinal rating scale: “never or rarely”, “sometimes”, “often”, or “always or 
almost always”. The total score is the summation of the scores assigned (from 1 
to 4) to each item with higher scores indicating more adjusted functioning. 
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Summation of specific items also yields six factor-derived psychosocial sub-
scales: peer relations, dependency, hostility, productivity, anxiety/depression, 
and withdrawal. Reliability and validity are described as adequate to good, e.g. 
alpha coefficient for the total score is 0.88 (n=449).13, 14 
Child Behaviour Checklist 
The Achenbach CBCL is one of the most widely used measures for the assess-
ment of behavioral problems and domains of competence.8 Based on a 113-item 
questionnaire, a total problem scale, two broadband scales (internalising and 
externalising behaviour problems) and eight narrowband scales (anxi-
ety/depression, withdrawal, physical complaints, social problems, thought 
problems, attention problems, rule breaking behaviour, aggressive behaviour) 
can be derived. For the purpose of this study only the narrowband scales were 
used. Resulting standardised T-scores are defined as “borderline” (67 to 70) and 
“clinical” (larger than 70, that is, above the 98th percentile). 
Participants 
Children with CP 
The major patient characteristics were collected from the medical files of the 
children and are displayed in Table 3.1. The 93 children with CP consisted of 59 
boys and 34 girls with a mean age of 12.3 years (SD 3.8; 4–18). Forty-four per 
cent of the children with CP were wheelchair dependent and 52% had a cogni-
tive level below 70. The percentages of children scoring in the clinical range on 
the eight narrowband scales of the CBCL (above the 98th percentile) are dis-
played in Table 3.2. It can be seen that for the areas of physical complaints 
(14%), social problems (8%) and attention problems (5%) larger proportions of 
children with CP scored above the 98th percentile than would be expected. 
 
Boys with DMD and healthy children 
The parents of 63 boys with DMD were recruited from the Dutch Parent Project 
Muscular Dystrophy, which is a parent advocacy group. The mean age of the 63 
boys with DMD was 10.8 years (SD 4.1; 3–23); 65% were wheelchair dependent. 
The parents of 100 healthy children were recruited at random from three dif-
ferent schools in the Southern part of the Netherlands; 95 agreed to participate. 
The mean age of the 48 healthy boys and 47 healthy girls was 7.7 years (SD 2.8; 
4–13). 
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Table 3.1 Characteristics of the children with CP 
 Mean (range) 
Frequency (%)
 Mean 
(range) 
Frequency 
(%) 
Numer of patients 93 Age (years) 12.3 (4–18) 
Sex  Sensory disability  
 Male 59 (63%)  Visual 15 (16%) 
 Female 34 (37%)  Auditory 2 (2%) 
Type CP  Feeding  
 Spastic unilateral 31 (33%)  I Without difficulties 75 (81%) 
 Spastic bilateral 59 (63%)  II Significant Difficulties 19 (21%) 
 Dyskinetic 2 (2%)  III Stoma 6 (7%) 
 Ataxic 1 (1%)  Missing 1 (1%) 
Cognitive level  Pain / discomfort  
 < 50 23 (25%)  None 58 (62%) 
 50–70 25 (27%)  Some - severe 33 (36%) 
 >70 45 (48%)  Missing 2 (2%) 
GMFCS  Communication Skills  
 1 28 (30%)  I Normal 57 (62%) 
 2 5 (5%)  II Problems 19 (20%) 
 3 19 (20 %)  III Alternatives 7 (8%) 
 4 18 (19%)  IV None 9 (10%) 
 5 23 (25%)  Missing 1 (1%) 
Wheelchair dependent  Level of hand functioning  
 Yes 41 (44%)  I No limitations 18 (19%) 
 No 52 (56%)  II Limitations with fine motor task in  
      both hands 
26 (28%) 
Family composition   III Needs assistance in performing tasks 20 (22%) 
 Two parents family 85 (91%)  IV Needs assistance and makes use of  
       adaptive equipment 
6 (7%) 
 One parent family 4 (4%)  V Requires assistance in everything 21 (23%) 
 Missing 4 (4%)  Missing 2 (2%) 
Epilepsy   Living area  
 None the last year 72 (77%)  Urban 47 (52%) 
 < 1 / month last year 14 (15%)  Countryside 44 (47%) 
 > 1 / month last year 7 (8%)  Missing 2 (2%) 
School type  Occupation parents  
 Normal education 33 (36%)  >1 parent works fulltime 59 (63%) 
 Special education 57 (61%)  Other situation 31 (33%) 
 Missing 3 (3%)  Missing 3 (3%) 
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Table 3.2 Percentages of children with CP (N= 86) scoring in the clinical range of the CBCL narrow-
band scales (above the 98th percentile) 
Scale % Scale % 
Anxiety / depression 1% Thought problems 1% 
Withdrawal 3% Attention problems 5% 
Physical complaints 14% Rule breaking behavior 0% 
Social problems 8% Aggressive behavior 2% 
 
Statistical analysis 
All data were entered into SPSS 18.0 for statistical analysis (RH). The accuracy 
of data entry was randomly checked and found correct by a different researcher 
(JH). Cronbach’s alpha was used to calculate the internal consistency of the 
PARS-III. Confirmatory factor analysis (CFA, AMOS 17) was performed to con-
firm the six domains of psychosocial functioning on the PARS-III questionnaire. 
Factor loadings above 0.6 were considered high and factor loadings below 0.4 
were considerd low. As an indication for criterion validity of the PARS-III bivari-
ate correlations with the eight narrowband scales of the CBCL were calculated. 
Subsequently, independent sample T tests were used to assess differences 
between PARS-III scores of children with CP, boys with DMD and healthy chil-
dren. P-values below 0.05 were considered significant. 
In order to establish a cut-off score, the same method as Witt et al, Pless et al 
and Hendriksen et al was used, meaning that 1 SD below the group mean is used 
as a cut-off score for poor psychosocial adjustment.15–17 
Finally, univariate and multivariate (forward entry, dummy variables) mod-
el testing was used to identify patient characteristics (Table 3.1) predictive for 
poor psychosocial adjustment in children with CP. 
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RESULTS 
Psychometric properties of the PARS-III when used for children with CP 
Good internal consistency for the total PARS-III score was found: a Cronbach’s 
alpha of 0.89. For the six subscales the alpha coefficient was 0.81 for peer rela-
tions; 0.56 for dependency; 0.83 for hostility; 0.80 for productivity; 0.76 for 
anxiety/depression and 0.76 for withdrawal. 
CFA confirmed the six domains of psychosocial functioning on the PARS-III 
questionnaire (Figure 3.1). Except for questions 6, 13 and 20, all factor loadings 
were adequate (8) and high (18). Exploratory factor analysis showed that ques-
tion 6 did load on the domain withdrawal. Questions 13 and 20 did not load on 
any. 
 
 
Figure 3.1 Confirmatory factor analysis of the structure of the PARS-III questionnaire 
P1-P28: questions on the PARS-III questionnaire; PR = peer relations; Dep = dependency; Host = 
hostility; Prod = productivity; With = withdrawal; Anx = anxiety and depression. Numbers indicate
factor loadings. 
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As an indication for criterion validity of the PARS-III bivariate correlations with 
the eight narrowband scales of the CBCL were calculated (Table 3.3). It can be 
seen that all correlations are in the expected directions (low adjustment scores 
on the PARS-III correlate with high problem scores on the CBCL). The PARS-III 
total score correlates significantly (r = -0.29 to r = -0.59) with all narrowband 
scales of the CBCL. Furthermore, it can be seen that the CBCL scale for social 
problems correlates highest with the PARS-III domain peer relations (r = -0.50). 
Also, as can be expected, the CBCL scale for aggression correlates highest with 
the PARS-III domain hostility (r = -0.68), the CBCL scale for anxiety/depression 
with the PARS-III domain anxiety (r = -0.58), and the CBCL scale for withdrawal 
with the PARS-III domain withdrawal (r = -0.43). 
 
Table 3.3 Bivariate correlations (r) between the PARS-III and the CBCL in children with CP 
 P A R S – I I I 
  Peer  Dep Host Prod Anx/Depr Withd Total 
 Anx/Depr -0.23 * -0.29 ** -0.12 -0.03 -0.58 *** -0.35 *** -0.39 *** 
 Withd -0.39 *** -0.45 *** -0.16 -0.24 * -0.40 *** -0.43 *** -0.52 *** 
 Somatic -0.40 *** -0.04 -0.16 -0.37 *** -0.21 -0.27 * -0.37 *** 
 Social  -0.50 *** -0.38 *** -0.42 *** -0.24 * -0.49 *** -0.37 *** -0.59 *** 
 Thought -0.03 -0.32 *** -0.21 -0.13 -0.15 -0.35 *** -0.29 * 
 Attention -0.22 -0.54 *** -0.46 *** -0.32 *** -0.27 * -0.34 *** -0.52 *** 
 Rule  -0.13 -0.57 *** -0.39 *** -0.07 -0.34 *** -0.28 ** -0.43 *** 
C 
B 
C 
L 
 Aggress -0.07 -0.52 *** -0.68 *** -0.24 * -0.40 *** -0.29 ** -0.56 *** 
All correlations are in the expected directions (low adjustment scores on the PARS-III correlate with 
high problem scores on the CBCL). * = p<.05; ** = p<.01; *** = p<.001; Peer = Peer Relations; Dep = 
Dependency; Host = Hostility; Prod = Productivity; Anx/Depr = Anxiety/Depression; Withd = With-
drawal; Somatic = Somatic Complaints; Social = Social Problems; Thought = Thought Problems; 
Attention = Attention Problems; Rule = Rule-breaking Behavior; Aggress = Aggressive Behavior 
Psychosocial adjustment profiles of children with CP, boys with DMD, and 
healthy children 
Children with CP achieve significantly lower psychosocial adjustment scores 
when compared to healthy children (p < 0.001), especially in the domains peer 
relations (p < 0.001), anxiety/depression (p < 0.01), withdrawal (p < 0.001), and 
productivity (p = 0.02) (Table 3.4). In general, boys with DMD do not differ sig-
nificantly from children with CP (p = 0.93). However, when looking at the do-
mains of psychosocial adjustment, children with CP score significantly lower 
than boys with DMD on peer relations (p = 0.03). 
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Table 3.4 Comparison of psychosocial adjustment scores in healthy children, children with CP and 
boys with DMD 
 Healthy Children Children with CP Boys with DMD 
 N Mean SD N Mean SD Sign1 N Mean SD Sign1 Sign2 
Peer relations 93 11.9 2.4 87 8.6 2.9 *** 62 9.6 2,8 *** * 
Dependency 93 13.5 2.0 85 12.9 2.1 ns 60 12.4 2,1 ** ns 
Hostility 93 21.4 2.9 85 21.3 3.0 ns 63 20.6 3,4 ns ns 
Productivity 91 11.0 2.3 87 10.0 2.9 * 60 10.7 2,5 ns ns 
Anxiety 93 22.5 1.7 87 21.6 2.4 ** 63 21.9 1,9 ns ns 
Withdrawal 91 15.6 1.0 91 14.2 2.0 *** 60 14.4 1,9 *** ns 
Total 88 95.7 7.1 77 88.6 10.4 *** 55 88.5 9,9 *** ns 
N = number of cases, * p < 0.05, ** p < 0.01, *** p < 0.001, ns = not significant 
Sign1 = significance compared to healthy children 
Sign2 = significance compared to children with CP 
Establishing a cut-off score 
Both Witt et al, Pless et al, and Hendriksen et al calculated 1 SD below the group 
mean and used this number as a cut-off score for psychosocial maladjustment.15–
17 They found cut-off scores of respectively 73.1 and 72.3. In this current study 
this method would result in a cut-off score of 78 (88.6 – 10.4) identifying the 16 
% (1 SD) of the children with CP showing the worst psychosocial maladjust-
ment. 
Factors predictive for less psychosocial adjustment in children with CP 
Using univariate and multivariate (forward entry, dummy variables) model 
testing it was found that the patient characteristics most predictive for lower 
PARS-III sub and total scores were gross motor function, level of hand function 
(LoH), communication skills (CS) and bilateral involvement of CP (Table 3.5). 
Put together in a model, these four patient characteristics could explain a sig-
nificant proportion (36%) of the variation in PARS-III total scores. 
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Table 3.5 Patient characteristics explaining differences in PARS-III domain scores (multivariate 
regression analysis) 
 Patient characteristic B SE p R2 F-ratio 
Peer relations Bilateral 
GMFCS5 
 
-2.54 
-1.33 
 
0.70 
0.59 
 
0.00 
0.03 
 
 
 
0.23 
 
 
12.24 
Dependency LoH-IV 
 
-3.17 
 
0.90 
 
0.00 
 
 
0.14 
 
12.31 
Hostility CS-III 
LoH-IV 
Age 
GMFCS5 
 
-4.20 
-3.29 
0.22 
-1.59 
 
0.96 
1.01 
0.07 
0.64 
 
0.00 
0.00 
0.00 
0.02 
 
 
 
 
 
0.38 
 
 
 
 
12.36 
Productivity GMFCS5 
Bilateral 
CS-IV 
 
-1.62 
-1.38 
-2.88 
 
0.76 
0.58 
1.29 
 
0.04 
0.02 
0.03 
 
 
 
 
0.28 
 
 
 
10.20 
Anxiety / depression - - - - - - 
Withdrawal CL<50 
 
-1.43 
 
0.48 
 
0.00 
 
 
0.10 
 
8.99 
Total GMFCS5 
Sign. feeding difficulties 
Bilateral 
LoH-IV 
 
-7.32 
-9.47 
 
-5.63 
-8.81 
2.63 
3.30 
 
2.16 
4.08 
0.00 
0.00 
 
0.00 
0.00 
 
 
 
 
0.36 
 
 
 
 
9.72 
Bilateral = Bilateral spastic CP, LoH-IV = Level of Hand function level IV: needs assistance and makes 
use of adaptive equipment, CS-III = Communication Skills level III: having to use alternative methods 
to communicate, CS-IV = Communication Skills level IV: no ways of communication, CL = Cognitive 
level, GMFCS = Gross Motor Function Classification System, B = beta, SE = Standard Error 
DISCUSSION 
Psychosocial adjustment of children with CP 
To the best of our knowledge this is the first study describing psychosocial ad-
justment in children with CP using the PARS-III questionnaire for parents. It 
shows that children with CP are reported to achieve less psychosocial adjust-
ment when compared to healthy children (Table 3.4). The first domain of sig-
nificantly lower psychosocial adjustment is peer relations, with lower gross 
motor function being an important predictive factor (Table 3.5). This can be 
explained by the fact that participation in daily life and leisure activities, key to 
developing peer relations, is less in children with more physical restriction.18, 19 
The second domain of lower scores in children with CP was anxi-
ety/depression. Sigurdardottir et al found lower IQ to be a risk factor for more 
anxiety.7 In the current study cognitive level was not found to be related to anxi-
ety (R2 = 0.012). In fact, none of the patient characteristics were. Possible expla-
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nations might be that Sigurdardottir et al studied preschool children and used 
the CBCL questionnaire, which is not specifically developed to assess psychoso-
cial adjustment. 
The third domain, in which children with CP show significantly lower psy-
chosocial adjustment scores, was withdrawal. Low cognitive level (IQ below 50) 
turned out to be the only predictor (B = -1.42; R2 = 0.10), which this time is in 
agreement with the study by Sigurdardottir et al.7 
Comparison to boys with DMD 
Overall, children with CP do not differ significantly from boys with DMD on the 
PARS-III total score (p = 0.92). However, children with CP score significantly 
lower than boys with DMD on the domain peer relations (p = 0.03). This could 
be due to the fact that during the initial phases of their disease boys with DMD 
are able to participate almost normally in life and therefore establish more and 
better peer relations. Furthermore, children with CP showed a trend towards 
lower scores on the domain of dependency (p = 0.09), reflecting higher inde-
pendence in boys with DMD as they are more able to live independent lives. 
The cut-off score 
A cut-off score (1 SD below the mean) of 78 was identified in this study. This 
means that children with CP scoring below 78 are at risk for psychosocial mal-
adjustment and merit further assessment. Even though the identified cut-off 
score can be helpful in clinical practice, the development of clinical norms based 
on a demographically representative sample would be highly useful. 
Predictive factors of psychosocial adjustment in children with CP 
The most important predictive factor for lower psychosocial adjustment was a 
higher restriction in gross motor function, i.e. higher GMFCS level, bilateral in-
volvement and worse hand function. This is a common observation in the litera-
ture.3, 20 A regression analysis model could explain 36% of variation in PARS-III 
adjustment scores, highlighting the complexity of both CP and psychosocial 
adjustment. 
Although pain is common in children with CP (35% of studied population 
had moderate to severe pain complaints), it was found that pain was not a sig-
nificant predictive factor for psychosocial adjustment on any of the 6 domains of 
the PARS-III. This is in contrast with previous studies in which pain resulted in 
lower QoL and more behavioral problems (measured by means of the KID-
SCREEN and SDQ respectively).3, 11 This discrepancy between our findings and 
literature may be due to the fact that dichotomous pain data was used, but also 
due to the fact that psychosocial adjustment and QoL are different concepts. For 
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example, in a study by Engel et al it was shown that in adults with CP it is not the 
pain itself that influences psychological functioning, but the coping strategies in 
reaction to the pain.21 
As already stated above, differences in psychosocial adjustment could only 
partially be explained using patient characteristics previously reported in litera-
ture. It is suggested that future studies should also include basic neurological 
substrates when investigating psychosocial adjustment. For example, for both 
CP and DMD it is known that the cerebellum can be involved in the pathogene-
sis. It has recently been shown that cerebellar injury in premature infants is 
associated with a high prevalence of cognitive, learning and behavioral disabili-
ties.22 Sophisticated MRI analyses (e.g. Diffusion Tensor Imaging and connec-
tivity analyses) would aid investigating such a relationship between the cerebel-
lum and psychosocial functioning in children with CP. Future research should 
compare PARS-III scores in children with CP with and without cerebellar in-
volvement. 
Limitations of this study 
This study has several limitations, some of which are almost inevitable in this 
field of research. 
The first limitation is that the data are cross-sectional and therefore no con-
clusions about causal relationships can be made. Consequently, the develop-
mental profile of psychosocial adjustment in children with CP remains unclear. 
A longitudinal – follow-up – study using the PARS-III questionnaire is advised in 
order to elucidate this developmental profile and find out whether different age 
periods (moving to another town, older brother going to college, hitting puberty, 
etc) are characterized by different psychosocial adjustment problems. 
The second limitation is the sole reliance on proxy reports. The literature on 
the best source to evaluate QoL and psychosocial adjustment is inconsistent at 
best. The WHO and the International Association for Child Psychology and Psy-
chiatry recommend that children should report their own QoL.23 However Le 
Coq et al found that in 8 to 11 year old pediatric asthma patients parents were 
more responsive and reliable reporters on a QoL measure.24 Then there is the 
limitation that some children might not be capable to self-report because of 
their age, cognitive impairments or disabilities.25 In this case, proxy-reports are 
the only way to evaluate QoL with their parents / caregivers being the most 
logical source of information as they are assumed to have intimate knowledge of 
the child. It is now becoming more and more accepted that there is no one single 
truth concerning concepts like QoL and psychosocial adjustment and therefore 
self-reports and proxy reports are complementary.26 With regard to the current 
study, self-reports would have been extremely difficult to obtain and interpret 
given the severity of disability of the majority of the children with CP. 
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Finally, in the absence of a golden standard for psychosocial maladjustment ROC 
curves cannot be produced and therefore identifying a cut-off score is arbitrary. 
In accordance with Witt et al, Pless et al and Hendriksen et al this study used 1 
SD below the mean as a cut-off score.15–17 This inevitably means that 16% of the 
children with CP will receive further assessment. Experience will tell whether 
this method over-, under- or appropriately identifies psychosocial maladjust-
ment. 
CONCLUSION 
This study showed the PARS-III to possess good internal consistency and crite-
rion validity when applied to children with CP and can therefore be used for 
both clinical screening and research purposes. Using this by-proxy question-
naire, it was found that children with CP achieve lower psychosocial adjustment 
scores when compared to healthy children, especially in the subdomains peer 
relations, anxiety/depression, withdrawal, and productivity. Future studies 
should aim at unraveling the developmental profile and risk factors for psycho-
social maladjustment. 
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ABSTRACT 
Background 
Cerebral palsy (CP) may cause severe spasticity, requiring neurosurgical proce-
dures. The most common neurosurgical procedures are continuous infusion of 
intrathecal baclofen and selective dorsal rhizotomy. Both are invasive and com-
plex procedures. We hypothesized that a percutaneous radiofrequency lesion of 
the dorsal root ganglion (RF-DRG) could be a simple and safe alternative treat-
ment. We undertook a pilot study to test this hypothesis. 
 
Methods 
We performed an RF-DRG procedure in 17 consecutive patients with CP with 
severe hip flexor / adductor spasms accompanied by pain or care-giving difficul-
ties. Six children were systematically evaluated at baseline, and 1 month and 6 
months after treatment by means of the Modified Ashworth Scale (MAS), Gross 
Motor Function Measure (GMFM), and a self-made caregiver’s questionnaire. 
Eleven subsequent children were evaluated using a Visual Analogue Scale (VAS) 
for spasticity, pain, and ease of care. 
 
Results 
A total of 19 RF-DRG treatments were performed in 17 patients. We found a 
small improvement in muscle tone measured by MAS, but no effect on the GMFM 
scale. Despite this, the caregivers of these six treated children unanimously stat-
ed that the quality of life of their children had indeed improved after the RF-
DRG. In the subsequent 11 children we found improvements in all VAS scores, in 
a range comparable to the conventional treatment options. 
 
Conclusion 
RF-DRG is a promising new treatment option for severe spasticity in patients 
with CP. Its definitive effectiveness remains to be defined in a randomized con-
trolled trial. 
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BACKGROUND 
Cerebral palsy (CP) is a central nervous system deficit resulting from a non-
progressive lesion in the developing brain. Although these brain lesions are 
static, the movement disorders that arise are not unchanging and are character-
ised by atypical muscle tone, posture, and movement.1 The spastic motor type is 
the most common form of CP and its conventional therapeutic management may 
include splinting / casting, physiotherapy, occupational therapy, oral spasmo-
lytics and anti-dystonic drugs, Botulinum Toxin-A (BTX-A) injections, orthopae-
dic procedures, and neurosurgical procedures. The most common neurosurgical 
procedures are continuous infusion of intrathecal Baclofen (ITB) and selective 
dorsal rhizotomy (SDR). Since its first description by Foerster in 1913, SDR has 
been modified by various researchers and has become a standard neurosurgical 
procedure to treat spasticity in patients with CP.2–5 However, as multi-level lam-
inectomies at the L1-S1 level are often required, the procedure is invasive and 
can lead to complications as transient urinary incontinence, chronic low back 
pain, and spinal deformity.6–9 Furthermore, considerable cooperation of the 
patient is required to successfully complete the postoperative rehabilitation 
program. 
An alternative for the SDR is a radiofrequency lesion of the dorsal root gan-
glion (RF-DRG), which has been used to treat chronic pain for over 30 years.10 
The RF-DRG is a simple and safe treatment with little side-effects.11, 12 In the 
1980’s several authors reported that the same procedure might be used to treat 
adult patients with spasticity.13, 14 More recently, we were able to show that an 
RF-DRG alleviates hip flexor spasms in 2 patients with CP.15 Patients with CP can 
also suffer from severe pain through spasticity, bone deformities or joint sub-
luxation, especially hip displacement and dislocation16, 17, which may lead, 
through an enhanced processing of afferent information within the spinal cord, 
to secondary pain.18 
We thus hypothesized that an RF-DRG may alleviate spasticity and pain in 
patients with CP, and we tested this hypothesis in a pilot study of 17 patients. 
METHODS 
Children with spastic CP were seen by a multi-disciplinary spasticity manage-
ment team (child neurologist, orthopaedic surgeon, and physician assistant 
child neurology) of the Maastricht University Medical Centre (MUMC). Individ-
ual treatment goals were determined after a careful assessment of the aetiology, 
functional ability, and associated impairments as a result of the spasticity. The 
RF-DRG treatment was considered in children with severe hip flexor / adductor 
spasms accompanied by pain or care giving difficulties. The procedure was ap-
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proved by the Institutional Review Board of the MUMC, according to Dutch gov-
ernmental regulations and informed consent from the caregivers was obtained 
for each patient. 
A total of 17 children were treated with RF-DRG (tables 4.1, 4.2). The sever-
ity of CP was based on the Gross Motor Function Classification System (GMFCS) 
for CP.19, 20 Hip(sub)luxation was classified according to the morphological hip 
classification system proposed by Robin et al. 21 
 
Table 4.1 Summary of 6 patients (Group A) treated with RF-DRG and systematically evaluated. 
 m/f Age 
(yr) 
Aet GMFCS
score 
RF-DRG Indication Improv 4w SE 4w Improv 6m SE 6m Hip  
morphology
     Left Right SpasPainCare Spas Pain Care  Spas Pain Care  Left Right
1 f 6 Asph V L1–2 L1–2 ■  ■ +   no +   no IV III 
2 f 12 Tr V L1–4 L1–4 ■ ■ ■ + + + no + + + no III I 
3 f 16 Prem V - L1–3  ■ ■  + + no  + + no II V 
4 f 11 Asph V L2–4 L2–4 ■   +   no +   no II IV 
5 m 7 Prem V L1–2 -  ■   -  yes  +  no V III 
6 f 14 Asph V - L1–3 ■ ■ ■ + + + no + + + no III V 
m: male; f: female; yr: years; spast: spasticity; Aet: Aetiology: Asph: Asphyxia; Tr: Trauma; Prem: 
Premature; SE: Side-effects; Improv: Improvement; 4w: 4 weeks; 6m: 6 months 
■: indication 
Improvement: +/-: summary of improvement/worsening measured by the self-made questionnaire 
 
Table 4.2 Summary of 11 patients (Group B) treated with RF-DRG and evaluated by VAS. 
 m/f Age 
(yr) 
SCPE GMFCS
Score 
RF-DRG-
left 
RF-DRG-
right 
Indication VAS 
pre 
Improvement
 
VAS 
post 
Δ-VAS SE Hip morphology
       Spas Pain Care  SpasPainCare    Left Right 
1 f 18 2 V L1–3 -  ■  8  +  2 6 no III V 
2 f 22 2 V L1–4 - ■ ■  10 + +  1.5 8.5 no ns ns 
3 f 10 2 V L1–2 L1–2 ■ ■  10 +   8 2 no V III 
4 m 16 2 V L1–3 -  ■  7  +  3 4 no II V 
5 m 16 2 V L1–4 - ■ ■  8.2  +  1.6 6.6 no IV V 
6 m 7 2 V - L1–3 ■   ns    ns  yes 0 III 
7 m 5 2 V L1–3 L1–3 ■  ■ ns   + ns  no IV IV 
8 f 11 2 V L1–2 -  ■  6  +  2 4 no * II 
9 f 10 2 V L1–2 - ■ ■ ■ 8  + + 5.5 2.5 no I I 
  12 2 V L1–2 - ■ ■ ■ 8  + + 5 3 no I I 
  14 2 V L1–2 - ■ ■ ■ 10    10 0 no I I 
10 m 5 2 V L1–4 L1–4 ■  ■ ns +   ns  no II V 
11 f 16 2 V L1–4 L1–4 ■ ■ ■ 8.7 + + + 3.1 5.6 no ns ns 
m: male; f: female; yr: years; SCPE: surveillance for cerebral palsy in Europe classification: (1) uni-
lateral; (2) bilateral * Osteomyelitis; ns: not scored; SE: Side-effects 
■: indication 
+: domain in which the improvement measured by VAS was noted 
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Six children (group A) were systematically evaluated at baseline, and 1 month 
and 6 months after treatment (table 4.1, table 4.3). In this group all assessments 
were performed by a physical therapist. The Modified Ashworth Scale (MAS) 
was used for the assessment of changes in muscle tone.22 In the MAS muscle 
tone is scored on a 6 point scale, in which “0” represents no hypertonia or no 
increase of muscle tone and “4” represents severe hypertonia and severe stiff-
ness of the extremities. In each patient hip flexion and adduction, knee flexion 
and extension, and dorsal and plantar flexion in the ankle were tested bilater-
ally. Functional improvement was assessed using the Gross Motor Function 
Measure (GMFM), a widely used scale consisting of 5 different locomotor do-
mains to evaluate treatment of spasticity in children with CP.23–25 Furthermore, 
we developed a more extensive questionnaire for caregivers. Besides items on 
pain, several items of daily activities of life, like dressing, undressing, and bath-
ing, were investigated. Data of the 6 systematically evaluated children were 
statistically analyzed using a students T-test and a Wilcoxon signed rank test. A 
p value of < 0.05 was considered to be statistically significant. All data are repre-
sented as means and standard error of means (SEM). 
 
Tabel 4.3 Ashworth scores of the first 6 patients: pre-operative, post-operative 4 weeks and 6 
months 
  Hipflexion Hip adduction Knee  
flexion 
Knee  
extension 
Ankle dorsal 
flexion 
Ankle plantar 
flexion 
Pt  L R L R L R L R L R L R 
1 Pre 1+ 1+ 1 2 1 2 0 0 3 3 0 0 
 Post4w 1 1 0 0 1 1 0 0 2 2 0 0 
 Post6m 1 0 1 1 1 0 0 0 3 2 0 0 
2 Pre 0 0 1 3 0 0 1 1 3 3 0 0 
 Post4w 0 0 1 1 0 0 1 1 1 1 0 0 
 Post6m 0 0 1 1 0 0 0 0 1 1 0 0 
3 Pre 0 1 1+ 2 1 1 2 2 3 3 0 1 
 Post4w 0 1+ 1+ 1 1+ 1 2 1+ 2 2 0 0 
 Post6m 2 1 2 1 2 1 0 0 2 2 0 0 
4 Pre 0 0 1 1 1+ 1+ 3 3 0 0 1 1 
 Post4w 0 0 0 0 2 2 0 0 1 0 0 0 
 Post6m 1 1 0 0 2 2 0 0 1 1 0 0 
5 Pre 2 0 0 1 0 1+ 2 2 2 2 1+ 1+ 
 Post4w 1 1 0 1 1 2 1 4 1 1 2 3 
 Post6m 2 0 0 0 2 4 0 0 2 3 0 0 
6 Pre 3 3 4 4 4 4 4 4 4 3 4 3 
 Post4w 0 0 1 0 3 1 2 3 2 1+ 2 2 
 Post6m 3 3 4 3 3 3 0 0 4 4 4 4 
Mean Pre 1 0.83 1.33 2.17 1.17 1.5 2 2 2.5 2.33 1 1 
 Post4w 0.33 0.5 0.75 0.5 1.33 1.17 1 1.5 1.5 1.17 1.67 0.83 
 Post6m 1.5 0.83 1.33 1.0 1.67 1.67 0.17 0 2.17 2.17 0.67 0.67 
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The subsequent 11 children (group B) were evaluated at 6 weeks and 3 months 
using a Visual Analogue Scale (VAS; figure 4.1), which was used to measure the 
severity of the individually formulated problems. We changed the evaluation 
methods, as we were not able to detect the kind of change that the caregivers 
unanimously did notice. Furthermore, literature had become available which 
showed that the MAS and the GMFM are not indicated to measure changes in 
these severely handicapped children.26–28 Instead we used a VAS, which is a 
valid pain-rating instrument.29 The VAS used in pain assessment is a straight 10 
cm horizontal line with anchor points of no pain (score 0) and unbearable pain 
(score 10). For our study we changed the anchor points into very satisfied 
(score 0) and very dissatisfied (score 10) to use the VAS uniformly for individu-
ally defined problems.30, 31 A VAS score for spasticity, pain, and ease of care was 
given by the caregivers, since the majority of the patients with CP were severely 
mentally handicapped. Usually the patient and his/her caregiver(s) are the best 
judges of the severity of the impairments accompanying spasticity, as they are 
the only people who can assess its impact on the daily life of the patient.32 Care-
givers of children with profound impairments note changes in function far more 
accurately than staff workers.33 
 
 
 
Figure 4.1 The VAS device 
Score 0 / “geen”: Very satisfied 
Score 10 / “meest”: Very dissatisfied 
RF-DRG procedure 
All patients were treated in our outpatient clinic, and RF-DRG was performed as 
described.12, 34 Under general anaesthesia, the patients were placed in prone 
position on an operating table. The level to be treated was based on clinical 
symptoms; afterwards stimulation was used to verify these levels. 
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The procedure was performed in tunnel vision, a technique for entering the 
electrode in the direct vision of the X-rays. Therefore, the C-arm (Ziehm elec-
tronics) was adjusted in such a way that the X-rays ran parallel to the end plates 
of the relevant level. Thereafter, the C-arm was rotated until the processus spi-
nosus projected over the contralateral facet column. With the C-arm in this pro-
jection, the injection point was found by projecting a metal ruler over the lateral 
part of the foramen intervertebrale. 
A 10-cm long, 22-G needle SMK-5 mm tip was inserted locally in the direc-
tion of the X-rays. Thereafter, the direction was corrected in such a way that the 
needle was being projected as a point on the screen. The direction of the radia-
tion beam was now modified to a profile (lateral) view, and the needle was in-
serted until the point was located in the craniodorsal part of the foramen in-
tervertebrale (Figure 4.2a). 
 
 
Figure 4.2 Photomicrograph showing the position of a RF electrode a: lateral view and b: anterior-
posterior view after injection of Omnipaque. 
 
In an AP view, the course of a small amount of contrast agent was followed with 
“real-time imaging”; it should spread out laterocaudally along the spinal nerve 
(Figure 4.2b). The stylet was removed and exchanged for the radio frequent 
probe. After checking the impedance (an indicator for the type of tissue next to 
the cannula tip), electrical stimulation was started at a rate of 2 Hz and the cor-
responding muscles were observed for contractions. At 2 Hz stimulation motor 
contractions should be observed in the area of the relevant muscles at a thresh-
old between 0.4 -0.8 Volts. 1 ml local anaesthetic solution (bupivacain 0.5%) 
was injected and radio frequent current was then led through the electrode in 
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order to increase the temperature to 67 0 C for 60 seconds. Total operating time, 
including anaesthesia, was about 45 minutes. All patients were discharged from 
the clinic the same day after full recovery from the anaesthesia. 
RESULTS 
A total of 19 RF-DRG treatments were performed in 17 patients. One patient 
received three interventions, as the effects gradually wore off. A summary of the 
clinical data, including treated levels and outcome measures, are given in table 
4.1 (group A: 6 patients) and table 4.2 (group B: 11 patients). In 2 patients a 
transient increase in pain after the RF-DRG procedure was noted, and 1 patient 
was successfully treated with Gabapentine for 4 weeks. No further side-effects 
(e.g. dysaesthesia or excessive weakness in the treated limbs) were reported. No 
significant differences were observed between the different lumbar levels for 
both the impedance and the stimulation threshold. 
Group A: In the first six systematically evaluated children (table 4.1) an im-
provement in muscle tone after RF-DRG was detected on both the short (4 
weeks) and long (6 months) term using the MAS. Especially the right hip adduc-
tors showed improvement on the MAS which went from 2.2 +/- 0.5 before RF-
DRG to 0.5 +/- 0.2 four weeks after RF-DRG and 1.0 +/- 0.4 six months after RF-
DRG (table 4.3). Due to the small sample size, no comment on the lack of signifi-
cance of a null result can be given. 
Using the GMFM no improvement was observed after RF-DRG treatment. At 
baseline a mean total score including all 5 domains of 17.2 % +/- 6 was found. 
After 4 weeks the score was 17.3 % +/- 7 and after 6 months the score was 16.2 
% +/- 6. 
Using the caregiver’s questionnaire, an improvement in ease and quality of 
care and pain was detected. Although statistically not significant, in four pa-
tients pain in the lower extremities decreased, at both 4 weeks and 6 months. In 
one patient there was no change in pain and in another patient pain increased at 
4 weeks but decreased at 6 months when compared to the baseline. 
Group B: Because of the abovementioned results we switched to a VAS to 
evaluate the initiated treatment in the subsequent patients. This score was 
available in 8 out of the 11 patients. The missing values are due to the fact that 
some caregivers did not feel comfortable judging their own child in a numerical 
way. During outpatient follow up, the evaluation of the VAS scores showed im-
provement in most of the defined treatment goals in most children (table 4.2). 
Most parents reported that the positive effects of the RF-DRG lasted at least 6–9 
months. 
In one patient (no. 9), the VAS score showed no change after the third pro-
cedure. Her flexor spasms were then successfully treated with Botulinum Toxin-
A injections in the iliopsoas and adductor muscles (Dysport, Ipsen). 
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DISCUSSION 
To test our hypothesis that RF-DRG may be a serious treatment option for se-
vere spasticity in children with CP, we undertook a pilot study in 17 patients. 
Our primary treatment goal was improvement of well-being and ease of care of 
patients with CP with severe hip flexor/adductor spasms and pain. Our first 6 
consecutively treated patients (Group A) were evaluated at baseline, 1 month 
after treatment, and 6 months after treatment using the GMFM and the MAS. We 
found a small improvement in muscle tone on the MAS, but no effect on the 
GMFM scale. Despite this, the caregivers of these six treated children unani-
mously stated that the quality of life of their children had indeed improved after 
the RF-DRG (data not shown, summary represented by +/- in table 4.1). This 
disagreement between the MAS and the judgement of the caregivers highlights 
the difficulties measuring change in these severely handicapped children. The 
MAS as a method for the evaluation of the treatment of spasticity in children 
with CP has been disputed before, although in adult populations the reliability of 
the MAS has been demonstrated.28 In a study in children with moderate to se-
vere spasticity, a wide variability in test-retest results was reported for the 
MAS.27 The assumption that the MAS exclusively measures spasticity is not en-
tirely right. The MAS measures a broader set of neural and musculoskeletal 
factors of non-velocity-dependent hypertonia in addition to spasticity itself.26 
Furthermore, we added up the MAS scores of different muscles to produce a 
summed Ashworth score, in order to compare with most previous studies. How-
ever, this might be methodologically incorrect as the Ashworth score is an ordi-
nal level measure.35 
For the next 11 patients we thus changed our evaluating system: instead of 
the MAS and the GMFM, we asked the caregivers to give a VAS score for spastic-
ity, pain, and ease of care at different time points. Using this outcome measure 
we were able to show a significant improvement in spasticity, pain, and ease of 
care after an RF-DRG procedure, lasting up to 9 months. In two patients we 
found a transient increase in pain, for which 1 patient received Gabapentine for 
4 weeks. This is a known transient procedure related event.36 Although this was 
not a controlled study, the amount of improvement in VAS scores is in the same 
range as in conventional treatments, e.g. ITB and SDR.30, 37 RF-DRG is thus a 
promising new treatment option for severe spasticity in patients with CP, and its 
definitive effectiveness remains to be defined in a randomized controlled trial. It 
is less invasive and probably has less side-effects than ITB and SDR, but its main 
disadvantage in this patient population is, of course, the temporary character of 
its effects. In this regard RF-DRG resembles BTX-A treatment, but its main ad-
vantage over this therapeutic option is its strong pain-reducing effect. Theoreti-
cally, repetitive RF-DRGs may lead to dysesthesias and causalgias, but we have 
not seen this in the one patient we treated three times.34 To prevent this possi-
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ble side-effect, more definitive effects of RF-DRG might perhaps be achieved 
with higher radiofrequency currents and temperatures during the procedure. 
Our pilot study does highlight the methodological problem of evaluating 
treatment effects in children with CP. As we were not able to conduct an exten-
sive battery of clinical tests in our pilot study, we had to select a few outcome 
measures. Using the MAS and the GMFM, we were not able to detect any benefi-
cial effects, which is in line with other studies.32 We had to resort to a VAS to 
find improvements in the condition of treated patients. In retrospect we should 
also have included the Pediatric Evaluation of Disability Inventory (PEDI), which 
is a generic standardized instrument used by the multidisciplinary team for 
evaluating functional performance, programme monitoring, documentation of 
functional development, and clinical decision-making.30, 37, 38 
The exact mechanism of action of an RF-DRG remains unknown. We recently 
reported an increase of proliferation inside the dorsal root ganglion after RF-
DRG adjacent to the ganglion without signs of neural tissue damage (e.g. necro-
sis) inside the ganglion.39 For years, the only mode of action of a radiofrequency 
lesion was thought to be through nerve damage due to thermocoagulation.40 
Recent experiments with pulsed radiofrequency treatment (a high-frequency 
current delivered in bursts of 20 ms followed by a silent period of 480 ms, dur-
ing which the generated heat is washed out) suggest that thermocoagulation is 
not the only mode of action.40, 41 A late and temperature-independent increase in 
the expression of the immediate early c-fos gene within the rat spinal cord was 
found after exposure of the cervical dorsal root ganglion to continuous radiofre-
quency (670 C) and pulsed radiofrequency current.42 In one model of spasticity, 
the locomotor abnormalities are thought to be the result of hyperexcitability of 
spinal interneurons involved in the spinal stretch reflex.43 Reduction of spinal 
input through de-afferentation is then the basic mechanism of RF-DRG. 
CONCLUSION 
Our pilot study on RF-DRG in 17 patients with CP with severe hip flexor/-
adductor spasms and pain shows that it may improve spasticity, pain, and ease 
of care, with a duration of up to 9 months. As the amount of improvement is in 
the same range as in conventional treatments, RF-DRG is thus a promising new 
treatment option for severe spasticity in patients with CP, and its definitive ef-
fectiveness remains to be defined in a randomized controlled trial. The main 
advantages are the less invasive character of RF-DRG compared to the SDR with 
the potential benefit of a shorter hospitalization period, and its clear pain-
reducing effect. 
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ABSTRACT 
Dyskinetic cerebral palsy (CP) is a movement disorder that is difficult to treat 
and which causes major disability. We report on two female patients (aged 5 
and 8 years) who experienced severe perinatal asphyxia and developed dyski-
netic CP, clinically characterized by choreoathetosis. 
Neuropsychological testing of these children showed a low average devel-
opmental quotient and no attentional deficits. Monotherapy with Levetiracetam 
(LEV) was initiated to improve balance control and fine motor skills. Treatment 
was evaluated by means of video analysis and the Visual Analogue Scale. In both 
children an impressive improvement of balance control and fine motor skills 
was observed. No side-effects occurred. Furthermore, both patients showed 
more interest for and pleasure during activities according to their parents. In a 
recent multidisciplinary evaluation of the initiated therapy, the parents, the 
therapist, and the rehabilitation doctor all confirmed that the effect initially 
observed was still present at 14 respectively 26 months after commencement of 
treatment. To our knowledge, this report on two patients with dyskinetic CP is 
the first suggesting that LEV may offer an alternative to the standard therapy of 
involuntary, uncontrolled movements in this group of patients. 
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BACKGROUND 
Cerebral palsy (CP) is a non-progressive disorder of posture or movement 
caused by a lesion of the developing brain. The Surveillance of Cerebral Palsy in 
Europe (SCPE) has classified CP into three main groups (spastic, dyskinetic, and 
ataxic), which are based on clear neurological signs indicating pathology of the 
cerebral motor systems (table 1.1).1 Dyskinetic CP presents with involuntary, 
uncontrolled, recurring, and, occasionally, stereotyped movements. The SCPE 
distinguishes between dystonic and choreoathetotic subtypes for dyskinetic CP. 
The pathophysiology of dyskinesia in CP is not fully elucidated, but existing 
evidence suggests that disorders of the basal ganglia (BG) play a role in this 
entity. 
The symptomatic treatment of this movement disorder is still very difficult. 
In a retrospective survey of 22 children with extrapyramidal CP, only a minority 
showed a functional improvement using trihexyphenidyl, which is a centrally 
active muscarinic antagonist.2 
Several anticonvulsants seem to be efficacious for the treatment of (parox-
ysmal) involuntary movement disorders. On the basis of a recent report about 
Levetiracetam (LEV) efficacy in the treatment of movement disorders, we start-
ed LEV in two patients with dyskinetic CP unresponsive to conventional drugs 
mostly used in such cases.3 
To our knowledge, this report on two patients with dyskinetic CP, is the first 
suggesting that LEV may offer an alternative to standard therapy of involuntary, 
uncontrolled movements in this group of patients. 
METHODS 
Informed consent of the parents was obtained for both patients. LEV was only 
started after the other available drugs usually prescribed had failed. Baclofen 
(GABA-agonist) and Artane (Muscarine-antagonist) were tried but did not show 
the desired effect. The initial dose of LEV was 2.5mg/kg/day. The dosage was 
titrated over weeks to months, based on response as well as tolerability. 
Cognitive functioning of both children was described using standardized in-
struments which could be used in children with serious disabilities, as formal 
testing with, for instance, the Wechsler Intelligence Scale for Children-III is not 
possible because of motor disabilities.4 We used the Peabody Picture Vocabulary 
Test - Third Edition (PPVT-III-NL)5 to describe receptive vocabulary, which is a 
commonly used screening test for verbal ability. Furthermore, a subtest from a 
standardized Dutch nonverbal intelligence test (subtest matrix analogies from 
the Snijders Oomen Nonverbal Intelligence Test)6 for which no motor response 
is necessary, was used. Using the Child Behavior Checklist (CBCL), which is a by-
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proxy instrument, general behavioural functioning, especially the existence of 
attentional problems, was assessed.7 
The patients were re-evaluated on a regular basis by an occupational thera-
pist, using video analysis. The parents regularly used the Visual Analogue Scale 
(VAS), an ordinal scale that ranges from 0 to 10, to score improvements on goals 
defined before treatment with LEV was started. The VAS is known as a valid and 
reliable measure for rating pain intensity in adults and children of more than 6 
years of age and has recently been found useful for evaluating therapy in chil-
dren with CP.8, 9 When clinicians are raters, the VAS validly identifies the mini-
mal clinically important difference on the Pediatric Evaluation of Disability In-
ventory.10 
Based on these two parameters combined with regular visits at our outpa-
tient department (LS and JSHV) a decision was made with the parents either to 
continue the drug or taper it off. 
Case 1 
A 5-year-old female experienced severe perinatal asphyxia (umbilical artery pH 
6.8). Pregnancy had been complicated by pre-eclampsia. Neurological examina-
tion was compatible with Sarnat II encephalopathy. During the first hours of life 
the infant experienced severe neonatal seizures, for which she was treated with 
midazolam. The electroencephalogram showed a burst suppression image with 
severe epileptic activity. MRI showed abnormal signal intensity within the basal 
ganglia and thalami. Furthermore, focal signal abnormalities in the posterior 
limb of the internal capsules were observed. 
From the beginning, she showed developmental delay and hypotonia. As 
time went by she developed a severe movement disorder characterized by in-
voluntary, uncontrolled, and occasional stereotyped movements, which can be 
classified as dyskinetic CP. Psychological examination showed that her vocabu-
lary quotient on the PPVT-III-NL was low average (quotient score 82). Matrix 
reasoning was in accordance with this level of verbal abilities (standard-score 
85). Her behaviour (reported by the parents using the CBCL) did not reveal sig-
nificant attentional problems. 
At the age of 5 years she was presented to the outpatient clinic for further 
treatment. The following goals were formulated: to improve sitting independ-
ently (balance control) and to improve grasping for and pointing towards ob-
jects (fine motor skills). Monotherapy with LEV was initiated, reaching a final 
dose of 5mg/kg/day. Raising this dose was suggested, but parents were satisfied 
since all the treatment goals were achieved. 
Evaluation of therapy and obtainment of VAS scores were carried out on a 
regular basis. After 3 months the child’s parents rated her balance control limi-
tations as 0 (before treatment: 8.2) and her limitations concerning grasping and 
fine motor skills as 3 (before treatment: 8.2). The patient is, for the first time in 
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her life, able to drink independently from a cup with two handles. Also, she is 
now able to bring a fork to her mouth after being handed the fork and she needs 
less assistance when colouring. The patient shows more initiative and pleasure 
during activities has increased according to her parents. At 6, 9, and 14 months 
after commencement of treatment VAS scores confirmed these improvements. 
Comparing videos before LEV treatment and 3 months after initiating medi-
cation, fewer fidgety movements of the trunk, less overextension of arms and 
hands during actions, and less (dystonic) co-movements of arms and mouth 
were seen. To our surprise she also showed marked improvement of speech and 
was now easier to understand. This was confirmed by a speech therapist. No 
side-effects were noted. 
In a recent multidisciplinary evaluation of the initiated therapy, the parents, 
the therapist, and the rehabilitation doctor all confirmed that the effect initially 
observed was still present 14 months later. 
Case 2 
An 8-year-old female was born by means of Ventouse delivery after normal 
pregnancy. She was suffering from severe peripartal asphyxia (pH 7.12) and had 
to be resucitated. 
From the beginning she showed developmental delay, axial hypotonia, con-
stant abnormal tongue protrusion, and abnormal spontaneous motor activity. At 
the age of 7 years she was re-evaluated. Neurological examination showed a 
cooperative child with good social contact, but with a severe dyskinetic move-
ment disorder, which, for example, made reaching for objects impossible. Fur-
thermore, an MRI was performed and showed abnormal signal intensity within 
the lateral thalami and in the dorsal putamen on both sides. 
Psychological examination showed that her vocabulary quotient on the 
PPVT-III-NL was in the low average range (quotient score 80). Her matrix rea-
soning was also low average (standard-score 78). CBCL behaviour report by the 
parents and teachers did not reveal significant attentional problems. 
Therapy with LEV was initiated to improve trunk balance and fine motor 
skills. The starting dose was 2.5mg/kg/day and was titrated to a final dose of 
10mg/kg/day. No side-effects were noted. 
Evaluation of therapy and obtainment of VAS scores were carried out on a 
regular basis. After 6 months, parents rated her balance control limitations as 5 
(before treatment: 7) and her fine motor skills limitations as 6 (before treat-
ment: 10). Again, the patient showed more interest in and pleasure during ac-
tivities according to her parents. 
Comparing videos before medication and 3 months after initiating medica-
tion one can see that she is now able to independently cut pieces of paper 
whereas before much assistance was needed. Both the number of uncontrolled 
movements and their ranges of motion decreased. 
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The child is now capable of holding a pencil with just three fingers and staying 
between the lines while previously she used her whole hand just to draw sev-
eral uncontrolled crude lines. While working on her computer she used to be 
able to click on a 5cm square, but this has now decreased to a 2cm square. 
In a recent multidisciplinary evaluation of the initiated LEV therapy, the 
parents, the therapist, and the rehabilitation doctor all confirmed that the effect 
initially observed was still present 26 months later. 
DISCUSSION 
The main difficulties for patients with choreoathetoid CP relate to their involun-
tary movements, which can be very powerful and extremely difficult to inter-
rupt, making purposeful movement impossible.11 In patients with Huntington 
disease, it was found that chorea, when moderate to severe, can cause major 
disability and have a significant negative impact on daily life.12 In Parkinson 
patients, it was found that dyskinesias are associated with a reduction of Quality 
of Life and with an increase in total health-related-costs.13 In children with cho-
reoathetoid encephalopathy after cardiac surgery, it was found that restrictions 
in the range of activities in which children participated (e.g. hobbies, clubs, 
sports) and difficulties in peer and sibling relationships led to poor total adap-
tive competence.14 
So one may conclude that choreoathetosis is a very disabling disease. Vari-
ous drugs have been tried but with no great success. We did not try the recom-
mended presynaptic and postsynaptic dopamine antagonists because of lack of 
experience. Furthermore, tetrabenazine is not available for the treatment of 
children in the Netherlands. 
To our knowledge, this is the first description of two patients with a non-
progressive, non-paroxysmal, dyskinetic movement disorder who have been 
treated with LEV to diminish choreoathetosis. 
Evaluation of LEV treatment was done both objectively, by video analysis, 
and subjectively, by VAS. After 6 months both video analysis and VAS showed 
that (limitations by) choreoathetosis had decreased while no side-effects had 
occurred. It is very unlikely that these positive effects are due to maturation or 
to training given the course over time. Reasons for not increasing the dose of 
medication any further were that parents felt that all the goals were accom-
plished and that adverse affects, like somnolence, obtundation, and Parkinson-
ism, of which they were informed beforehand, should be avoided.15, 16 
Based on the results achieved with these two patients we may conclude that 
LEV may be used as an alternative to treat unmanageable choreoathetosis of a 
non-progressive kind, e.g. in children with dyskinetic CP. This is important be-
cause choreoathetosis appears to be a very severe and disabling condition 
which is difficult to treat. This could partly be due to the differences in patho-
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physiology between the two aspects of the condition, i.e. athetosis can be treat-
ed by increasing dopaminergic activity in the BG, while chorea can be treated by 
decreasing dopaminergic activity.2 
These findings and our results suggest that LEV might reduce choreoatheto-
sis by means of another pathway. So far, the synaptic vesicle protein SV2A has 
been identified as the binding site for LEV, but the molecular action of SV2A is 
still unknown.17 
Further and larger studies are needed to confirm the positive effects of LEV 
on choreo-athetosis in patients with a non-progressive, non-paroxysmal, dyski-
netic movement disorder. 
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ABSTRACT 
Objective 
This study examined the validity and efficacy of the Visual Analogue Scale (VAS) 
when evaluating spasticity treatment in an outpatient setting. 
 
Patients and methods 
We used a parent-reported VAS device to evaluate the effects of Botulinum Tox-
in A (BTX-A) treatment. Data were collected on 55 children with cerebral palsy 
(CP). Individual goals of treatment were formulated in close consultation with 
the caregivers. The categories of treatment options were improvement of pain, 
problems with nursing, sitting position, standing, and walking. 
 
Results 
Seventy-four interventions were performed in 55 children with CP. A statisti-
cally significant effect was found for improvement of nursing, standing, and 
walking. No statistically significant effect for pain was found, probably because 
of small numbers. In seven children there was no effect at all. Side-effects were 
observed in five children. A positive (not significant) correlation was found be-
tween the VAS and the Modified Tardieu for those children who also underwent 
gait analysis. 
 
Conclusion 
Using a VAS device, beneficial effects were found for nursing, standing, and 
walking after BTX-A treatment. Evaluating spasticity treatment by use of the 
VAS has important advantages as it is a quick and easy method for evaluating 
individually defined treatment goals in an outpatient setting, in which time-
consuming evaluations are not an option. 
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INTRODUCTION 
Cerebral palsy (CP) is the most common cause of childhood physical disability. 
Its clinical presentation can be very diverse, although 70–80% of the patients 
have spastic clinical features.1 
Spasticity is a motor disorder characterized by a velocity-dependent in-
crease in muscle tone with exaggerated tendon jerks.2 Several studies have 
shown the benefits of intramuscular Botulinum Toxin Type A (BTX-A) injections 
for the management of spasticity in children with CP.3–5 Studies indicate that 
parents of children with CP consider BTX-A treatment to be an acceptable form 
of therapy.6 
BTX-A inhibits cholinergic transmission at neuromuscular synapses and re-
laxes muscles. Clinical effects are usually observed after 2–5 days and last for 
16–24 weeks.7–9 Although evaluation of therapy is essential, there is no quick 
and easy to use outcome measure available to evaluate the effects of BTX-A in-
jections in spastic children in daily clinical practice. In spite of its clear limita-
tions, the standard clinical scale for measuring spasticity at function level of the 
International Classification of Functioning, Disability, and Health (ICF, WHO 
2001) is the Ashworth Scale.10 However, the Ashworth Scale does not measure 
spasticity exclusively, it has low inter-rater reliability, and it lacks precision and 
sensitivity for measuring smaller changes in spasticity.11–13 
Although the Gross Motor Function Measurement (GMFM) is widely ac-
cepted as the best available quantitative measure for gross motor function in CP 
at activity level of the ICF, it is of limited value when determining functional 
benefits in severely affected children.14 
In our outpatient clinic patients with different degrees of severity of CP are 
seen. Goals for BTX-A treatment are defined together with parents or caregivers 
and the children themselves. To quantify their satisfaction in functioning within 
these goals, a Visual Analogue Scale (VAS) is used. This is a subjective measure 
in which caregivers or children themselves are able to assess their level of func-
tioning with regard to sitting, standing, and walking (activity level of the ICF). In 
more severely affected patients pain or ease of caregiving can be rated with the 
VAS. In ICF terms, this will influence participation and quality of life. 
In this article, the results of BTX-A injections on nursing, sitting, standing, 
walking, and pain in a group of children with CP as evaluated by means of the 
VAS are presented. Furthermore, correlations will be made between the VAS, a 
subjective measure, and more objective measures at function level of the ICF in 
patients able to walk. 
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PATIENTS AND METHODS 
In order to evaluate our daily clinical practice, we prospectively collected data 
on 55 children with CP (25 males; 30 females) with a mean age of 8.3 years (SD 
3.3) at the moment of the first intervention (table 6.1). Patients were carefully 
selected for BTX-A treatment by a multidisciplinary team of specialists (LR, LS, 
JV, and physiotherapists). Depending on the individually formulated goals the 
target muscle groups for treatment were defined. The treatment goals are 
shown in table 6.2. Children were included for treatment only after informed 
consent of the caregivers. 
 
Table 6.2 Defined intervention goals 
 GMFCS Walking Pain Nursing Standing 
Diagnosis      
 Unilateral 1 12 1 - 2 
 3 1 - - - 
 Bilateral 1 6 1 - - 
 2 11 - - - 
 3 14 - 5 4 
 4 11* 1 6 4 
 5  1 13 5 
* Indoor walking and transfer 
Intervention 
The children received BTX-A injections (Dysport, Ipsen) under general anaes-
thesia in the day-care department of the Maastricht University Medical Centre 
(LR, LS, and JV). Each patient was given an individual clinical examination in 
order to determine which muscles to inject. Spastic hypertonia of a specific 
muscle disturbing strength and/or function or causing pain or difficulty in care-
giving was a criterion to inject. The target muscles were located with the help of 
electrical stimulation. 
Maximum dosage: 23 MU/kg bodyweight, limited to no more than 400 units 
per limb, within an overall maximum dose of 1200 MU per session. After treat-
ment, all children were discharged on the same day and they continued with 
their physical therapy. They were followed up at the outpatient clinic 6 and 12 
weeks after intervention. 
Outcome measures 
Individual goals of treatment were formulated in close consultation with the 
caregivers. The categories of treatment goals were improvement of pain, prob-
lems with nursing, sitting position, standing, and walking. 
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The VAS was used to measure the severity of the individually formulated prob-
lems. The VAS is a valid and reliable measure in rating pain intensity.15 The VAS 
used in pain assessment is a straight 10cm horizontal line with anchor points of 
no pain (score 0) and unbearable pain (score 10). We changed the anchor points 
into very satisfied (score 0) and very dissatisfied (score 10) in order to use the 
VAS uniformly for the individually defined problems. On the day of the interven-
tion, one of the authors (LS or JV) asked the caregivers to define their goal of the 
treatment and to assess their VAS score. The instrument used to rate the VAS 
score is shown in figure 6.1. 
 
 
 
Figure 6.1 The VAS device 
‘Geen’ ¼ very satisfied (score 0), ‘Meest’ ¼ very dissatisfied (score 10). 
 
We correlated the VAS with a Passive Range Of Motion (PROM), Angle Of Catch 
(AOC) and the Modified Tardieu for children who were able to walk. 
Follow-up of each child took place at 6 and 12 weeks after intervention and 
a VAS score was rated. For statistical analysis the most improved post-treatment 
VAS score was used. 
The caregivers were not informed about their pre-treatment score. Fur-
thermore, information about side-effects and complications was collected. 
Statistical analysis 
The data were analyzed using SPSS 11.0.l. We used a paired sample t-test to 
compare the pre- and post-treatment VAS scores. One-way Anova was used to 
analyze sex differences affecting the dependent measures caregiving, standing, 
walking, and pain perception. One-way Anova was also used to test differences 
in aetiology and type of CP related to the effect of intervention on dependent 
measures. In order to calculate the correlations between the VAS and the PROM, 
AOC, and Modified Tardieu, we used the Spearman’s rho. 
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RESULTS 
Seventy-four interventions were performed in 55 children. In tables 6.1 and 6.3, 
the main clinical characteristics of the children included are shown. The mean 
age at the first intervention was for both girls and boys 8.3 years. Most of the 
children treated were premature born children (32 out of 55) with bilateral 
spastic CP (29 out of 32). 
 
Table 6.3 Diagnosis, GMFCS, aetiology and sex of the treated population 
  Aetiology  
 GMFCS Premature Asphyxia Other Total 
  Male Female Male Female Male Female  
Diagnosis         
Unilateral 1  1  2  1 3 5 12 
 3      1  1 
Bilateral 1  2  1    1  4 
 2  2  4 1 1  1  9 
 3  7  6   1  14 
 4  3  3   1   7 
 5  1  2 3 1 1  8 
 
 Total 16 16 3 5 6 9 55 
 
The number of interventions, the number of muscles treated, and the total dose 
of BTX-A used are shown in table 6.1. 
Most interventions were bilateral (60 out of 74) and multilevel (50 out of 
74). In some children, more than one goal was formulated by the caregivers. The 
most frequently formulated goal was improvement of walking (56 times), fol-
lowed by nursing (24 times) and standing (15 times). Improvement of pain as 
an initial goal was formulated only 4 times. 
In table 6.4 the results of a paired sample t-test are shown, comparing pre- 
and post-treatment related to the outcome variables. A statistically significant 
effect is found for improvement of care (p≤0.000), standing (p≤0.000), and 
walking (p≤0.000). No statistically significant effect is found for pain (p=0.180) 
probably because of small numbers. 
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Table 6.4 Mean, standard deviation and significance comparing pre- and post treatment VAS scores 
on the variables caregiving, standing, walking and pain 
Variable N Pre-treatment Post-treatment Difference t-value 
  Mean SD Mean SD Mean SD  
Walking 56 6.62 1.61 3.27 1.56 3.35 2.41 10.40*** 
Pain  4 6.58 2.34 3.03 3.13 3.55 4.07 1.74n.s. 
Care 24 6.68 1.50 3.12 1.63 3.57 2.13 8.22*** 
Standing 15 6.89 2.04 3.22 1.60 3.67 1.96 7.27*** 
n.s. not significant; * p < 0.05; ** P < 0.01; *** p < 0.001 
 
Using an one-way Anova no statistically significant sex differences were found 
in treatment effect: boys reacted the same as girls to the outcome variables. 
Furthermore, no significant differences were observed between aetiology (pre-
term birth versus term asphyxia). Statistical analysis comparing diagnostic 
groups (unilateral versus bilateral spastic CP) on the outcome variables could 
not be performed because of the small number of cases. 
In table 6.5, the Spearman correlations between VAS scores (walking) and 
three clinical examinations of tone (PROM, AOC, and the Modified Tardieu) are 
presented. The following muscles were tested: quadriceps femoris, hamstrings, 
soleus, and gastrocnemius. In most cases, interventions were mainly restricted 
to gastrocnemius and hamstrings. Therefore, only these data could be analyzed. 
As we expected a positive relationship, an one-tailed test was used. Both PROM 
and AOC are not significantly correlated to the VAS. The VAS was positively cor-
related to the PROM for both muscle groups and to the AOC for the hamstrings. 
There was a negative correlation between the VAS and the AOC of the gas-
trocnemius. The Modified Tardieu was positively related to the VAS for all mus-
cles investigated and significant for the left gastrocnemius. 
 
Table 6.5 Spearman non-parametric correlation coefficient between VAS and PROM, AOC and Tar-
dieu for walkers wit a gait analysis 
 N ΔPROM ΔAOC ΔTardieu 
Gastrocnemius     
 Left 19 0.15n.s. -0.03n.s. 0.39* 
 Right 22 0.03n.s. -0.14n.s. 0.20n.s. 
Hamstring     
 Left 15 0.22n.s. 0.12n.s. 0.18n.s. 
 Right 18 0.24n.s. 0.13n.s. 0.07n.s. 
Δ : difference PROM, AOC and Tardieu (before and after treatment); PROM: passive range of motion; 
AOC: angle of catch; n.s. : not significant; * p < 0.05; ** P < 0.01; *** p < 0.001 
 
In seven children (12.7%) there was no effect at all. Side-effects were observed 
7 times in five children. One infant suffered from a flu-like illness and three had 
gastro-intestinal complaints: diarrhea (2) and constipation (1). In two children 
walking worsened and one child showed more instability during standing. In 36 
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of the 74 (48.6%), interventions a positive effect was observed for more than 12 
weeks. 
DISCUSSION 
We evaluated the effect of BTX-A treatment on spasticity in children with CP in 
our outpatient clinic. Using a VAS device we found a beneficial effect on nursing, 
standing, and walking after BTX-A treatment. In previous studies, the beneficial 
effect of BTX-A treatment on pain and function has been demonstrated.3–5 The 
effect of BTX-A on walking is not clear. In the Cochrane review of Ade-Hall no 
significant effect was found.16 In articles in which parental satisfaction with 
functional ability was measured, positive effects are reported.17, 18 The results in 
our study concur with the above mentioned studies. 
The main problem in studies evaluating spasticity treatment is the assess-
ment of spasticity. 
In a recent Cochrane review of anti-spastic agents for multiple sclerosis, the 
reviewers describe both the understanding of the pathophysiology and the abil-
ity to measure spasticity as seriously deficient.19 
The Ashworth Scale still is the golden standard for evaluating spasticity 
treatment today.10 The Ashworth Scale as a method for the evaluation of spastic-
ity has been disputed before, although in adult populations the reliability of the 
Ashworth Scale has been demonstrated.20 In a study in children with moderate 
to severe spasticity, a wide variability in test–retest results was reported for the 
Ashworth Scale.21 Furthermore, the Ashworth Scale does not comply with the 
concept of spasticity, i.e. a velocity-dependent increase in muscle tone.13 
In our study, we did not routinely use the Ashworth Scale for the assess-
ment of the treated children because of the above mentioned reasons. 
For measuring gross motor function in CP, the GMFM is widely accepted as 
the best available quantitative method. However, it is of limited value when 
determining functional benefits in severely affected children.14 
The Tardieu Scale (TS) is a very comprehensive, but very time-consuming 
method to assess patients. Therefore its feasibility is questioned, especially for 
use in children.13 The ‘dynamic component’ is a measure derived from the TS 
and is a clinical measure of spasticity according to the literature.17 It can be cal-
culated as the difference between the PROM at a very slow passive stretch and 
the AOC at a fast velocity stretch. However, it has been shown that the calculated 
difference adds together the variances of both joint angles, resulting in very 
wide inter-sessional variations.22 Therefore, it is probably better to compare the 
PROM and the AOC separately before and after treatment.13 
Table 6.5 shows the correlations of the differences found with PROM, AOC, 
and the dynamic component with the differences found with the VAS. Although 
a positive correlation was found most of the time, it is clear that there is a sub-
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stantial difference between the currently used standards for evaluating spastic-
ity and the VAS which measures the impact of the treatment on the daily life of 
the patient and caregiver. 
The VAS is a valid and reliable measure for rating pain intensity in adults 
and children over 6 years of age.15 In adults it has also been used for measuring 
satisfaction, feelings, quality of sleep, dyspnea, emotional function, fatigue and 
appeared to be responsive and valid.23–26 In pediatric patients, aged 5–17 years, 
the VAS has also been applied to measure anxiety, sadness, anger, worry, happi-
ness, and fatigue.27, 28 The VAS showed preliminary reliability and validity for 
both child self-report and parent-proxy report.28 When clinicians are raters, the 
VAS validly identifies the minimal clinically important difference on the Pediat-
ric Evaluation of Disability Inventory.29 
Evaluating spasticity treatment with the use of the VAS has several impor-
tant advantages. First, it is a quick and easy method for evaluating treatment in 
an outpatient setting, in which time-consuming evaluations are not an option 
and where there is a need for such an instrument.11 Secondly, it is a subjective 
measure of the effects that BTX-A treatment has had on individually chosen 
goals. Usually the patient and his/her caregiver(s) are the best judges of the 
severity of the spasticity, as they are the only people who can assess its impact 
on the daily life of the patient.30 It is known that caregivers of children with 
profound impairments note changes in function far more accurately than staff 
workers.31 
In spasticity after a spinal cord injury, it has been recommended to use both 
the VAS and other clinical evaluation methods (Modified Ashworth Scale) before 
starting therapeutically interventions.32 Another method for outcome meas-
urement is Goal Attainment Scaling (GAS), introduced in the late 60’s by Kiresuk 
and Sherman.33 An individual goal scale for each patient is developed during an 
interview. Outcome is measured on a 5-point scale. The GAS can be adminis-
tered by unqualified persons, nevertheless some training is advocated. Although 
the GAS is found to be an appropriate scale for the evaluation of outcome after 
intervention, the scale development time (first goal setting) is estimated at 45 
minutes.34, 35 In a busy outpatient clinic the scale development time of the GAS is 
at a clear disadvantage compared to the quick assessment with the VAS used in 
our study. Possibly, a further study could be set up to correlate the VAS with the 
GAS. 
Our study results show that the VAS, although subjective, is a valid, easy, 
and quick method for evaluating spasticity treatment in an outpatient setting. 
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CONSTIPATION AFTER BOTULINUM TOXIN-A 
INJECTIONS IN LOWER AND UPPER LIMB 
MUSCLES:  
A transitory systemic autonomic adverse 
effect. Report of three cases. 
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ABSTRACT 
We report three patients who developed transient constipation after receiving 
therapeutic doses of Botulinum Toxin-A (BTX-A) for spasticity of the lower 
limbs (two cases) and the upper limb (one case). Constipation was observed 
within the first week after treatment. In all three cases, this symptom resolved 
completely and almost simultaneously with disappearance of the therapeutic 
effects of BTX-A. None of the patients had previously received BTX-A injections. 
Two patients received a second treatment and both presented the same auto-
nomic cholinergic remote symptoms. The third patient refused a second treat-
ment due to the complication noted earlier. Familiarity with this autonomic 
systemic side-effect of BTX-A is essential for those who treat patients already at 
risk for gastro-intestinal dysfunction. Because the adverse effects were treatable 
and transitory, we believe that constipation per se is not an absolute contra-
indication, if from a therapeutic point of view, BTX-A is indicated. 
 
 
 
C O N S T I P A T I O N  A F T E R  B T X - A  I N J E C T I O N S  
 83 
INTRODUCTION 
In the past 20 years, Botulinum Toxin-A (BTX-A) has been used for a wide spec-
trum of therapeutic and cosmetic indications, whether or not approved by the 
Food and Drug Administration (FDA).1 One of such indications not approved by 
the FDA, but widely studied and reported in the medical literature, is spasticity 
due to cerebral palsy (CP)2–4 or due to acquired brain injury.5–7 
BTX-A prevents presynaptic release of acetylcholine at the neuromuscular 
junction and as a result chemodenervation develops in the injected muscle.8, 9 
The toxin, in therapeutic doses, is considered to be effective and safe. Remote 
adverse effects are rare and include flu-like symptoms, anaphylactic reactions, 
and excessive fatigue.10 Nevertheless, treatment of spasticity due to CP with 
BTX-A can be limited by the escape of the toxin from the muscle causing local 
and distant side-effects. 
We report three cases of patients suffering from severe spasticity, who re-
peatedly experienced a period of constipation as an important and disabling 
systemic autonomic cholinergic side-effect after BTX-A treatment for spasticity. 
Case 1 
An eleven-year old boy, suffering from spasticity and epilepsy due to CP, was 
referred to the outpatient clinic because of impaired mobility and nursing prob-
lems. Clinical examination showed a severely mentally handicapped boy, who 
was able to assist while being transferred from bed to wheelchair and even to 
make some steps if supported. Furthermore, body hygiene and dressing were 
hindered by hip adductor spasms. The possibility of treating the patient with 
BTX-A injections was discussed with his parents, and the following treatment 
goals were defined: to facilitate nursing and to improve mobility. 
We determined the muscles to be injected by clinical examination. Spastic 
hypertonia of a specific muscle leading to functional limitations was the crite-
rion to inject. 
Therapy was initiated with informed consent of the parents. The child re-
ceived BTX-A injections under general anaesthesia in the day-care department 
(JV). The target muscles were identified by muscular electrical stimulation. 
Dysport® from Ipsen was used according to the recommended maximum dos-
age: 23 IU/kg bodyweight, limited to no more than 400 units per limb, within an 
overall maximum dose of 1200 IU per session, with a dilution of 500 units in 2 
ml NaCl 0.9%. The child’s bodyweight was 25 kg. The adductor longus, sem-
itendinosus, semimembranosus, and soleus muscles were injected with 50 IU of 
Dysport® each, and the gastrocnemius muscles with 100 IU (total dose 600 IU). 
The patient was seen at our outpatient clinic at 6 and 12 weeks after the in-
tervention. We evaluated the effects and side-effects by means of a standardised 
questionnaire. Caregivers had to fill out a list with all side-effects possible. The 
C H A P T E R  V I I  
 84 
Visual Analogue Scale (VAS), an ordinal scale that ranges from 0–10 with 0 be-
ing the optimal situation and 10 the worst situation, was also used to evaluate 
the intervention.12 During follow-up, the mother observed an improvement on 
mobility (pre-treatment VAS: 5, post-treatment VAS: 1.3) and on facilitation in 
nursing (pre-treatment VAS: 4, post-treatment VAS: 2.2). However, as a remark-
able side-effect she reported severe constipation, starting 4 days after the 
treatment, for which medication (macrogolum) was necessary. 
The positive effects on mobility and nursing facilities lasted for more than 3 
months and with lessening of these positive effects, the gastro-intestinal dys-
function wore off. After 4,5 months the clinical therapeutic effect was no longer 
detectable and at the same time macrogolum could be withdrawn. 
One year after the first intervention there was a new request for repeated 
treatment because of increasing nursing and mobility problems. After a careful 
examination and discussing the systemic side-effect of constipation observed 
the first time, a decision was made to repeat the initial treatment. Under the 
same conditions and with a bodyweight of 30 kg, the same muscles were in-
jected with the same dose. The defined goals were reached but the same sys-
temic gastro-intestinal side-effect of constipation was observed. Again, as the 
positive effects on mobility and nursing diminished, the side-effect faded away. 
Case 2 
This 19-year-old male was admitted to the rehabilitation department four 
months after a severe head trauma with diffuse axonal injury leading to im-
pairments of his cognitive functions, speech, and locomotion. At admission the 
patient presented a tetraplegia with generalized spasticity (Modified Ashworth 
Scale - MAS - 2 and 3) of upper and lower limbs, accompanied by a severe dimin-
ished range of motion of the knee and ankle joints bilaterally. Orthotic treatment 
was initiated. The patient was unable to stand and walk and was dependent for 
all transfers. During the rehabilitation program he eventually developed painful 
spasms in both legs. Oral spasmolytic medication (Baclofen and Tizanidine) at 
maximal therapeutic doses was insufficient. Treatment with BTX-A was then 
discussed and the patient and his parents gave informed consent. He had never 
been treated with BTX-A before. 
One month after admission, the patient received his first BTX-A injection 
(Botox® from Allergan). The semitendinosus, the semimembranosus, and the 
biceps femoris muscles of the left leg were treated with 100 units of Botox® 
each; 300 units in total (maximum recommended doses by the manufacturer: 
600 units) in a dilution of 100 units in 5 ml NaCl 0.9%. Approximately 6 days 
after the injections a significant reduction of the muscle tone of the left leg was 
observed. The painful spasms disappeared. About 10 days after the treatment 
the patient reported severe constipation accompanied by abdominal pain. 
Treatment with laxatives (Bisacodyl and lactulose) was necessary. After two 
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months, the intestinal function improved and at the same time the therapeutic 
effect of BTX-A diminished, although the range of motion could be maintained 
with orthotic support. 
Four months after the first treatment a second treatment with BTX-A was 
given, aiming to reduce the severe hypertonia of the calf muscles of the right leg. 
The following therapeutic scheme was used, with the same dilution as before: 
gastrocnemius muscle: 140 units and soleus muscle: 60 units. Within one week 
after BTX-A treatment the muscle tone of the right lower leg decreased substan-
tially and a corrective orthosis for the ankle joint could be fitted. Almost simul-
taneously with the reduction of the muscle tone in the leg the patient again 
complained about constipation. He also reported tiredness and difficulty with 
swallowing. Treatment with laxatives was started again. After one month the 
constipation wore off and the medication could be withdrawn. This time the 
reduction of muscle tone lasted for six weeks after BTX-A therapy. 
Electromyography of distant muscles of the upper limbs could not be per-
formed due to the severe spasticity. 
In view of the generalized character of the spasticity it was decided to treat 
this patient with intrathecal Baclofen (ITB). After a successful therapeutic trial 
one year ago a Synchromed® infusion system was implanted. At the time of this 
report the spasticity remains under control (MAS 1) and so far no systemic 
complaints have been reported. 
Case 3 
A 19-year-old woman sustained severe brain injury after a ten meters fall. The 
Glasgow Coma Score at admission to the Intensive Care Unit was 6. Magnetic 
resonance imaging of the brain showed diffuse contusional lesions and oedema. 
Furthermore, she presented a lesion of the third cranial nerve and multiple frac-
tures of the pelvis, left clavicle, acromion, and several ribs. A splenectomy had to 
be performed due to a spleen rupture. The hospital stay was complicated by a 
pulmonary embolism and a deep venous thrombosis. She also developed het-
erotopic ossification at the left hip and the right knee. Half a year later, the pa-
tient was referred to the rehabilitation centre for further treatment. At admis-
sion the patient presented a hypertonic tetraplegia, with limited range of motion 
of the left elbow and both knees. She was not able to stand without support and 
was unable to walk even with walking aids or manual assistance. She was oth-
erwise incontinent for urine and completely dependent for all daily activities, 
including eating and personal hygiene. 
The MAS was 2 for the right arm, and 1 for the left arm and both legs. How-
ever, the spasticity of the left arm increased during the following months to a 
MAS 3, but patient’s mother refused pharmacological treatment either with 
systemic spasmolytic medication or local neuromuscular blocks. Intensive phys-
ical therapy and orthotic management for the elbow and knee contractures re-
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sulted in a slight improvement of the range of motion of the right arm and the 
knees. Nevertheless, the muscle tone of the left arm increased further, causing 
painful spasms of the arm. Eventually, one year after trauma, patient’s mother 
gave her consent for treatment of the left arm with BTX-A injections. Dysport® 
(Ipsen) was used in a volume of 2.5 ml per vial of 500 units. The left biceps mus-
cle was injected at two sites with 150 units of Dysport® each and the brachiora-
dial muscle with 200 units; 500 units in total. 
The patient was evaluated two weeks after the injections. A remarkable re-
duction of the spasticity of the left arm flexors was seen (MAS 1). She was able 
to dissociate flexor and extensor movements selectively. However, the mother 
reported that three days after BTX-A treatment her daughter was hindered by 
severe constipation and was feeling more tired than usual. She also noticed that 
speech articulation and swallowing had become more difficult. At first, the con-
stipation responded positively to treatment with Bisacodyl. However, the pa-
tient decided on her own to withdraw the medication and the constipation ap-
peared again. After resuming the Bisacodyl one week later, the constipation 
wore off. These symptoms persisted during three months. The therapeutic effect 
on the left arm lasted for five months after the initial BTX-A treatment. Because 
of the aforementioned complication, the patient and her mother refused a sec-
ond injection. At the last control visit, two years after trauma, the range of mo-
tion of the left arm was maintained with orthotic support and the elbow flexors 
showed a MAS of 2. She reported no gastrointestinal nor swallowing complaints. 
DISCUSSION 
Although the therapeutic goals were reached in all three patients, they repeat-
edly showed severe constipation as an autonomic side-effect after treatment 
sessions with BTX-A injections. As the colon is not in close proximity to the in-
jection sites, this symptom is likely related to a systemic effect of BTX-A. We 
have performed this treatment in over 50 children and over 200 adults. After 
each intervention, a list with all possible side-effects had to be filled out by the 
patient or by the caregiver. All these data were entered into a database. Al-
though in 10 patients side-effects occurred, only in these three patients consti-
pation was reported during evaluation. 
The action of BTX-A appears to be limited to cholinergic terminals where 
BTX-A inhibits release of acetylcholine and co-transmitters in both somatic and 
cholinergic autonomic terminals.8, 9 In the first patient described a slow repeti-
tive stimulation of a motor nerve (RNS) was performed in order to investigate 
the presumed systemic reaction on BTX-A (figure 7.1). Electromyographic re-
cordings were made from the hypothenar while stimulating the ulnar nerve at 
the wrist. The amplitude of the initial response was normal, but after prolonged 
3 Hz stimulation a slight decrementing response occurred. An average of 11% 
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decrement in amplitude was visible from sixth to eighth compound muscle ac-
tion potentials. This indicates that fewer muscle fibers responded to nerve stim-
ulation during a train of stimuli, due to generalized blockage of acetylcholine 
release in nerve terminals. The patient did not show generalized weakness. 
 
 
Figure 7.1 In the first patient described a slow repetitive stimulation of a motor nerve (RNS) was
performed in order to investigate the presumed systemic reaction on BTX-A. EMG recordings were 
made from the hypothenar while stimulating the ulnar nerve at the wrist. The amplitude of the 
initial response was normal, but after prolonged 3 Hz stimulation a slight decrementing response
occurred. An average of 11% decrement in amplitude was visible from sixth to eighth compound 
muscle action potentials. This indicates that fewer muscle fibers responded to nerve stimulation 
during a train of stimuli, due to generalized blockage of acetylcholine release in nerve terminals. The
patient did not show generalized weakness. 
 
The efficacy of BTX-A in children with adductor spasticity was demonstrated in 
a randomized controlled trial by Mall et al. using the Goal Attainment Scale.3 The 
safety profile of BTX-A (Dysport®) in patients with muscle hypertonia was ret-
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rospectively studied by Bakheit et al. and they reported adverse events in only 
7% of treatment.13 Incidence of adverse effects was related to the total dose 
rather than the dose calculated on basis of body weight. The highest incidence of 
adverse events was observed in patients who received more than 1000 IU of 
BTX-A per treatment session. Constipation as a remote autonomic side-effect 
was not reported in this publication. 
Autonomic function as a measure of side-effects using Dysport® in a range of 
doses (18–44IU/kg) was studied by Robertshaw et al.14 Their hypothesis was 
that BTX-A might reduce parasympathetic activity and, therefore, cardiac vari-
ability. They conclude that BTX-A is safe using the standard dosage. Only 1 out 
of 30 children had distant side-effects, which lasted for 6 weeks. Constipation 
was not mentioned as a side-effect. 
Autonomic side-effects occur far more often after Botulinum Toxin-B (BTX-
B).15 In a group of 30 patients (24 cervical dystonia; 6 hyperhidrosis) constipa-
tion was observed as a remote side-effect in 3 patients. 
In a double blind randomized trial, autonomic function after BTX-A or B was 
studied in patients with cervical dystonia.16 More patients treated with BTX-B 
showed constipation as compared to those treated with BTX-A (3/9 vs 0/11). 
In a retrospective study, constipation as a side-effect of BTX-A (Botox®) 
treatment on upper limb impairment and function was observed in 1 of 18 pa-
tients (aged 2–17 years).17 Furthermore, severe dysphagia has been reported as 
a remote side-effect of BTX-B treatment of the lower limbs and lumbar paraspi-
nal muscles in a 29-year-old woman.18 
Our patients repeatedly showed constipation as an adverse remote effect in 
response to BTX-A interventions. An explanation for this individual sensitivity is 
difficult. Probably it is in line with the observed interpersonal variability in au-
tonomic ratio (AR) as described by Robertshaw et al. studying the effects of 
BTX-A on ECG parameters.14 This study reported that the child suffering from 
distal side-effects for 6 weeks, had the lowest AR. 
Dysfunction observed in the gastro-intestinal tract is not uncommon in neu-
rologically handicapped patients. The enteric nervous system contains more 
neurons than the spinal cord.19 Therefore, it is not surprising that generalized 
insults to the central nervous system (i.e. asphyxia or ischemia) may result in 
significant neural dysfunction in the gastro-intestinal tract as is shown for the 
spinal cord.20 On the other hand, feeding and intake problems may result from 
various (motor)problems other than the increased muscle tone observed in 
these patients. However, from a clinical point of view there is a strong indication 
that the gastro-intestinal problems in these 3 patients appeared in connection 
with the BTX-A treatment. 
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CONCLUSION 
We conclude that severe constipation may be an autonomic systemic side-effect 
of BTX-A treatment due to blockade of autonomic neurons via systemic spread. 
Knowledge of this possible side-effect is important for those who treat patients 
already at risk for gastro-intestinal dysfunction. A carefully taken clinical history 
during the treatment period makes prevention and management possible. Be-
cause the adverse effects were treatable and transitory, we believe that consti-
pation per se is not an absolute contra-indication if, from a therapeutic view 
point of view, BTX-A treatment is indicated. 
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ABSTRACT 
Background 
A couple of years ago, Hoving et al performed methodologically well-designed 
studies on ITB therapy in 17 children with intractable spastic CP. Follow-up 
showed positive effects on pain, ease of care, and mental health to be present 1 
year after pump implantation. 
Long-term results of ITB therapy in children with intractable spastic CP are 
limited, especially with regard to outcomes relevant to the patient and his / her 
caregivers. 
 
Aims 
The aims of this long-term follow-up study were threefold: I: to determine 
whether or not beneficial effects of ITB therapy are still present 6–9 years after 
commencement of treatment in the 17 children initially described by Hoving et 
al, II: to describe the course of these effects over time, and III: to investigate 
whether or not caregivers would still choose ITB therapy for their child consid-
ering the advantages and disadvantages they have experienced. 
 
Methods 
The parents of the 17 children filled out the Child Health Questionnaire (CHQ), 
current satisfaction on a Visual Analogue Scale regarding previous set treatment 
goals, a questionnaire concerning functioning of their child, and a self-made 
questionnaire. 
 
Results 
One parent did not return the CHQ questionnaire. Previous identified beneficial 
effects were found to still be present 6–9 years after commencement of treat-
ment. Minimal improvement can still be expected 12 months after pump-
implantation, especially for individually defined treatment goals and physical 
QoL. Ninety-four percent of the care-givers would choose for ITB treatment 
again. 
 
Conclusion 
This study shows that beneficial effects after ITB are still present 6–9 years after 
commencement of treatment in non-ambulant children. Minimal improvement 
can still be expected 12 months after pump-implantation, especially for indi-
vidually defined treatment goals. Ninety-four percent of the care-givers would 
choose for ITB treatment again.  
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INTRODUCTION 
Intrathecal baclofen (ITB) therapy is the direct administration of Baclofen into 
the intrathecal space by means of a neurosurgically placed cathether. The cathe-
ter is attached to a pump which is implanted subcutaneously or subfacially in 
the abdomen. This invasive treatment modality has been proven effective for 
the treatment of intractable spasticity in non-ambulant children with cerebral 
palsy (CP).1–4 ITB therapy has the large advantage of by-passing the blood-brain-
barrier (BBB). Orally administered Baclofen passes the BBB poorly and there-
fore results in high blood levels (hence side-effects) and almost undetectable 
cerebrospinal fluid levels of Baclofen (hence low therapeutic effect). When ad-
ministrating Baclofen intrathecally a hundredth part of the oral dose of Baclofen 
is sufficient to effectively reduce spasticity.5 Therefore the side-effects encoun-
tered when Baclofen is administered orally can be prevented. 
Between 2006 and 2009, Hoving et al published the results of a Dutch na-
tional study in seven articles addressing safety, efficacy, and cost-effectiveness 
of ITB therapy in a group of 17 carefully selected children with intractable spas-
tic CP. At that time there was a lack of methodologically well-designed studies in 
this field. Therefore, they used a double blind, randomised, placebo-controlled 
design for the ITB dose-finding test treatment study and a prospective, random-
ised design for the open-label pump implantation study. In this Dutch national 
study, continuous infusion of ITB (CITB) relieved pain, facilitated ease of care, 
and improved mental health. The majority of children could extend their activi-
ties and participation. During a mean follow-up of 18.4 months (12–24), Hoving 
et al recorded 80 adverse events. Eight adverse events were serious, but none 
were life-threatening and none of the children needed to be hospitalised. During 
the last follow-up visit, 15 of the 17 children and/or their parents stated that 
they were satisfied with CITB and would participate in all ITB related proce-
dures again. Two parents were not sure they would have the pump implanted in 
their child again, in spite of the achieved individual treatment goals. 
Since then several interesting articles and commentaries have been pub-
lished. Recently, Morton et al found ITB therapy to improve quality of life (QoL; 
comfort, ease of care) and to reduce muscle tone and spasms in 38 non-
ambulant children aged 5–16 years with spastic CP over a sustained period of 
18 months after pomp implantation.6 Minimal effects on function, participation 
in society, and contracture formation were found.6 
In a reply to this study Miller made two important remarks.7 Firstly, he stat-
ed that expecting to observe a functional gain after ITB therapy in non-ambulant 
children with CP is unrealistic. Most of the times the goal is to improve comfort 
and facilitate care-giving, which can be reported by care-givers. Secondly, he 
criticized the short term follow-up on a treatment that is probably going to be 
continued for 50–60 years. 
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Another recently published study is the one by Motta et al in which it was stated 
that ITB improves Gross Motor Function Measurement scores, Ashworth scale 
scores, Barry-Albright dystonia scores, and functional ability in 37 patients (18 
males, 19 females; GMFCS level 2: n=9; level 3: n=13; level 4: n=7; level 5: n=8).8 
In a reply to this study Krach highlighted some methodologically limitations 
of the study by Motta et al, but also stated that these limitations might be inevi-
table in children with neurodisability.9 She suggested the single-participant 
experimental design that uses the individual as his / her own comparison as an 
option for future research. This merits the establishment of sufficient baseline 
measurements. 
Acting upon these remarks made by Miller and Krach we prolonged the 
well-designed study by Hoving et al 6–9 years after pump implantation.3, 4, 10 Our 
aim was to study: I: whether or not beneficial effects of ITB therapy are still 
present 6–9 years after commencement of treatment, II: the course of effects 
after ITB treatment over time, and III: whether or not caregivers would still 
choose this treatment modality for their child again considering the advantages 
and disadvantages of ITB therapy now known. 
METHODS 
Design 
This prospective follow-up study is a continuation of the prospective Dutch 
national study on the efficacy and safety of CITB in 17 children with intracable 
spastic CP (figure 1).3, 4, 10 Their parents were informed about the study and all 
agreed to participate. 
 
 
Figure 8.1 Follow-up diagram of the 17 children with intractable spastic CP treated with CITB
therapy 
 
This follow-up study was approved by the Medical Ethics Committee of the 
Maastricht University Medical Centre (MUMC) according to Dutch governmental 
guidelines. 
Participants 
The 17 children with bilateral CP consisted of 9 girls and 8 boys with a mean age 
of 21.1 years (SD 3.1; 14–25). One boy was GMFCS level 3; 1 boy and 1 girl were 
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both GMFCS level 4; 14 children were GMFCS level 5. Mean follow-up on pump 
implantation was 7.5 years (SD 0.9; 6–9). 
Outcome measures 
After all these years we were mainly interested in the QoL and the satisfaction 
for the initially defined treatment goals of these children. The child health ques-
tionnaire (CHQ) and the visual analogue scale (VAS) were chosen as outcome 
measures as these instruments have shown to be capable of detecting improve-
ments.3, 4, 10 
The CHQ is a generic QoL instrument which measures 14 unique physical 
and psychosocial concepts.11 In this present study the 50-item, parent-form was 
used (CHQ-PF50). All domains are scored on a 0–100 scale with higher scores 
reflecting better QoL. Physical and psychosocial summary scores can be derived 
from the separate CHQ profile scores which have a mean of 50 and an SD of 10 
in the general population. 
To measure satisfaction the VAS was used. This is a straight 10-cm horizon-
tal line with the anchor points “very satisfied” (score 10) and “very dissatisfied” 
(score 0). This is opposite to how the VAS is commonly used, but in line with the 
previous studies by Hoving et al. Although, the parents were reminded of the 
three treatment goals defined before pump-implantation, they were not in-
formed about the previous scores. They scored their current satisfaction with 
regard to these goals on the VAS. The mean of these 3 VAS scores was used for 
statistical analysis (individual VAS). VAS scores for improvement of ease of care 
and relief of pain were analyzed separately as these were the most frequently 
formulated treatment goals. 
Additionally, we wanted to know whether or not caregivers would still 
choose ITB therapy for their child at present considering the advantages and 
disadvantages encountered over the last 6–9 years. As caregivers might not be 
aware of changes detected by the CHQ questionnaire and the VAS, we used a 
questionnaire which addresses improvement / worsening of functioning of their 
child by means of 40 questions. Questions are scored on a 5-point Likert scale 
(“A lot worse” – “Slightly better” – “The same” – “Slightly better” – “A lot bet-
ter”). This questionnaire was developed by Staal et al who used it to identify 
areas of positive improvement after ITB therapy in 49 individuals.12 It has also 
been used by Krach et al in order to evaluate satisfaction regarding ITB therapy 
in 100 patients / caregivers.13 This questionnaire was carefully translated into 
Dutch. 
Furthermore, parents answered questions with regard to pain caused by the 
ITB pump, side-effects at present time, hospitalizations, and surgeries since ITB 
pump implantation, and finally whether or not they would choose ITB therapy 
for their child again. 
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Statistical analysis 
PASW statistics 18 was used for statistical analysis. The non-parametric Wil-
coxon Signed Rank Test was used to compare present CHQ and VAS scores to 
baseline and 1 year post-implantation CHQ and VAS scores. 
RESULTS 
The caregivers of all 17 children participated in the study. Only one caregiver 
did not return the CHQ questionnaire due to an ongoing divorce. All other data 
were available. 
Beneficial effects of ITB therapy 6–9 years after commencement of 
treatment 
In table 1 the means and standard deviations of CHQ and VAS scores of the 17 
children at 4 different moments in time can be found: before pump implantation 
(baseline), at 6 months post-implantation, at 12 months post-implantation, and 
at present (6–9 years after pump-implantation). Furthermore, present CHQ and 
VAS were compared to scores at baseline and scores at 12 months post-
implantation. It can be seen that there are no statistically significant differences 
between present scores and scores at 12 months post-implantation. The posi-
tive effects on pain, ease of care, and mental health are still present. Moreover, 
additional benefits have appeared i.e. significantly improved scores on the Par-
ent Impact – Emotional subscale, Parent Impact – Time subscale, and the Physi-
cal Summary. 
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The course of effects of ITB therapy over time 
Figure 2 shows the course of 4 outcome measures over time: the physical (PhS) 
and psychosocial summary scores (PsS) of the CHQ questionnaire, and the VAS 
scores for improvement of pain and ease of care. It is evident that treatment 
effects are still present 6–9 years after commencement of treatment. Although it 
seems that the effect stabilizes, minimal improvement can still be expected 12 
months after pump-implantation, especially for individually defined treatment 
goals. Furthermore, it appears that improvements in terms of physical QoL (CHQ 
PhS) need more time to become evident. At 12 months post-implantation there 
was no statistically significant difference compared to baseline (p = 0.16); how-
ever, at 6–9 years post-implantation there is (p = 0.02). 
 
 
Figure 8.2 Box and whisker plots of 2 VAS scores (pain and ease of care) and 2 CHQ summary scores
(PhS and PsS) 
Caregivers chosing ITB therapy for their child again 
The advantages as measured by means of the CHQ and the VAS have already 
been described (figure 2). In addition, parents rated improvement / worsening 
for 40 domains of functioning on a 5-point Likert scale (figure 3). It can be seen 
that improvements were more frequent than worsening for all questions, except 
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for questions 6 (drooling) and 19 (bladder control). Improvements were most 
frequently noted for questions 1 (ability to transfer), 27 (startle movements, 
sudden jerks), and 29 (sleeping at night). 
 
Figure 8.3 Caregivers responses to 40 questions with regard to improvement / worsening of functioning after 6–9 years 
of CITB treatment 
 
The disadvantages were measured in terms of pain caused by the pump, device 
related problems, number of hospitalizations, number of surgeries, and side-
effects at present time. Two out of seventeen children were reported to experi-
ence pain caused by the pump. During these 6–9 years of follow-up 11 device-
related problems were encountered: 2 pump-related problem (failure of the 
pump; subsidence of the pump), 6 drain-related problems (drain too high: 2; 
drain too low: 1; drain too superficial: 1; drain obstructed: 2), and 3 refill-
related problems. Every child was hospitalized at least once since pump-
implantation (28 hospitalizations in total; range 1–4). Most of these were ITB-
related (18/28), but mainly involved substitution of the pump (15/18). Three 
out of 17 children underwent orthopedic surgery (all scoliosis). Forty-three 
side-effects at present were reported for 17 children. 
If given the choice, sixteen parents (94%) would choose ITB therapy for 
their child again, and 1 parent was not sure. 
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DISCUSSION 
Previous studies have addressed the long-term effects of ITB therapy in children 
with CP. However, most of them were retrospective, had a broad range of fol-
low-up months, did not include QoL and other subjective outcome measures, did 
not perform sufficient baseline measurements, included both ambulant and 
non-ambulant children, had large numbers of drop-outs, and / or included 
(adult) patients with spasticity not due to CP.14–19 In our opinion, the present 
study is unique because of the systematical evaluation of the 17 ITB treated 
children over a long period of time. At baseline and at 3, 6, 9, and 12 months 
after pump-implantation a comprehensive set of outcome measures was used 
and the outcome measures showing benefits were also used in this present 
study 6–9 years after pump implantation. 
It was shown that the previous identified positive effects on pain, ease of 
care, and mental health are still present 6–9 years post-implantation. Moreover, 
additional benefits have appeared, e.g. significantly improved scores on the 
Parent Impact – Emotional subscale, and the Parent Impact – Time subscale. 
According to the CHQ manual this means that care-givers experience fewer feel-
ings of emotional worry / concern and fewer limitations in time available for 
personal needs due to the child’s physical and / or psychosocial health.11 It is 
difficult to tell whether this is a direct result of ITB therapy or whether this 
would also occur in parents of children with CP not receiving ITB therapy. An 
ever growing amount of experience in caring for their children could explain the 
decrease in worries and concern and the increase in time for personal needs of 
the care-givers. 
Another additional benefit was present 6–9 years after pump implantation, 
i.e. significantly improved scores on CHQ PhS. The subscales that contribute 
most profoundly to the PhS are physical functioning, role/social limitations 
(physical), bodily pain/discomfort, and general health.11 It appears that im-
provements in CHQ PhS need more than 12 months to become evident (figure 
2). A possible explanation for this observation is that improvements in terms of 
CHQ PhS require more than a reduction in spasticity alone. New possibilities 
have to be explored and practiced, which takes some time. On the other hand, a 
reduction in spasticity will cause an immediate effect on pain and ease of care 
(figure 2). 
Although it seems that the improvements reach somewhat of a plateau 12 
months after pump-implantation, minimal improvement can still be expected at 
that time, especially for individually defined treatment goals. This is important 
information for children and care-givers (who consider ITB therapy). 
Regardless of the side-effects, the complications, and the necessity of even-
tually substituting the pump, 94% of the care-givers would choose ITB therapy 
for their child again. This is a common finding in literature, highlighting the high 
satisfaction with ITB therapy.2, 13, 20–22 
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Although this study is one of the first with such an extensive follow-up on ITB 
therapy in children with intractable spastic CP, this is only the beginning. Large 
groups of children receiving ITB therapy should be measured by means of mul-
tiple outcome measures at baseline and systematically up until 50–60 years 
after pump implantation. Using both objective and subjective outcome measures 
in both quantitative and qualitative designed studies are needed to determine 
the very long-term effects of ITB therapy. 
Limitations 
This study has several limitations. 
Firstly, the questionnaires were filled out by the care-givers and not the pa-
tients themselves. However, in this present study self-reports would have been 
extremely difficult to obtain and interpret given the severity of disability of the 
majority of the children with CP. In this case, parents / caregivers are the most 
logical source of information as they are assumed to have intimate knowledge of 
the child. 
Secondly, the questionnaire developed by Staal et al has not been vali-
dated.12 The development of a well-constructed, validated, and easy to adminis-
ter long-term outcome measure specific for ITB treatment would be highly use-
ful. This should include both beneficial effects of ITB therapy on all domains of 
the ICF and detrimental effects in terms of side-effects, complications, hospitali-
zations, and surgeries. 
Finally, we did not search for correlations with other factors that might in-
fluence outcome such as major life events, additional treatments, and aging. 
CONCLUSION 
This study shows that beneficial effects after ITB are still present 6–9 years after 
commencement of treatment in non-ambulant children. Minimal improvement 
can still be expected 12 months after pump-implantation, especially for indi-
vidually defined treatment goals. Ninety-four percent of the care-givers would 
choose for ITB treatment again. This information is very useful for physicians 
and can be used to inform patients and their care-givers who are considering 
ITB therapy. Future studies should aim at measuring large groups of children 
receiving ITB therapy by means of multiple outcome measures at baseline and 
systematically up until 50–60 years after pump implantation. 
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ABSTRACT 
Objective 
To compare the quality of life (QoL) of 8–18 year old children with cerebral 
palsy (CP) in the Southern part of the Netherlands to a sample of European chil-
dren from the general population and to investigate factors associated with 
possible differences. 
 
Design 
A cross-sectional KIDSCREEN-52 (by-proxy version) study. 
 
Subjects / patients 
The parents of 80 out of 81 children (mean age 13.4 years, SD 2.98; 49 boys, 31 
girls; Gross Motor Function Classification System (GMFCS) level 1: 21, 2: 5. 3: 16, 
4: 18, 5: 20) agreed to participate. 
 
Methods 
Two-sample T-tests were used to compare domain scores between groups. Re-
gression analysis was used to identify factors associated with deviant QoL 
scores. 
 
Results 
Significantly higher QoL compared to the reference population was reported for 
the parent relation & home life and school environment domains. Significantly 
lower QoL was reported for the physical well-being, social support & peers, and 
social acceptance domains. Lower cognitive levels, less communication skills, 
and higher GMFCS levels were associated with some of the above mentioned 
domains of QoL. 
 
Conclusion 
This study exposed and provided possible explanations for problem domains of 
QoL in children with CP living in the Southern part of the Netherlands. This in-
formation can be used to inform caregivers and service-providers. 
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INTRODUCTION 
In recent years there has been increasing interest in the Quality of Life (QoL) of 
children with Cerebral Palsy (CP) (figure 9.1: pubmed search; MeSH terms: 
“Quality of life” AND “Cerebral Palsy”). The World Health Organization (WHO) 
defines QoL as “an individual’s perception of their position in life in the context 
of culture and value systems in which they live, and in relation to their goals, 
expectations, standards, and concerns”.1 Technically speaking QoL is not a defi-
nition; it is a concept, an invention of the human mind to construct a model of 
the world.2 As with all human inventions, it is not perfect and therefore QoL 
does not represent one single truth. Nevertheless, attempts should be made to 
capture and analyse this QoL in the best way possible as it may expose problem 
areas in chronically ill children and could lead to treatment opportunities. 
 
 
Figure 9.1 Number of publications on QoL 
of patients with CP (pubmed; MeSH terms: 
“Quality of life” AND “Cerebral Palsy”) 
 
There are several instruments claiming to be able to assess QoL of children with 
CP, e.g. the Pediatric QoL Questionnaire CP Module (PedsQL), the Child Health 
Questionnaire (CHQ), the CP QoL questionnaire for children (CP QoL-Child), and 
the KIDSCREEN. As all these different QoL instruments make it more and more 
difficult for researchers and clinicians to interpret and compare data found, 
studies have been conducted to identify the most appropriate QoL questionnaire 
for their purpose.3–5 Although clearly the most commonly used instrument in-
ternationally5–7, the CHQ was outperformed conceptually and psychometrically 
by the KIDSCREEN in a study by Davis et al with 204 primary caregivers of chil-
dren with CP.3 The KIDSCREEN is a modern, generic QoL instrument, which uses 
questions based on focus-groups with children and adolescents all over Eu-
rope.8–10 It focuses entirely on subjective perceptions, has shown to possess 
excellent psychometric properties, can be used for both disabled and non-
C H A P T E R  I X  
 106 
disabled children, and can be reported by both the children themselves and 
their caregivers.8–11 
Previous studies have assessed QoL of children with CP. Several smaller 
studies found contradicting results.6, 7, 12, 13 The largest study so far (Study of 
Participation of Children with CP Living in Europe (SPARCLE), 7 European coun-
tries, KIDSCREEN-52) found that QoL of children with CP aged 8–12 years is, on 
average, similar to that of children in the general population on practically all 
domains.14 This study provided clues that children with CP have a slightly better 
school environment, but experience lower autonomy. Specific factors were 
found to be associated with lower QoL in certain domains, e.g. pain is associated 
with less QoL in the physical and psychological well-being and self-perception 
domains.15 Greater limitations, on the other hand, led to higher or lower QoL 
depending on the domain. However, impairment and pain could only explain a 
small amount of variance in QoL, which is therefore likely to be largely deter-
mined by social and environmental factors. 
Given that social and environmental factors can differ significantly between 
countries and even regions and since the Netherlands did not participate in the 
SPARCLE study, a study was performed to describe the QoL of the entire popula-
tion of children with CP in the Southern part of the Netherlands by means of the 
by-proxy version of the KIDSCREEN-52. As a first step the QoL profile of these 
children will be displayed. Next, a comparison is made to the QoL of a European 
sample of children (including Dutch children) from the general population9 in 
order to determine problem domains in Dutch children with CP. Finally, factors 
associated with problem domains of QoL are investigated. 
METHODS 
Design 
The parents of all 81 children with CP aged 8–18 years seen at the outpatient 
clinic of the Maastricht University Medical Centre (MUMC), were informed about 
the study and were asked whether they were willing to participate. All except 
one agreed to participate. After permission was obtained, parents were sent the 
by-proxy version of the KIDSCREEN-52 and a questionnaire concerning basic 
characteristics (table 9.1). 
This cross-sectional study was approved by the Medical Ethics Committee 
(MEC) of the MUMC according to Dutch governmental guidelines. 
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Table 9.1 Characteristics of the children with CP living in the Southern part of the Netherlands 
 Mean (range) 
Frequency (%)
 Mean (range) 
Frequency (%) 
N 80 Age (years) 13.4 (8–18) 
Sex  Sensory disability  
 M 49 (61%)  Visual 14 (18%) 
 F 31 (39%)  Auditory 2 (3%) 
Type CP  Feeding  
 Spastic unilateral 26 (33%)  I: Without difficulties 64 (80%) 
 Spastic bilateral 52 (65%)  II: Significant Difficulties 9 (11%) 
 Dyskinetic 1 (1%)  III: Stoma 6 (8%) 
 Ataxic 1 (1%)  Missing 1 (1%) 
Cognitive level  Pain / discomfort  
 < 50 22 (28%)  None 50 (63%) 
 50–70 22 (28%)  Some - severe 28 (35%) 
 >70 36 (45%)  Missing 2 (3%) 
GMFCS  Communication Skills  
 I 21 (26%)  I: Normal 47 (59%) 
 II 5 (6%)  II: Problems 17 (21%) 
 III 16 (20%)  III: Alternatives 7 (9%) 
 IV 18 (23%)  IV: None 8 (10%) 
 V 20 (25%)  Missing 1 (1%) 
Wheelchair dependent  Level of hand functioning  
 Yes 38 (48%)  I: No limitations 15 (19%) 
 No 42 (53%)  II: Limitations with fine motor task in  
 both hands 
22 (28%) 
Family composition   III: Needs assistance in performing  
 tasks 
18 (23%) 
 Two parents family 73 (91%)  IV: Needs assistance and makes use of 
 adaptive equipment 
5 (6%) 
 One parent family 3 (4%)  V: Requires assistance in everything 18 (23%) 
 Missing 4 (5%)  Missing 2 (3 %) 
Epilepsy   Occupation parents  
 None the last year 62 (78%)  ≥1 parent works fulltime 53 (66%) 
 < 1 / month last year 13 (16%)  Other situation 24 (30%) 
 > 1 / month last year 5 (6%)  Missing 3 (4%) 
Schooltype  Parental qualification  
 Normal education 27 (34%)  None 4 (5%) 
 Special education 50 (63%)  Below university 67 (86%) 
 Missing 3 (4%)  University degree 7 (9%) 
Living area   Missing 2 (3%) 
 Urban 40 (50%)   
 Countryside 38 (48%)   
 Missing 2 (3%)   
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Participants 
The 80 children with CP consisted of 49 boys and 31 girls with a mean age of 
13.4 years (SD 2.98). Forty-eight per cent of the CP children were wheelchair 
dependent and 55% had cognitive levels below 70. The major patient and socio-
demographic characteristics are displayed in table 9.1. 
Outcome measures 
The KIDSCREEN-52 is a generic QoL instrument for children aged 8–18 years and 
was validated psychometrically with 22110 European children from the general 
population all over Europe.9, 10 It consists of 52 items assessing QoL in ten do-
mains (table 9.2). Items are scored on a 5-point Likert-scale (“never-seldom-
sometimes-often-always” / “not at all-slightly-moderately-very-extremely”). 
Missing values are to be replaced by the mean of the other items belonging to the 
same domain if no more than 1 item is missing for that domain. 
 
Table 9.2 Explanation of the KIDSCREEN domains9, 14 
Domain Aspects measured 
Physical Well-being Physical activity, energy, and fitness 
Psychological Well-being Positive emotions and satisfaction with life 
Moods & Emotions Negative moods, boredom, and stress 
Self-Perception Self, bodily appearance, and body image 
Autonomy Freedom of choice and self-determination in leisure time 
Parent Relation & Home Life Interactions and relationships with parents and the socioemo-
tional atmosphere at home 
Financial Resources Adequacy of pocket money relative to peers 
Social Support & Peers Social support available from friends and peers 
School Environment Learning and feelings about school and teachers 
Social acceptance Social acceptance or rejection by peers, including bullying 
 
Two ways of calculating domain scores are used in literature. First, item re-
sponses can be summed for each domain and are then rescaled to a 0–100 scale 
(sum-scores), with higher scores indicating better QoL. These sum-scores are 
used when describing the QoL profile of a population.15, 16 Second, Rasch Person 
Parameters can be computed for each dimension, which are then transformed 
into T-scores with a mean of 50 and an SD of 10. Higher T-scores indicate higher 
QoL. T-scores are used when comparing QoL between populations.14 
In this study, both sum-scores and T-scores will be used to describe the QoL 
profile of the population of children with CP living in the Southern part of the 
Netherlands. This will enable future studies to compare their results to Dutch 
children with CP. 
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T-scores will be used to compare the QoL of children with CP living in the 
Southern part of the Netherlands to a sample of European children (aged 8–18 
years) from the general population. Unfortunately, as parent-reported T-scores 
are not available for the European population of children with CP, no compari-
son can be made to this group of children.15 
Statistical analysis 
After all the parents returned the questionnaires all data were entered into SPSS 
18.0 for statistical analysis (RH). Afterwards, data entry was randomly checked 
and found correct by another researcher (JH). 
The SPSS syntax provided by the KIDSCREEN group Europe was used to cal-
culate Rasch Person Parameters and T-scores for each of the ten domains.17 
Furthermore, item responses were summed and rescaled to a 0–100 score 
(sum-scores). Floor and ceiling effects were considered to be present if the pro-
portions of respondents with the maximal resp. minimal scores for each domain 
were > 15%.18 Stata/ES 9.0 was used to perform two-sample T tests in order to 
compare the T-scores of the children with CP living in the Southern part of the 
Netherlands to the general population of European children.9, 15 Given the num-
ber of hypotheses tested, an alpha of 0.01 was considered significant. 
Regression models were used to investigate the association between patient 
and sociodemographic characteristics and T-scores of domains in which chil-
dren with CP living in the Southern part of the Netherlands score significantly 
different compared to the sample of European children from the general popula-
tion. Linear regression analysis was used which meant that logistic transforma-
tion of the social acceptance and parent relation & home life domains had to be 
performed, as scores in these domains were not distributed normally. All factors 
identified using univariate (SPSS 18.0, dummy variables, p<0.1) model testing 
were used for the subsequent multivariate model testing. 
RESULTS 
QoL profile of Dutch children with CP 
In figure 9.2 box and whisker plots of the sum-scores of the 10 KIDSCREEN-52 
domains of the 80 children with CP living in the Southern part of the Nether-
lands can be found. It is clear that the studied population scores relatively low in 
the physical well-being and social support & peers domains compared to the 
other domains of QoL. In table 9.3 the exact sum-scores (mean, SD, median, in-
terquartile range, floor and ceiling effect) can be found. For the parent relation & 
home life, financial resources, and social acceptance domains ceiling effects 
were observed. No floor effects were observed. 
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Figure 9.2 Box and whisker plots of the KIDSCREEN sum-scores for 80 children with CP living in the 
South of the Netherlands 
 
Table 9.3 Sum-scores of 80 children with CP living in the Southern part of the Netherlands 
Domains No. of  
items 
CP - Southern part of the Netherlands 
Sum-scores 
  Mean SD Median IQR Floor effect % Ceiling effect %
Physical Well-being 5 58.0 21.5 55.6 38.9 – 77.8 0.0 2.5 
Psychological Well-being 6 77.5 14.9 75.0 66.8 – 87.5 0.0 10.0 
Moods & Emotions 7 78.8 16.1 82.1 67.9 – 92.9 0.0 6.3 
Self-Perception 5 78.0 15.1 80.0 68.8 – 90.0 0.0 10.0 
Autonomy 5 72.1 15.3 75.0 60.0 – 80.0 0.0 6.3 
Parent Relation & Home Life 6 84.3 13.9 87.5 75.0 – 95.8 1.3 18.8 
Financial Resources 3 73.2 26.0 75.0 58.3 – 100.0 3.8 23.8 
Social Support & Peers 6 49.2 27.6 54.2 25.0 – 75.0 5.0 2.5 
School Environment 6 80.3 17.9 83.3 70.8 – 95.8 1.3 8.8 
Social acceptance 3 83.3 19.0 91.7 75.0 – 100.0 1.3 35.0 
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Comparison to a sample of European children from the general population 
T-scores (mean, SD, comparison to a sample of European children from the gen-
eral population) can be found in table 9.4. Again, low scores for the physical 
well-being and social support & peers domains are reported. Also, the children 
are reported to have low QoL in the social acceptance domain compared to the 
sample of European children from the general population. In contrast, signifi-
cantly higher QoL is reported for parent relation and home life and the school 
environment domains. 
 
Table 9.4 T-scores of 80 children with CP living in the Southern part of the Netherlands compared 
to a sample of European children from the general population 
Domains No. of items   
  N Mean SD p* 
Physical well-being 5 74/80 41.1 9.7 0.00 
Psychological well-being 6 77/80 51.7 10.3 0.13 
Moods & emotions 7 76/80 48.7 11.5 0.27 
Self-perception 5 74/80 50.7 9.9 0.57 
Autonomy 5 71/80 48.0 8.4 0.09 
Parent relation & home Life 6 74/80 54.8 10.3 0.00 
Financial resources 3 60/80 52.7 10.9 0.04 
Social support & peers 6 65/80 40.0 15.4 0.00 
School environment 6 71/80 56.4 11.1 0.00 
Social acceptance 3 78/80 46.9 11.7 0.01 
* Significance compared to the general population of European children (N = 15485 – 15897; Mean ≈ 
50.00; SD ≈10.00, depending on the domain)9 
Factors associated with domains of significantly different QoL in Dutch 
children with CP 
Patient characteristics and sociodemographic factors (table 9.1) were investi-
gated to see whether they were significantly associated with the physical well-
being, parent relation & home life, social support & peer relations, school envi-
ronment, and social acceptance domains (table 9.5). For the physical well-being 
domain it was found that higher GMFCS level was associated with lower T-
scores. Less communication skills and lower cognitive levels were associated 
with lower T-scores in the social support & peers and school environment do-
mains. Furthermore, parents with no educational qualification rated their childs 
QoL in the parent relation & home life domain higher. For the social acceptance 
domain no associated factors could be identified. 
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Table 9.5 Factors associated with low QoL domains (T-scores) in Dutch children with CP (multi-
variate analysis) 
Domain  Independent variable B p 
Physical well-being GMFCS   
  Level 1 0.0 NA 
  Level 2 -11.5 0.00 
  Level 3 -10.6 0.00 
  Level 4 -14.8 0.00 
  Level 5 -16.5 0.00 
Parent relation & home life Parental qualification   
  No qualification 0.0 NA 
  Below university -1.1 0.00 
  University degree -1.0 0.00 
Social support & peers Communication skills   
  I: normal 0.0 NA 
  II: Problems -10.5 0.04 
  III: Alternatives -2.6 0.71 
  IV: none -15.7 0.02 
 Cognitive level   
  > 70 0.0 NA 
  50–70 -1.0 0.82 
  < 50 -13.5 0.01 
School environment Communication skills   
  I: normal 0.0 NA 
  II: Problems 3.6 0.06 
  III: Alternatives 4.7 0.01 
  IV: none 5.3 0.00 
 Cognitive level   
  > 70 0.0 NA 
  50–70 3.1 0.04 
  < 50 3.7 0.00 
Social acceptance No factor identified   
NA = not applicable 
DISCUSSION 
To the best of our knowledge this is the first study to investigate QoL of Dutch 
children with CP by means of the KIDSCREEN-52. The main strength of this 
study is that 99% of the parents of all children with CP seen at the outpatient 
clinic of the MUMC participated. The overall QoL profile of children with CP 
living in the Southern part of the Netherlands seems to be quite similar to the 
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QoL profile of children with CP as found in the SPARCLE study.14, 15 For example, 
relatively high scores on the school environment domain and relatively low 
scores on the autonomy domain were found, which is in accordance with the 
study by Dickinson et al.14 These findings confirm the usefulness of the KID-
SCREEN-52 across national borders. In this present study it was found that chil-
dren with CP living in the Southern part of the Netherlands are reported to have 
low QoL on three KIDSCREEN-52 domains compared to a sample of European 
children from the general population, i.e. the physical well-being, social support 
& peers, and social acceptance domains. 
Less physical well-being 
According to the KIDSCREEN group Europe low scores in the physical well-
being domain mean that more children than usual feel physically exhausted, 
unwell, and unfit.9 In this present study it was found that higher GMFCS levels 
were associated with lower QoL in this domain. This is a logical finding and is in 
accordance with the studies by Dickinson et al and Arnaud et al.14, 15 However, 
both Arnaud et al and Dickinson et al found pain to be associated with lower 
QoL scores. This was not the case in the present study. This discrepancy be-
tween our findings and literature may be due to the fact that dichotomous pain 
data were used. Furthermore, it could be that the relationship between QoL and 
pain is not as obvious as we expect it to be. For example, in a study by Engel et al 
it was shown that in adults with CP it is not the pain itself that influences psy-
chological functioning, but the coping strategies in reaction to the pain.19 
More family, less friends? 
It is intriguing to see that these Dutch children with CP are reported to have 
significantly higher QoL in the school environment and parent relation & home 
life domains and significantly lower QoL in the social support & peers and social 
acceptance domains compared to a sample of European children from the gen-
eral population. This is a pattern not observed in the European population of 
children with CP. We came up with two possible, non-exclusive explanations: 
one based on quantitative research, the other on qualitative research. 
With regard to the first, in a large, cross-sectional survey study using the 
KIDSCREEN-52 among 16.210 children in children and adolescents 8–18 years 
old in 11 European countries, Analitis et al found that living in the Netherlands 
holds the highest odds ratio (1.68) of being bullied.20 These results could explain 
why more Dutch children with CP than usual feel tormented, bullied, and re-
jected by peers. The observed pattern leads to the assumption that Dutch people 
committed to these children (parents, family, teachers, etc) have a significant 
positive contribution to their QoL, while non-committed others (peers) might 
bully and negatively influence their QoL. 
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The second explanation is based on qualitative research by Parkinson et al who 
investigated the extent of agreement between children with CP and their care-
givers concerning their views on what contributed to the children QoL.21 They 
conducted qualitative interviews with 26 children with CP and 35 caregivers 
and came to the conclusion that there is considerable overlap but also some 
divergence. For example, children reported enjoying being on their own from 
time to time. Caregivers do not appreciate these attitudes and put substantial 
effort into creating opportunities for their child to be included socially. The in-
terviewers found them very concerned about their child’s experiences of being 
isolated or bullied by other children, often emphasizing this more than the chil-
dren themselves. In other words, it is very well possible that low QoL on the 
social support & peers and social acceptance domains is due to concerns of the 
caregivers rather than what the children experience themselves. This is in ac-
cordance with our PARS-III study in which it was shown that children with CP 
psychosocially adjust to their motor and accompanying problems by with-
drawal, without establishing sufficient and comprehensive peer relations. The 
question remains: who is right? Is it acceptable for children with CP to withdraw 
and enjoy time spent on their own, or are the caregivers right by stating that the 
children underestimate the risk and consequences of being socially isolated and 
that effort has to be put into engineering opportunities for their child to be in-
cluded socially? 
Comparison to the QoL of other patient populations in the Netherlands 
Several other studies have investigated the QoL profile of specific patient popu-
lations in the Netherlands by means of the KIDSCREEN. For example, van Dijk et 
al found 65 child and adolescent retinoblastoma survivors to report good QoL 
compared to the reference population, with even significantly higher QoL for the 
moods & emotions and autonomy domains.22 Smets et al found no significant 
difference in QoL between 35 children with a positive carrier status for inher-
ited cardiovascular diseases and the reference population.23 The same was ob-
served by Michielsen et al in 56 children and adolescents with congenital lower 
limb deficiency (LLD).24 Therefore, we can state the QoL profile of Dutch chil-
dren with CP to be unique as significant lower QoL was reported for three do-
mains. As single physical (LLD) or psychological (fear of sudden cardiac death or 
recurrence of cancer) factors do not seem to influence QoL, one could argue that 
it is the interaction of multiple impairments met by Dutch children with CP 
which causes the decrease in QoL in certain domains. 
Limitations of this study 
An important limitation of this study is the sole reliance on proxy reports. The 
literature on the best source to evaluate QoL is inconsistent at best. The WHO 
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recommends that children should report their own QoL.25 Furthermore, a recent 
study has shown that, especially in children with chronic neurological disorders, 
parent-children agreement is suboptimal and that parents under-report subjec-
tive aspects of well-being.26 However Le Coq et al found 8 to 11 year old pediat-
ric asthma patients to be less responsive and less reliable reporters on a QoL 
measure compared to their parents.27 It is now becoming more and more ac-
cepted that there is no one single truth concerning QoL and therefore self-
reports and proxy-reports are complementary.28 With regard to the present 
study, self-reports would have been extremely difficult to obtain and interpret 
given the severity of disability of the majority of the population of the children 
with CP. This problem is omnipresent which is probably best illustrated by the 
SPARCLE study itself in which 318 out of the 818 selected children with CP 
could not self-report.14 In this case, proxy-reports are the only way to evaluate 
QoL with their parents / caregivers being the most logical source of information 
as they are assumed to have intimate knowledge of the child. This inevitably 
means that parents have to judge how their children experience life. 
Furthermore, no data on parental stress was collected. Arnaud et al have 
shown that parents with higher levels of stress were more likely to report poor 
QoL on all domains.15 
Finally, it was not possible to compare parent-reported T-scores of Dutch 
children with CP to parent-reported T-scores of an European sample of children 
with CP as these are not reported in literature.15 The authors suggest publica-
tion of these T-scores in order to let future studies be able to compare the QoL 
of their population of children with CP to an European standard. 
CONCLUSION 
This study describes the QoL profile of 80 children with CP living in the South-
ern part of the Netherlands as measured by means of the by-proxy version of 
the KIDSCREEN-52. The children studied are reported to have relatively low 
QoL in the physical well-being, social support & peers, and social acceptance 
domains, but relatively high QoL in the parent relation & home life and the 
school environment domains. These findings provide a better understanding of 
the QoL of Dutch children with CP. They can be used to inform caregivers and 
service-providers and to focus health programs aiming to increase QoL in this 
group of children towards identified problem domains. 
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GENERAL DISCUSSION 
Topic specific discussions can be found at the end of each chapter. This general 
discussion will focus on three issues encountered repeatedly while writing this 
thesis. The first issue is the problems and dilemmas associated with measuring 
concepts. The second issue is the rationale of evaluating your outpatient clinic. 
The third and final issue is the surplus value of qualitative research. 
MEASURING CONCEPTS 
During this thesis attempts have been made to measure several concepts, i.e. 
QoL and psychosocial adjustment. Concepts are inventions of the human mind 
to construct a model of the world.1 They are abstract and cannot be touched, 
felt, or seen. Nevertheless, the significance of concepts like QoL and psychosocial 
adjustment is widely recognized. Therefore, these abstract and unobservable 
concepts have to be translated into something concrete and measurable. This 
process is called operationalisation and requires several criteria with regard to 
validity, consistency, stability, and reliability to be met.2 Fortunately, the KID-
SCREEN group Europe and Stein & Jessop have already done this and provided 
the clinician / researcher with valid and reliable tools to measure QoL (KID-
SCREEN) and psychosocial adjustment (PARS-III) respectively.3, 4 However, 
results found still have to be interpreted with caution and considerable 
knowhow. Let us take the concept of QoL. QoL is defined as “an individual’s per-
ception of their position in life in the context of culture and value systems in 
which they live, and in relation to their goals, expectations, standards, and con-
cerns”.5 In a very large, comprehensive, multi-centre study published in the 
Lancet it was concluded that the QoL of children with CP is similar to that of 
other children on all domains.6 The authors stated that pity and sorrow are 
therefore not in place. Another study investigated QoL of child and adolescent 
retinoblastoma survivors and found that their QoL is comparable to the general 
population with even significantly higher QoL on the moods & emotions and the 
autonomy domains.7 Does this mean that the QoL of a child with CP fighting has 
spastic movements in his wheelchair is similar to that of his brother outside 
playing soccer and that we should wish for everybody to get retinoblastoma? 
Probably not. It most likely means that determinants of QoL have shifted in chil-
dren with CP and that surviving retinoblastoma makes people more aware of 
certain domains of QoL when approached by a researcher interested in their 
QoL. Furthermore, admitting that your or your child’s QoL is below average is a 
hard thing to do. The psychological effects when asked to judge your own or 
your child’s QoL have not yet been studied. However, indirect evidence for a 
biased representation of one’s own QoL comes from studies on self-presentation 
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and narcissism on facebook, the planets largest social networking platform to-
day. It is repeatedly found that people tend to self-promote and over-represent 
their lives.8–11 
In my opinion two aspects of concepts like QoL and psychosocial adjustment 
are the most useful and the most interpretable: 1) the profile expressed in dif-
ferent domains; 2) the development over time. 
Studying the domains of QoL in a population of patients may expose prob-
lem areas which could lead to treatment options. In our KIDSCREEN study on 
the QoL of Dutch children with CP (chapter IX) we found that these children are 
reported to have significantly higher QoL on the school environment and parent 
relation & home life domains and significantly lower QoL on the social support 
& peers and social acceptance domains. This observation leads to the assump-
tion that Dutch people committed to these children (parents, family, teachers) 
have a significant positive contribution to their QoL, while non-committed oth-
ers (peers) might negatively influence their QoL. These results are in accordance 
with the results obtained in our PARS-III study on psychosocial adjustment in 
Dutch children with CP (chapter III) in which we found low scores on the peer 
relations domain of psychosocial adjustment. It therefore makes sense to focus 
future health programs aiming to raise QoL in children with CP towards improv-
ing peer relations and social acceptance of these chronically impaired children. 
The development of QoL over time was also studied in this thesis. This was 
done in children with CP who received an ITB pump in order to treat intractable 
spasticity (chapter VIII). It was shown that the positive effects on pain, ease of 
care, and mental health identified in the first year after commencement of 
treatment are still present today. Moreover, additional benefits have appeared, 
e.g. significantly improved scores on the Parent Impact – Emotional and the 
Parent Impact – Time subscales of the CHQ. According to the CHQ manual this 
means that care-givers experience fewer feelings of emotional worry / concern 
and fewer limitations in time available for personal needs due to the child’s 
physical and / or psychosocial health.12 It is difficult to tell whether this is a 
direct result of ITB therapy or whether this would also occur in parents with 
children not receiving ITB therapy. An ever growing amount of experience in 
caring for their children could explain the decrease in worries and concern and 
the increase in time for personal needs of the care-givers. 
Another additional benefit was present 6–9 years after pump implantation, 
i.e. significantly improved scores on CHQ PhS. The subscales that contribute 
most profoundly to the PhS are physical functioning, role/social limitations 
(physical), bodily pain/discomfort, and general health.12 It appears that im-
provements in CHQ PhS need more than 12 months to become evident (figure 
8.2). A possible explanation for this observation is that improvements in terms 
of CHQ PhS require more than a reduction in spasticity alone. New possibilities 
have to be explored and practiced, which takes some time. On the other hand, a 
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reduction in spasticity will cause an immediate effect on pain and ease of care 
(figure 8.2). 
EVALUATING YOUR OUTPATIENT CLINIC 
Part of this thesis could be interpreted as a so-called audit. An audit measures 
clinical practice against current standards. It is a slightly odd type of research. In 
stead of searching for the right thing to do, it is checked whether or not the right 
thing is being done. In the United Kingdom it is standard practice for young 
doctors to perform an audit while in their foundation years.13 An audit serves 
multiple purposes. A cochrane review concluded that an audit can improve the 
practice of health care professionals.14 Furthermore, in these times where there 
is both an increasing demand on clinicians to implement evidence based medi-
cine and optimize health care interventions routinely as an increasing pressure 
to rationalize treatment costs, evaluating your outpatient clinic seems a logical 
thing to do. The main problem, especially when treating severely handicapped 
children, is the lack of a quick, simple, and meaningful outcome measure. For 
example, it is not reasonable to expect clinicians to evaluate all children with CP 
receiving BTX-A injections by means of the PEDI, which takes over 1 hour per 
session. 
During this thesis a VAS was used multiple times for different purposes. It 
was, along with other more sophisticated and time-consuming instruments, 
used to evaluate the effects of BTX-A treatment, ITB treatment, and RF-DRG 
treatment in children with CP. In chapter VI we showed that a VAS was able to 
measure effect of BTX-A treatment and that overall correlations with standard 
evaluation instruments were in the expected direction. Besides being a quick 
and easy method for evaluating treatment in a busy outpatient setting, the VAS 
is a subjective measure of the effects that treatment has on individually chosen 
goals. We would like to argue that it is this subjective nature of the VAS that 
makes it very suitable to evaluate treatment effects in children with CP at the 
severe end of the spectrum. Expecting to measure functional gain after treat-
ment is not realistic in these children and most of the times is not the desired 
treatment goal set by the child and his caregivers. Usually the child and his care-
givers are the best judges of the impact that the treatment has had on the daily 
life of the child. Furthermore, it is known that caregivers of children with pro-
found impairments note changes in function far more accurately than staff 
workers. Small changes, noticed by caregivers but not picked up by conventional 
outcome measures, can add significant improvement to lives of children with CP 
and their caregivers. 
Using this subjective VAS and other more objective and time-consuming in-
struments (Tardieux, MAS, CHQ, KIDSCREEN) we found evidence supporting the 
use of BTX-A, ITB, and RF-DRG treatment in the population of children with CP 
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seen at the outpatient clinic of the MUMC. These results verify the methods used 
to treat children in this university hospital. Furthermore, caregivers and chil-
dren with CP can now be informed about the anticipated effects of several 
treatments not only based on data reported in literature but also based on re-
sults obtained by the local multidisciplinary CP working group. 
QUALITATIVE RESEARCH 
Traditionally, research in medicine has been quantitative by nature. These stud-
ies consist of identifying a problem, formulating a hypothesis, conducting an 
experiment, followed by supporting or dismissing the hypothesis. This is con-
sidered true research by many. 
However, over the last decade there has been increasing interest for qualita-
tive research. Boyd described qualitative research as broadly stated questions 
about human experiences and realities studied through sustained contact with 
persons in their natural environment, and producing rich, descriptive data that 
aid in understanding those person’s experiences.15 
Although qualitative studies have not been performed as part of this thesis, 
they have been very useful in the interpretation of data found. This was particu-
larly true for the KIDSCREEN study (chapter IX). In this study we assessed the 
QoL of all children with CP living in the Southern part of the Netherlands. Bear-
ing in mind the severity of CP in these children, we were forced to use the by-
proxy version of the KIDSCREEN-52. Using this generic QoL instrument it was 
found that children with CP living in the Southern part of the Netherlands are 
reported to have significant lower QoL on three domains: physical well-being, 
social support & peers, and social acceptance. Less QoL on the physical well-
being domain makes sense considering the GMFCS levels, the frequency of re-
ported pain, and the accompanying impairments in these children. However, 
interpreting the results on the social support & peers and social acceptance 
domains posed somewhat of a problem, especially since these data were re-
ported by care-givers. In other words, a QoL problem was identified however 
possible explanations for this observation were lacking. We came up with two 
possible, non-exclusive explanations: one based on quantitative research, the 
other on qualitative research. With regard to the first, in a large, cross-sectional 
survey study using the KIDSCREEN-52 among 16.210 children in children and 
adolescents 8–18 years of age in 11 European countries, Analitis et al found that 
living in the Netherlands holds the highest odds ratio (1.68) of being bullied.16 
These results could explain why more Dutch children with CP than usual feel 
tormented, bullied, and rejected by peers. The second explanation is based on 
qualitative research by Parkinson et al who investigated the extent of agreement 
between children with CP and their caregivers concerning their views on what 
contributed to the children’s QoL.17 They conducted qualitative interviews with 
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26 children with CP and 35 caregivers and came to the conclusion that there is 
considerable overlap but also some divergence. For example, children reported 
enjoying being on their own from time to time, while caregivers tended not to 
value these attitudes and put considerable effort into engineering opportunities 
for their child to be included socially. The interviewers found them very con-
cerned about their child’s experiences of being isolated or bullied by other chil-
dren, often emphasizing this more than the children themselves. In other words, 
it is very well possible that low QoL on the social support & peers and social 
acceptance domains is due to concerns of the caregivers rather than what the 
children experience themselves. This is in accordance with our PARS-III study 
(chapter III) in which it was shown that children with CP psychosocially adjust 
to their motor and accompanying problems by withdrawal, without establishing 
sufficient and comprehensive peer relations. The question remains: who is 
right? Is it acceptable for children with CP to withdraw and enjoy time spent on 
their own, or are the caregivers right by stating that the children underestimate 
the risk and consequences of being socially isolated and that effort has to be put 
into engineering opportunities for their child to be included socially? Again, this 
highlights the necessity of measuring concepts like QoL and psychosocial ad-
justment through time as this would show the long-term consequences of with-
drawal and the lack of social support in these children. 
Another surplus value of qualitative research will be discussed. As already 
stated before, measuring treatment effect in children with CP poses somewhat 
of a challenge. Expecting large improvement in severely impaired children is 
unfortunately most often not realistic. However, small improvements, no matter 
how little, can make a huge difference. Against this background the following 
example is discussed. 
In our long-term follow-up study on the effects of ITB treatment on intrac-
table spasticity in children with CP (chapter VIII), multiple evaluation instru-
ments were used. Among others, these included the CHQ, the KIDSCREEN, three 
self-made questionnaires (pain, function, complications, surgeries, hospitaliza-
tions, outpatient clinic visits), the Lifestyle Assessment Questionnaire for CP 
(LAQ-CP), the PARS-III, the CBCL and the SEV (manuscript in preparation). For 
one child treated with ITB only minimal improvements on all of these instru-
ments were reported by the caregivers. However, when asked if they would 
choose for ITB treatment for their child again, considering the advantages (ef-
fects) and disadvantages (surgeries, complications, outpatient visits, and hospi-
talizations) experienced over all those years, they were absolutely positive. 
They stated that the slight increase in the range of leg abduction, improved ease 
of care and dressing dramatically. Thus, in this case a qualitative interview shed 
an entirely different light on results obtained by quantitative research. 
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CONCLUSION 
In this thesis several clinical and therapeutic aspects of CP have been studied. 
The psychosocial adjustment (chapter I) and QoL (chapter IX) of children with 
CP seen at the outpatient clinic of the MUMC were investigated. Conventional 
treatments, like BTX-A (chapter IV) and ITB (chapter VI), and their complica-
tions (chapter V) have been evaluated and their effectiveness was confirmed. 
Furthermore, new treatments, like RF-DRG (chapter II) and Levetiracetam 
(chapter III), have been researched and found promising. The main message of 
this thesis is the following. When treating children with CP it is essential to un-
derstand their way of coping with their often severe disabilities and limitations 
and how this influences their QoL. Subsequently, treatment goals have to be set 
that are both obtainable and desired by both the child and his caregivers. Not 
only does one have to select the right treatment option, but also the right evalu-
ation method. 
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This thesis addressed clinical and therapeutic aspects of cerebral palsy (CP). 
Several aspects of overall assessment, treatment, and its evaluation were stud-
ied in the population of children with CP seen at the outpatient clinic of the 
Maastricht University Medical Centre (MUMC). 
 
CP is a major health problem as it affects 1 in 400 children making it the most 
common developmental disorder associated with lifelong disability. It is defined 
as a static, but often changing disorder of movement and posture due to a defect 
or lesion to the developing fetal or infant brain. In addition to their motor prob-
lems, children with CP often have impairments of learning, hearing, vision, and 
communication and frequently have seizure disorders. As a first step of this 
thesis a study was performed to see how these children adjust to their often 
severe disabilities and limitations. Therefore, in chapter III the psychosocial 
adjustment of children with CP is described. The main problem in this research 
area is that there are few standardized instruments specifically developed to 
assess psychosocial adjustment in children with a chronic illness. One very suit-
able instrument but not previously used in children with CP is the Psychosocial 
Adjustment and Role Skills Scale - III (PARS-III). The parents of all 94 children 
with CP (aged 4–18 years) seen at the outpatient clinic of the MUMC were in-
formed about the study and asked to participate. All except one agreed and were 
sent the PARS-III questionnaire. The 93 children with CP consisted of 59 boys 
and 34 girls with a mean age of 12.3 years (SD 3.8; 4–18). Forty-four per cent of 
the children with CP were wheelchair dependent and 52% had a cognitive level 
below 70. Ninety-five healthy children and 63 boys with Duchenne Muscular 
Dystrophy (DMD) were used as reference groups. As the PARS-III had never 
before been applied to children with CP, its use had to be justified first. Results 
showed good internal consistency for the total PARS-III score: an alpha of 0.89. 
Confirmatory Factor Analysis confirmed the six domains of psychosocial func-
tioning on the PARS-III questionnaire in children with CP. Based on these results 
the PARS-III scores of children with CP were investigated. It was found that they 
achieve significantly lower psychosocial adjustment scores when compared to 
healthy children (p = 0.00), especially on the domains peer relations (p = 0.00), 
anxiety/depression (p = 0.00), withdrawal (p = 0.00), and productivity (p = 
0.02). Overall, they did not differ significantly from boys with DMD (p = 0.93), 
however, they scored significantly lower on the domain peer relations (p = 
0.03). 
It was found that the patient characteristics most predictive for lower PARS-
III domain and total scores were less gross motor function, a lower level of hand 
function, less communication skills, and bilateral spastic CP. Put together in a 
model, these four patient characteristics could explain a significant proportion 
(36%) of the variation in PARS-III total scores. 
It was concluded that the PARS-III questionnaire for parents can be used in 
children with CP. Using this questionnaire, it was found that children with CP 
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achieve lower psychosocial adjustment scores when compared to healthy chil-
dren, especially in the domains peer relations, anxiety/depression, withdrawal, 
and productivity. It was suggested that a better understanding of why and when 
children with CP develop psychosocial maladjustment could lead to opportuni-
ties to alter the course of coping and therefore improve their quality of life 
(QoL). 
 
The most common motor problem in children with CP is spasticity. Besides in-
trathecal Baclofen (ITB), selective dorsal rhizotomy (SDR) is one of the most 
commonly performed neurosurgical procedures. As multi-level laminectomies 
at the L1-S1 level are often required, the procedure is invasive and can lead to 
complications as transient urinary incontinence, chronic low back pain, and 
spinal deformity. Furthermore, considerable cooperation of the patient is re-
quired to successfully complete the postoperative rehabilitation program. We 
hypothesized a percutaneous radiofrequency lesion of the dorsal root ganglion 
(RF-DRG) to be a simple and safe alternative treatment. In chapter IV the pilot 
study undertaken to test this hypothesize is reported. The RF-DRG treatment 
was considered by the multi-disciplinary spasticity management team of the 
MUMC in children with severe hip flexor / adductor spasms accompanied by 
pain and / or care giving difficulties. During this pilot study a total of 19 RF-DRG 
procedures were performed in 17 children. 
The first six children were systematically evaluated at baseline, and 1 month 
and 6 months after treatment by means of the Modified Ashworth Scale (MAS), 
the Gross Motor Function Measure (GMFM), and a caregiver’s questionnaire. An 
improvement in muscle tone after RF-DRG was identified on both the short (1 
month) and long (6 months) term using the MAS. No functional improvement on 
the GMFM could be detected. Using the caregiver’s questionnaire, improvements 
in ease and quality of care and pain were found. 
The following 11 children were evaluated at 6 weeks and 3 months after in-
tervention using a Visual Analogue Scale (VAS), which was used to measure 
change on individually formulated treatment goals. We changed the evaluation 
methods, as we were not able to detect the kind of change that the caregivers 
unanimously did notice. Furthermore, studies were being published that 
showed that the MAS and the GMFM are not suitable to measure changes in 
these severely handicapped children. The VAS scores showed improvement on 
most of the defined treatment goals in most children. Most parents reported 
that the positive effects of the RF-DRG lasted at least 6–9 months. 
It was concluded that RF-DRG is a promising new treatment option for se-
vere spasticity in children with CP. The main advantages are its less invasive 
character compared to the SDR with the potential benefit of a shorter hospitali-
zation period, and its clear pain-reducing effect. We suggested a randomized 
controlled trial to define its definitive effectiveness. 
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Less common than the spastic subtype of CP is the dyskinetic subtype. Its path-
ophysiology is not fully elucidated, but existing evidence suggests that dysfunc-
tion of the basal ganglia (BG) plays a role in this entity. As with most diseases in 
which the causes are not yet fully understood, the symptomatic treatment of 
this movement disorder remains very difficult. Several anticonvulsants seem to 
be efficacious for the treatment of (paroxysmal) involuntary movement disor-
ders. On the basis of a recent report about Levetiracetam (LEV) efficacy in the 
treatment of movement disorders, we started LEV in two female patients (aged 
5 and 8 years) with dyskinetic CP unresponsive to conventional drugs mostly 
used in such cases. These 2 cases are described in chapter V. Both patients ex-
perienced severe perinatal asphyxia and subsequently developed dyskinetic CP, 
clinically characterized by choreoathetosis. Neuropsychological testing of these 
children showed a low average developmental quotient and no attentional defi-
cits. Monotherapy with LEV was initiated to improve balance control and fine 
motor skills. Treatment was evaluated by use of video analysis and VAS. In both 
children an impressive improvement of balance control and fine motor skills 
was observed. No side-effects occurred. Furthermore, both patients showed 
more interest for and pleasure during activities according to their parents. Dur-
ing multidisciplinary evaluations of the initiated therapy, the parents, the thera-
pist, and the rehabilitation doctor all confirmed that the effect initially observed 
was still present at 14 respectively 26 months after commencement of therapy. 
This is the first report suggesting that LEV may be used as an alternative to treat 
unmanageable choreoathetosis of a non-progressive kind, e.g. in children with 
dyskinetic CP. This is important because choreoathetosis appears to be a very 
severe and disabling condition which is difficult to treat. This could partly be 
due to the differences in pathophysiology between the two aspects of the condi-
tion, i.e. athetosis can be treated by increasing dopaminergic activity in the BG, 
while chorea can be treated by decreasing dopaminergic activity. These findings 
and our results suggest that LEV might reduce choreoathetosis by means of 
another pathway. So far, the synaptic vesicle protein SV2A has been identified as 
the binding site for LEV, but the molecular action of SV2A is still unknown. 
Further and larger studies are needed to confirm the positive effects of LEV 
on choreoathetosis in patients with a non-progressive, non-paroxysmal, dyski-
netic movement disorder. 
When treating children with CP, evaluation of treatment is essential. Fur-
thermore, there is an increasing need for clinicians to evaluate their daily clini-
cal practice. One of the most commonly performed treatments in children with 
CP is Botulinum toxin A (BTX-A) injections to reduce spasticity. The main prob-
lem is that there is no simple, quick, and useful outcome measure available to 
evaluate these kinds of treatments. In spite of its clear limitations, the standard 
clinical scale for measuring spasticity remains the Ashworth Scale. However, the 
Ashworth Scale does not measure spasticity exclusively, it has low inter-rater 
reliability, and it lacks precision and sensitivity for measuring smaller changes 
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in spasticity. Although the GMFM is widely accepted as the best available quanti-
tative measure for gross motor function in CP, it is of limited value when assess-
ing functional benefits in severely affected children. In chapter VI we hypothe-
sized that a simple VAS could be a quick and useful tool to evaluate the effects of 
BTX-A injections on spasticity in daily clinical practice. Therefore, we prospec-
tively collected data on 55 children with CP (25 males; 30 females) with a mean 
age of 8.3 years (SD 3.3) who were carefully selected by a multi-disciplinary 
team of specialists to be treated with BTX-A injections. Goals for BTX-A treat-
ment were defined in close consultation with the parents / caregivers and the 
children themselves. Treatment goals were improvement of pain, problems with 
nursing, sitting position, standing, and walking. On the day of the intervention, 
the caregivers were asked to score the present situation for the selected treat-
ment goals on a VAS (0 = very satisfied; 10 = very dissatisfied). VAS scores and 
side-effects were assessed at follow-up 6 and 12 weeks after treatment. Fur-
thermore, for children who where able to walk three clinical examinations of 
tone (passive range of motion (PROM), angle of catch (AOC), and the Modified 
Tardieu) were performed for the hamstrings and gastrocnemius muscles. 
Seventy-four interventions were performed in 55 children. The most fre-
quently formulated goal was improvement of walking (56 times), followed by 
improvement of nursing (24 times) and improvement of standing (15 times). A 
statistically significant effect was found for improvement of care (p≤0.00), 
standing (p≤0.00), and walking (p≤0.00). No statistically significant effect was 
found for pain (p=0.18), probably because of small numbers. The VAS was posi-
tively but not significantly correlated to the PROM for both muscle groups and 
to the AOC for the hamstrings. There was a negative but not significant correla-
tion between the VAS and the AOC of the gastrocnemius. The Modified Tardieu 
was positively correlated to the VAS for all muscles investigated and significant 
for the left gastrocnemius. In 36 of the 74 (48.6%) interventions a positive effect 
was observed for more than 12 weeks. 
We concluded that a VAS was able to measure treatment effect and that 
overall correlations with standard evaluation instruments were in the expected 
direction. Evaluating spasticity treatment with the use of the VAS has several 
important advantages. Firstly\, it is a quick and easy method for evaluating 
treatment in an outpatient setting, in which time-consuming evaluations are not 
an option and where there is a need for these kinds of instruments. Secondly, it 
is a subjective measure of the effects that BTX-A treatment has had on individu-
ally chosen goals. Usually the patient and his/her caregiver(s) are the best judg-
es of the severity of the spasticity, as they are the only people who can assess its 
impact on the daily life of the patient. 
 
Besides evaluating the effect of BTX-A treatment on spasticity, the clinician has 
to be aware of possible side-effects. In the group of 55 children described in 
chapter VI side-effects were observed 7 times in five children treated with BTX-
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A injections. One of those side-effects was constipation. Chapter VII describes 
this up until now unknown side-effect of BTX-A treatment in this and two other 
patients treated with BTX-A injections. Constipation was observed within the 
first week of BTX-A treatment. In all three cases, this symptom resolved com-
pletely and almost simultaneously with disappearance of the therapeutic effects 
of BTX-A. Two patients received a second treatment and both presented the 
same autonomic cholinergic remote symptoms. The third patient refused a sec-
ond treatment due to the side-effect noted earlier. 
As the colon is not in close proximity to the injection sites, the constipation 
is most likely caused by a systemic effect of BTX-A. This presumption was made 
even more likely after electromyography (EMG) of the hypothenar muscles 
while stimulating the ulnar nerve at the wrist in 1 patient. The amplitude of the 
initial response was normal, but after prolonged 3 Hz stimulation a slight dec-
rementing response occurred. An average of 11% decrement in amplitude was 
visible from sixth to eighth compound muscle action potentials. This indicates 
that fewer muscle fibers than normal responded to nerve stimulation during a 
train of stimuli, i.e. due to generalized blockage of acetylcholine release in nerve 
terminals. 
We concluded that familiarity with this autonomic systemic side-effect of 
BTX-A is essential for clinicians treating patients already at risk for gastro-
intestinal dysfunction. Because the adverse effects were treatable and transi-
tory, we suggested that constipation per se is not an absolute contra-indication, 
if from a therapeutic point of view, BTX-A is indicated. 
 
Another, not yet discussed treatment option in the management of spastic CP is 
ITB therapy. A couple of years ago, Hoving et al performed methodologically 
well-designed studies on ITB therapy in 17 children with intractable spastic CP. 
Follow-up showed positive effects on pain, ease of care, and mental health to be 
present 1 year after pump implantation. 
However, long-term results of ITB therapy in children with intractable spas-
tic CP are still limited, especially with regard to outcomes relevant to the patient 
and his / her caregivers. Therefore, we re-evaluated these 17 patients 6–9 years 
(mean 7.5 years, SD 0.9) after commencement of treatment. The results can be 
found in chapter VIII. 
The parents of these 17 children (9 girls, 8 boys; mean age 21.1 years, SD 
3.1, 14–25; GMFCS level 3: n = 1, level 4: n = 2, level 5: n = 14) filled out the Child 
Health Questionnaire (CHQ), current satisfaction on the VAS regarding previous 
set treatment goals, a questionnaire concerning functioning of their child, and a 
self-made questionnaire. 
It was found that the CHQ and VAS scores had not changed significantly 
since 12 months post-implantation. The positive effects on pain, ease of care, 
and mental health were still present. Moreover, additional benefits had ap-
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peared i.e. significantly improved scores on the Parent Impact – Emotional sub-
scale, Parent Impact – Time subscale, and the Physical Summary. 
Although it seems that the effects eventually stabilize, minimal improve-
ment can still be expected 12 months after pump-implantation, especially for 
individually defined treatment goals. Furthermore, it appears that improve-
ments in terms of physical QoL (CHQ PhS) need more time to become evident. At 
12 months post-implantation there was no statistically significant difference 
compared to baseline (p = 0.16); however, at present there is (p = 0.02). 
Regardless of the side-effects, the complications, and the necessity of even-
tually substituting the pump, 94% of the care-givers would choose ITB therapy 
for their child again. 
We concluded that this study confirmed the long-term beneficial effects of 
ITB-therapy in children with intractable spastic CP and should be considered as 
a first step towards studies with even longer and more extensive follow-up. 
 
So far the emphasis of this thesis has been on the treatment and its evaluation of 
motor problems in children with CP. However, children with CP are often faced 
with a broad spectrum of accompanying problems, e.g. impairments of learning, 
hearing, vision, communication, sleep, sexual functioning, and seizure disorders. 
There is increasing interest in the consequences of the combination of motor 
problems and these accompanying problems on the QoL of these children with 
CP. Therefore, in chapter IX the QoL of all children with CP aged 8–18 years 
seen at the outpatient clinic is described. 
Acting upon the largest study on QoL of children with CP so far (Study of 
Participation of Children with CP Living in Europe (SPARCLE), 7 European coun-
tries), we used the same QoL instrument, i.e. the KIDSCREEN-52. This is a mod-
ern, generic QoL instrument, which uses questions based on focus-groups with 
children and adolescents all over Europe. The KIDSCREEN-52 focuses entirely 
on subjective perceptions, has shown to possess excellent psychometric proper-
ties, can be used for both disabled and non-disabled children, and can be re-
ported by both the children themselves and their caregivers. 
The parents of all 81 children with CP aged 8–18 years seen at the outpa-
tient clinic of the MUMC, were informed about the study and the parents of 80 
children (31 girls, 49 boys; mean age 13.4 years, SD 2.98; 44% wheelchair de-
pendent; 55% cognitive levels below 70) were willing to participate. T-scores 
were used to compare the QoL of Dutch children with CP to the QoL of over 
15.000 children from the general European population. It was found that Dutch 
children with CP are reported to have relatively low QoL in the physical well-
being, social support & peers, and social acceptance domains, but relatively high 
QoL in the parent relation & home life and the school environment domains. For 
the physical well-being domain it was found that higher GMFCS level was asso-
ciated with lower T-scores. Less communication skills and lower cognitive levels 
were associated with lower T-scores in the social support & peers and school 
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environment domains. Furthermore, parents with no educational qualification 
rated their childs QoL in the parent relation & home life higher. For the social 
acceptance domain no associated factors could be identified. 
We found it intriguing to see that these Dutch children with CP are reported 
to have significantly higher QoL in the school environment and parent relation & 
home life domains and significantly lower QoL in the social support & peers and 
social acceptance domains compared to a sample of European children from the 
general population. We came up with two possible, non-exclusive explanations 
for this pattern not observed in the European population of children with CP. 
First of all, living in the Netherlands holds the highest odds ratio of being bullied 
and this could explain why more Dutch children with CP than usual feel tor-
mented, bullied, and rejected by peers. Secondly, qualitative research has shown 
that children with CP enjoy being on their own from time to time. This is in ac-
cordance with our PARS-III study (chapter III) in which it was shown that chil-
dren with CP psychosocially adjust to their motor and accompanying problems 
by withdrawal, without establishing sufficient and comprehensive peer rela-
tions. Caregivers do not appreciate these attitudes and put substantial effort 
into creating opportunities for their child to be included socially. In other words, 
it is very well possible that low QoL on the social support & peers and social 
acceptance domains is due to concerns of the caregivers rather than what the 
children experience themselves. 
We concluded that these findings provide a better understanding of the QoL 
of Dutch children with CP and that they can be used to inform caregivers and 
service-providers, and to focus health programs aiming to increase QoL in this 
group of children towards identified problem domains. 
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Dit proefschrift beschrijft klinische en therapeutische aspecten van cerebrale 
parese (CP). Verschillende aspecten van behandeling en evaluatie werden be-
studeerd in de populatie kinderen met CP die gezien wordt op de polikliniek van 
het Maastricht University Medical Centre (MUMC). 
 
CP is een groot gezondheidsprobleem. Het wordt gezien bij 1 op de 400 nieuw-
geborenen waardoor het de meest voorkomende ontwikkelingsstoornis is die 
gepaard gaat met levenslange handicaps. De definitie van CP stelt dat het een 
niet-progressieve bewegings- en houdingsstoornis is t.g.v. schade aan het zich 
ontwikkelende brein van de foetus of het jonge kind. Naast motorische proble-
men ontwikkelen kinderen met CP vaak leerstoornissen, epileptische stoornis-
sen en problemen ten aanzien van het gehoor, visus of communicatie. 
 
Als eerste onderdeel van dit proefschrift werd gekeken hoe deze kinderen om-
gaan met hun vaak ernstige handicaps en beperkingen. In hoofdstuk III wordt 
de psychosociale aanpassing van kinderen met CP beschreven. Het grootste 
probleem in dit onderzoeksgebied is dat er maar weinig gestandaardiseerde 
instrumenten zijn die specifiek ontwikkeld zijn om psychosociale aanpassing bij 
kinderen met een chronische aandoening te onderzoeken. Een zeer geschikte, 
maar nog niet eerder voor kinderen met CP gebruikte vragenlijst is de Psycho-
social Adjustment and Role Skills Scale III (PARS-III). De ouders van alle 94 kin-
deren (4–18 jaar oud) die gezien worden op de polikliniek van het MUMC wer-
den gevraagd om deel te nemen aan de studie. Op één na gaven alle ouders toe-
stemming en kregen de PARS-III vragenlijst toegestuurd. De groep van 93 kin-
deren bestond uit 59 jongens en 34 meisjes. De gemiddelde leeftijd bedroeg 12.3 
jaar (SD 3.8; 4–18). Vierenveertig procent van de kinderen was rolstoelgebon-
den en 52% had een cognitief niveau onder de 70. Als referentie werd de psy-
chosociale aanpassingsdata van 95 gezonde kinderen en 63 jongen met Du-
chenne’s Musculaire Dystrofie (DMD) gebruikt. Omdat de PARS-III vragenlijst 
niet eerder gebruikt werd voor kinderen met CP, moest in eerste instantie het 
gebruik ervan gerechtvaardigd worden. Testen lieten een goede interne consis-
tentie zien: een Cronbach’s alfa van 0.89. Confirmatory Factor Analysis beves-
tigde de 6 domeinstructuur van de PARS-III vragenlijst wanneer deze gebruikt 
wordt voor kinderen met CP. Vervolgens konden de PARS-III scores van kinde-
ren met CP bestudeerd worden. Er werd gevonden dat ze lager scoorden qua 
psychosociale aanpassing dan gezonde kinderen (p = 0.00), m.n. op de domei-
nen “peer relations” (p = 0.00), “anxiety/depression” (p = 0.00), “withdrawal” (p 
= 0.00) en “productivity” (p = 0.02). Over het algemeen verschilden de kinderen 
met CP niet van jongens met DMD (p = 0.93). Echter, wanneer men kijkt naar de 
verschillende domeinen van psychosociale aanpassing, scoorden de kinderen 
met CP significant lager dan jongens met DMD op het domein “peer relations” (p 
= 0.03). Middels univariate en multivariate (forward entry, dummy variables) 
regressie analyse werd gevonden dat grove motorische functie, mate van hand-
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functie, communicatie kunde en bilaterale CP de patiëntkarakteristieken waren 
met de grootste associatie met PARS-III scores. Wanneer men deze 4 patiëntka-
rakteristieken samen in een regressiemodel zet, kan een significant gedeelte 
(36%) van de variatie in PARS-III scores verklaard worden. 
De conclusie luidde dat de PARS-III vragenlijst voor ouders bruikbaar is 
voor het meten van psychosociale aanpassing in kinderen met CP. Middels deze 
vragenlijst toonden wij aan dat kinderen met CP lager scoorden qua psychosoci-
ale aanpassing dan gezonde kinderen, m.n. op de domeinen “peer relations”, 
“anxiety/depression”, “withdrawal” en “productivity”. Een beter begrip van 
onjuiste psychosociale aanpassing kan mogelijkheden bieden tot het optimalise-
ren van copingsmechanismen bij deze kinderen met een chronische aandoening. 
Dit kan vervolgens bijdragen aan een betere kwaliteit van leven (QoL). 
 
Het meest voorkomende motorische probleem bij kinderen met CP is spastici-
teit. Indien er sprake is van ernstige spasticiteit, kan neurochirurgisch ingrijpen 
noodzakelijk zijn. Naast intrathecale Baclofen (ITB) behandeling, is selectieve 
dorsale rhizotomie (SDR) één van de meest uitgevoerde neurochirurgische pro-
cedures. Hierbij zijn vaak laminectomieën op meerdere niveaus van L1-S1 nodig 
en tevens bestaat er een aanzienlijk risico op tijdelijke urine incontinentie, 
chronische lage rugpijn en spinale deformiteiten. Verder is er een aanzienlijke 
medewerking van de patiënt nodig om het intensieve post-operatieve revalida-
tietraject succesvol te doorlopen. Wij veronderstelden dat een percutane radio-
frequente laesie van het achterste wortel ganglion (RF-DRG) een simpel en vei-
lig alternatief zou kunnen vormen voor SDR. In hoofdstuk IV wordt deze hypo-
these getoetst middels een pilot studie. Een RF-DRG behandeling werd door de 
multi-disciplinaire spasticiteitswerkgroep van het MUMC overwogen bij kinde-
ren met ernstige heup flexor / adductor spasmes die gepaard gingen met pijn of 
moeilijkheden rondom de verzorging. Uiteindelijk werden gedurende deze pilot 
studie bij 17 kinderen 19 RF-DRG behandelingen uitgevoerd. De eerste 6 kinde-
ren werden systematisch geëvalueerd vlak voor de start van behandeling en 1 
en 6 maanden na behandeling. Evaluatie geschiedde middels de Modified Ash-
worth Scale (MAS), de Gross Motor Function Measure (GMFM) en een zelfde 
gemaakte vragenlijst voor verzorgers. De MAS liet een verbetering van spierto-
nus na RF-DRG behandeling zien op zowel de korte (1 maand) als de lange (6 
maanden) termijn. Op het gebied van functie kon geen verbetering worden ge-
vonden middels de GMFM. De zelfgemaakte vragenlijst voor verzorgers liet een 
verbetering zien in het gemak en de kwaliteit van verzorging en een verminde-
ring van pijn. 
De volgende 11 kinderen werden geëvalueerd middels een Visual Analogue 
Scale (VAS). Deze werd voor aanvang van de behandeling en vervolgens 6 we-
ken en 3 maanden na behandeling gescoord voor individueel gestelde behan-
deldoelen. Wij achtten deze verandering van evaluatiemethode noodzakelijk 
daar we met behulp van de gebruikte evaluatie instrumenten niet in staat waren 
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de effecten van behandeling te detecteren die de verzorgers van deze kinderen 
unaniem wel aangaven. Daarbij kwam dat er in de literatuur studies verschenen 
die lieten zien dat de MAS en de GMFM niet geschikt waren om effect van be-
handeling te evalueren bij deze groep van ernstig gehandicapte kinderen. De 
VAS scores lieten verbetering zien bij de meeste van de van tevoren vastgestelde 
doelen. Volgens het merendeel van de ouders waren de effecten de RF-DRG 
behandeling 6 tot 9 maanden later nog steeds aanwezig. 
De conclusie naar aanleiding van deze pilot studie luidde dat RF-DRG een 
veelbelovende mogelijkheid is voor de behandeling van ernstige spasticiteit bij 
kinderen met CP. De grote voordelen zijn het minder invasieve karakter van RF-
DRG t.o.v. SDR, een mogelijk kortere opnameduur en een duidelijk pijnvermin-
derend effect. Een RCT is nodig om de definitieve plaats van RF-DRG bij de be-
handeling van spastische CP te bepalen. 
 
Een subtype van CP dat minder vaak voorkomt dan spastische CP is dyskineti-
sche CP. De pathofysiologie van dyskinetische CP is vooralsnog niet geheel op-
gehelderd. Huidige literatuur suggereert een dysfunctioneren van de basale 
ganglia (BG) als oorzaak voor de klinische symptomen. Net zoals als geldt voor 
andere ziektes waarbij de oorzaak onduidelijk blijft, is de symptomatische be-
handeling van deze bewegingsstoornis vaak erg moeilijk. Enkele anti-epileptica 
lijken werkzaam in de behandeling van (paroxysmale) onvrijwillige bewegings-
stoornissen. Naar aanleiding van een recent case report over de werkzaamheid 
van Levetiracetam (LEV) bij bewegingsstoornissen, startten wij LEV bij twee 
meisjes (5 en 8 jaar oud) die niet reageerden op de conventionele medicatie 
voor dit type aandoening. Deze twee casussen worden beschreven in hoofdstuk 
V. Beide meisjes maakten perinataal ernstige asfyxie door en ontwikkelden ver-
volgens dyskinetische CP die klinisch gekenmerkt werd door choreoathetosis. 
Neuropsychologisch onderzoek van deze kinderen wees uit dat er sprake was 
van een laagnormaal ontwikkelingsniveau zonder aandachtsstoornissen. Mono-
therapie met LEV werd gestart om balans en fijne motoriek te verbeteren. Effect 
van behandeling werd geëvalueerd aan de hand van videoanalyse en VAS scores. 
Bij beide kinderen werd een indrukwekkende verbetering geconstateerd op het 
gebied van balans en fijne motoriek. Er traden geen bijwerkingen op. Verder 
gaven de ouders aan dat de kinderen meer interesse hadden gekregen voor 
activiteiten en hiervan ook meer plezier ondervonden. Tijdens een recente mul-
tidisciplinaire evaluatie van de therapie, 14 en 26 maanden na start van de me-
dicatie, waren de ouders, de artsen en de fysiotherapeuten het met elkaar eens 
dat het effect van behandeling nog steeds aanwezig was. 
Dit zijn de eerste twee casussen die suggereren dat LEV mogelijk een alter-
natieve behandelmogelijkheid is voor non-progressieve choreoathetosis, zoals 
die bij kinderen met dyskinetische CP. Dit is belangrijk daar choreathetosis een 
sterk invaliderende en moeilijk te behandelen aandoening is. Dit is mogelijk 
terug te voeren op de verschillen in pathologie tussen de twee aspecten van het 
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ziektebeeld. Athetosis kan namelijk verminderd worden door dopaminerge 
activiteit in de BG te verhogen, terwijl chorea verminderd kan worden door 
dopaminerge activiteit in de BG juist te verlagen. Deze bevindingen en de door 
ons beschreven casussen suggereren dat LEV choreoathetosis mogelijk middels 
een andere pathway vermindert. Men heeft de bindingsplaats voor LEV inmid-
dels achterhaald (synaptic vesicle protein SV2A), echter het moleculaire wer-
kingsmechanisme van dit eiwit is vooralsnog onbekend. 
Toekomstige, goed opgezette studies zijn nodig om het positieve effect van 
LEV op choreo-athetosis bij patiënten met een non-progressieve, non-
paroxysmale, dyskinetische bewegingsstoornis te bevestigen. 
 
Wanneer men kinderen met CP behandelt, is evaluatie van deze behandeling 
essentieel. Hier bovenop komt dat er tegenwoordig onder dokters een grote 
behoefte aan het evalueren van hun dagelijkse klinische praktijk bestaat. Een 
van de meest uitgevoerde behandelingen bij kinderen met CP is het injecteren 
van Botulinum toxine A (BTX-A) met als doel spasticiteit te verminderen. Het 
grootste probleem is echter dat er geen simpele, snelle en zinvolle methode 
beschikbaar is om dit type behandelingen te evalueren. Ondanks zijn duidelijke 
beperkingen, wordt de Ashworth Scale voor dit doeleinde nog steeds het meest 
gebruikt. Echter, de Ashworth Scale meet niet enkel spasticiteit, heeft een lage 
inter-rater betrouwbaarheid en is niet in staat om kleine veranderingen in spas-
ticiteit op te pikken. Ondanks dat de GMFM wereldwijd als beste kwantitatieve 
instrument wordt beschouwd voor het meten van grof motorisch functioneren, 
heeft deze maar beperkte waarde wanneer het gaat om ernstig beperkte kinde-
ren. In hoofdstuk VI veronderstelden wij dat een simpele VAS een eenvoudig, 
snel en zinvol instrument zou kunnen zijn om de effecten van BTX-A behande-
ling van spasticiteit te evalueren. Om dit te onderzoeken verzamelden we pro-
spectief data van 55 kinderen met CP (25 jongens; 30 meisjes) met een gemid-
delde leeftijd van 8.3 jaar (SD 3.3) die zorgvuldig geselecteerd werden door een 
multi-disciplinaire spasticiteitswerkgroep om behandeling middels BTX-A injec-
ties te ondergaan. Doelstellingen van behandeling werden samen met de ouders 
/ verzorgers en de kinderen vastgesteld. De categorieën waarop verbetering 
werd nagestreefd betroffen pijn, verzorging, zitten, staan en lopen. Op de dag 
van behandeling werd aan de ouders / verzorgers gevraagd om op een VAS de 
huidige situatie per categorie te scoren. Hierbij betekende een score van 0 op de 
VAS dat de huidige situatie totaal niet problematisch was en een score van 10 
dat de huidige situatie problematischer kon zijn. Zes en 12 weken na start van 
behandeling werden wederom VAS scores bepaald en werd er gekeken of er 
bijwerkingen waren opgetreden. Verder werd er voor kinderen die konden lo-
pen 3 klinische onderzoeken van tonus verricht (passive range of motion 
(PROM), angle of catch (AOC) en Modified Tardieu) voor de hamstrings en de 
gastrocnemius spieren. 
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Bij 55 kinderen werden uiteindelijk 74 interventies verricht. Bij sommige kinde-
ren werd van tevoren meer dan één doel gesteld. De meest geformuleerde doel-
stelling was het verbeteren van lopen (56 keer), gevolgd door het verbeteren 
van verzorging (24 keer) en verbeteren van staan (15 keer). Een statistisch sig-
nificant effect van behandeling werd gevonden voor verbetering van verzorging 
(p ≤ 0.00), staan (p ≤ 0.00) en lopen (p ≤ 0.00). Waarschijnlijk t.g.v. het kleine 
aantal patiënten bij wie vermindering van pijn werd nagestreefd, werd er geen 
significant effect voor deze doelstelling gevonden (p = 0.18). De VAS liet een 
positieve, maar statistisch geen significante correlatie zien met de PROM voor 
de twee spiergroepen en met de AOC voor de hamstrings. Er was sprake van een 
negatieve, maar statistisch geen significante correlatie tussen de VAS en de AOC 
voor de gastrocnemius. De Modified Tardieu was positief gecorreleerd aan de 
VAS voor de onderzochte spiergroepen en significant m.b.t. de linker gastroc-
nemius. In 36 van de 74 (48.6%) interventies werd geconstateerd dat het posi-
tieve effect van behandeling langer dan 12 weken aanhield. 
We concludeerden dat een simpele VAS in staat was om effect van behande-
ling te meten en dat de correlaties met de conventionele evaluatie methoden in 
de te verwachten richting waren. Het evalueren van spasticiteit met gebruik van 
een VAS heeft een aantal belangrijke voordelen. Ten eerste is het een snelle en 
eenvoudige methode voor het evalueren van behandeling tijdens een polikli-
nisch spreekuur, waar ingewikkelde en tijdrovende evaluatiemethoden nu een-
maal geen optie zijn. Ten tweede meet een VAS op een subjectieve manier het 
effect van behandeling op vooraf gestelde doelen. Het is bekend dat de patiënt 
en zijn of haar ouders / verzorgers de beste beoordelaars zijn van de spastici-
teit, daar zij de enige zijn die in staat zijn om de impact op het dagelijks leven in 
te schatten. 
 
Naast het evalueren van het effect van BTX-A behandeling, moet de behandelend 
arts ook aandacht hebben voor mogelijke bijwerkingen. In de groep van 55 kin-
deren die beschreven wordt in hoofdstuk VI werden bij 5 kinderen in totaal 7 
bijwerkingen geconstateerd na behandeling met BTX-A injecties. Bij één kind 
trad constipatie op als bijwerking. In hoofdstuk VII wordt deze vooralsnog 
onbekende bijwerking van BTX-A behandeling beschreven bij dit kind en nog 2 
andere jongvolwassenen die ook behandeld werden met BTX-A. 
Constipatie werd in alle 3 de gevallen binnen 1 week na behandeling gecon-
stateerd. Deze bijwerking verdween uiteindelijk volledig en dit ging samen met 
het verdwijnen van de gunstige effecten van de BTX-A injecties. Twee patiënten 
ondergingen een tweede serie van BTX-A injecties en weer traden dezelfde au-
tonome cholinerge bijwerkingen op. De derde patiënt weigerde een vervolgbe-
handeling i.v.m. de destijds opgetreden constipatie. 
Het colon is niet nabij de injectieplaatsen gelegen en daarom is de constipa-
tie het beste te verklaren als een systemische bijwerking van de BTX-A behande-
ling. Deze aanname werd nog waarschijnlijker gemaakt door het verrichten van 
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een EMG studie in 1 patiënt. Er werd een EMG gemaakt van de hypothenaire 
spieren terwijl de nervus ulnaris t.h.v. de pols gestimuleerd werd. De amplitudo 
van het initiële signaal was normaal, maar na langer durende stimulatie (3 Hz) 
trad een licht decrement in amplitudo op. Een gemiddelde van 11% decrement 
in amplitudo was zichtbaar van de zesde tot de achtste compound van actiepo-
tentialen. Dit duidt erop dat minder spiervezels dan normaal reageren op een 
zenuwprikkel tijdens een reeks van stimuli. Oorzaak hiervoor is een algehele 
blokkade van acetycholine vrijkomst in de zenuwuiteinden. 
We concludeerden dat kennis van deze autonome en systemische bijwer-
king van BTX-A behandeling belangrijk is voor behandelaars van deze kinderen 
die sowieso al een grotere kans op gastro-intestinaal disfunctioneren hebben. 
Omdat de bijwerkingen goed te behandelen waren en van voorbijgaande aard 
bleken, stelden we voor dat constipatie an sich niet als absolute contra-indicatie 
beschouwd dient te worden in geval BTX-injecties therapeutisch geïndiceerd 
zijn. 
 
Een andere, tot dusver niet besproken behandeloptie van spasticiteit bij kinde-
ren met CP is ITB behandeling. Een aantal jaar geleden, verrichtten Hoving et al 
methodologisch zeer goed opgezette studies naar ITB behandeling bij 17 kinde-
ren met CP met moeilijk behandelbare spasticiteit. Follow-up liet zien dat posi-
tieve effecten op pijn, verzorgingsgemak, and “mental health” nog steeds aan-
wezig waren 1 jaar na pomp-implantatie. 
Echter, lange termijnsresultaten van ITB behandeling bij kinderen met CP 
met moeilijk behandelbare spasticiteit ontbreken vooralsnog. Daarom herevalu-
eerden wij de 17 patiënten beschreven door Hoving et al 6–9 jaar (gemiddeld 
7.5 jaar, SD 0.9) na start van behandeling. De resultaten staan beschreven in 
hoofdstuk VIII. 
Aan de ouders van deze 17 kinderen (9 meisjes, 8 jongens, gemiddelde leef-
tijd 21.1 jaar, SD 3.1, 14–25; GMFCS level 3: n = 1, level 4: n = 2, level 5: n = 14) 
werd gevraagd verschillende vragenlijsten in te vullen, te weten de Child Health 
Questionnaire (CHQ), een functioneringsvragenlijst, een zelf gemaakte vragen-
lijst en hun huidige tevredenheid op een VAS m.b.t. de doelen gesteld voor aan-
vang van behandeling. 
Eén ouder stuurde de CHQ niet terug. Alle overige data waren beschikbaar 
voor analyse. 
Analyse liet dat CHQ en VAS scores niet significant veranderd waren t.o.v. de 
laatste evaluatie 12 maanden na pomp plaatsing. De positieve effecten op pijn, 
verzorgingsgemak en “mental health” waren nog steeds aanwezig. Bovendien 
waren er ook op andere schalen significante verbeteringen duidelijk geworden: 
de Parent Impact – Emotional subschaal, Parent Impact – Time subschaal en de 
Physical Summary. 
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Alhoewel het lijkt dat het behandeleffect na verloop van tijd stabiliseert, mag 
men toch ook nog 12 maanden na pomp plaatsing kleine verbeteringen ver-
wachten, m.n. m.b.t. de individueel gestelde behandeldoelen. 
Verder lijkt het erop dat verbetering op de Physical Summary meer tijd no-
dig had om tot stand te komen. Twaalf maanden na pomp plaatsing was er na-
melijk nog geen statistisch significant effect zichtbaar (p = 0.16), maar inmiddels 
wel (p = 0.02). 
Ondanks de bijwerkingen, de complicaties, en de noodzaak om uiteindelijk 
de pomp te vervangen, zou 94% van de ouders / verzorgers opnieuw voor ITB 
behandeling voor hun kind kiezen. 
Wij concludeerden dat deze studie de positieve effecten van ITB behande-
ling van kinderen met CP op de lange termijn bevestigt. Deze studie moet gezien 
worden als een eerste stap richting nog langere en uitgebreide follow-up stu-
dies. 
 
Tot dusver heeft dit proefschrift zich gericht op de behandeling van motorisch 
problemen bij kinderen met CP en de evaluatie hiervan. Echter, kinderen met CP 
worden geconfronteerd met meer dan enkel motorische problematiek. Leer-
stoornissen, epileptische stoornissen, problemen met het gehoor, zicht of com-
municatie, slaapproblemen en sexuele problematiek zijn aan de orde van de dag. 
Er is de laatste jaren in de literatuur in toenemende mate belangstelling voor de 
gevolgen die deze combinatie van motorische en bijkomende problematiek 
heeft op de QoL van deze kinderen. Daarom wordt in hoofdstuk IX de QoL van 
alle kinderen met CP die gezien worden op de poli van het MUMC beschreven. 
In navolging van de tot nu toe grootste studie naar de QoL van kinderen met 
CP (Study of Participation of Children with CP Living in Europe (SPARCLE), 7 
Europese landen), gebruikten ook wij de KIDSCREEN-52 vragenlijst om QoL te 
meten. Dit is een moderne, generieke QoL vragenlijst die gebruik maakt van 
vragen die ontwikkeld zijn in focus-groups met Europese kinderen en jongvol-
wassen. De KIDSCREEN-52 richt zich volledig op subjectieve percepties, heeft 
uitstekende psychometrische eigenschappen, kan gebruikt worden voor zowel 
geïnvalideerde als gezonde kinderen en kan door zowel kinderen zelf als door 
hun ouders ingevuld worden. 
De ouders van alle 81 8–18 jarige kinderen met CP die gezien worden op de 
polikliniek van het MUMC werden geïnformeerd over de studie en de ouders 
van 80 kinderen (31 meisjes, 49 jongens; gemiddelde leeftijd 13.4 jaar, SD 2.98; 
44% rolstoelgebonden; 55% cognitieve niveau onder de 70) waren bereid mee 
te doen. Er werd gebruik gemaakt van T-scores om de QoL van Nederlandse 
kinderen met CP te vergelijken met de QoL van meer dan 15.000 Europese kin-
deren van de algemene populatie. Het bleek dat volgens hun ouders Nederland-
se kinderen met CP relatief laag scoorden op de domeinen “physical well-being”, 
“social support & peers” en “social acceptance”, terwijl ze juist hoog scoorden op 
de domeinen “parent relation & home life” en “school environment”. 
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Hogere GMFCS levels waren geassocieerd met lagere T-scores op het domein 
“physical well-being”. Minder communicatievaardigheden en een lager cognitief 
niveau waren geassocieerd met lagere T-scores op de domeinen “social support 
& peers” en “school environment”. Verder bleek dat ouders zonder vervolgop-
leiding hogere scores rapporteerden op het domein “parent relation & home 
life”. Geen van de onderzochte factoren waren geassocieerd met het domein 
“social acceptance”. 
Het fascineerde ons om te zien dat, in vergelijking met de Europese kinde-
ren van de algemene populatie, deze Nederlandse kinderen met CP volgens hun 
ouders significant hogere QoL hadden op de domeinen “school environment” en 
“parent relation & home life”, maar significant lagere QoL hadden op de domei-
nen “social support & peers” en “social acceptance”. Twee mogelijke, elkaar niet 
uitsluitende verklaringen werden voor deze observatie aangedragen. Ten eer-
ste, uit onderzoek is gebleken dat men in Nederland de hoogste odds ratio kent 
om gepest te worden, wat zou kunnen verklaren dat meer Nederlandse kinde-
ren met CP dan gebruikelijk zich gepest, gekweld en afgewezen voelen. 
Ten tweede, kwalitatief onderzoek heeft laten zien dat kinderen met CP van 
tijd tot tijd graag op zich zelf willen zijn. Dit is in overeenstemming met onze 
PARS-III studie waarin we vonden dat kinderen met CP zich psychosociaal aan-
passen aan hun motorische en bijkomende problemen door zich terug te trek-
ken en hierdoor ook weinig vriendschappen ontwikkelen. Ouders / verzorgers 
maken zich zorgen over dit terugtrekgedrag en stoppen veel moeite in het cre-
eren van mogelijkheden voor hun kind om sociaal betrokken te worden. Met 
andere woorden, het is zeer wel mogelijk dat de lage QoL scores op de domei-
nen “social support & peers” en “social acceptance” eerder te danken is aan de 
zorgen van de ouders / verzorgers dan aan ervaringen van kinderen zelf. 
Wij concludeerden dat bovenstaande onderzoeksresultaten bijdragen aan 
een beter begrip van de QoL van Nederlandse kinderen met CP en dat deze in-
formatie gebruikt kan worden om ouders en behandeld artsen te informeren. 
Verder kunnen hierdoor ook gezondheidsprogramma die beogen QoL in deze 
groep van kinderen te verbeteren, gericht worden op geïdentificeerd probleem 
domeinen. 
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Dit proefschrift is tot stand gekomen vanuit een gezamenlijke inspanning door 
een aantal mensen van zeer verschillende disciplines.  
Allereerst wil ik bedanken mijn vader. Hij stimuleerde mij al vroeg tijdens 
mijn studie geneeskunde om onderzoek te gaan doen. Iets waar ik hem eigenlijk 
nu pas voor het eerst voor bedank. Samen met je vader onderzoek doen, is iets 
waar velen over kunnen spreken, maar slechts enkelen over mee kunnen pra-
ten. Ik zal eerlijk zijn, het is een hele beproeving geweest. Veelvuldig heb ik mijn 
vader vervloekt als hij weer aan kwam zetten met een nieuwe deadline, een te 
bouwen database of de zoveelste stapel uitgeprinte artikelen. En dit niet alleen 
tijdens werkuren, maar ook thuis, vlak voor het voetballen of tijdens het hout-
hakken. Achteraf gezien was dit een perfecte infrastructuur voor een jonge, 
onervaren onderzoeker.  
Lieve pap, bedankt voor alles. Je was altijd bereid mijn artikelen te lezen en 
van commentaar te voorzien. Je bracht me in contact met neurologen, neurochi-
rurgen, orthopeden, revalidatie-artsen, bewegingswetenschappers, fysiothera-
peuten, statistici, etc. Je zorgde ervoor dat ik de moed erin hield als ik het even 
allemaal niet meer zag zitten en voor elk probleem had jij zo een oplossing. Jij 
excelleert als arts, wetenschapper, docent, mentor en bovendien als vader. Jij 
bent de promotor van mijn leven. Ik ben trots op jou.  
Professor doctor Beuls, Emile, u bent vanaf het begin af aan bij mijn promo-
tie betrokken geweest. Uw kritische blik is een enorme meerwaarde geweest. 
Van alle keren dat ik bij u thuis in Lanaken kwam, kan ik mij niet herinneren dat 
u ooit niet zat te studeren. Uw oneindige nieuwsgierigheid en leergierigheid 
werken aanstekelijk.  
Professor doctor Van Oostenbrugge, Robert, u raakte pas in een later stadi-
um bij mijn promotie betrokken en dat terwijl u vroeger al op mij als baby hebt 
gepast. U gaf mij de kans om als arts-onderzoeker binnen uw vakgroep mijn 
proefschrift af te ronden. Bedankt voor het geschonken vertrouwen. 
Doctor Hendriksen, Jos, jij hielp mij op alle mogelijke gebieden. Met het op-
zetten van een studie, met de statistiek, met het interpreteren van resultaten, 
met het schrijven van een artikel en met het verwerken van commentaar. Wat je 
ook aan je hoofd had, je maakte altijd tijd voor me. Ontzettend bedankt voor de 
begeleiding op alle fronten.  
Ruben, vriend, wat hebben wij lopen stoeien met die databasen en vragen-
lijsten, op jouw of mijn kamer, op het ziekenhuis en in Kempenhaeghe. Met jouw 
toewijding, je punctualiteit en het gemak waarmee je schrijft, zal jouw promotie 
niet lang op zich laten wachten. De databasen doen we niet meer, de biertjes 
wel. 
Doctor de Louw, Anton, jij was de begeleider van mijn eerste artikel. Ik weet 
nog goed de woensdagen dat ik naar Wahlwiller reed om op jullie prachtige 
hoeve aan ons manuscript te werken. Jij leerde mij een artikel schrijven. 
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Yvonne, jij introduceerde mij op het ganglab en bracht mij als eerste in contact 
met kinderen met CP. Jouw uitgebreide databasen zijn van onschatbare waarde 
geweest.  
 Dokter Kessels, Fons, met veel plezier kwam ik langs op jouw kamer met 
een statistische vraag. Je beantwoordde mijn vraag en zadelde mij vervolgens op 
met vele andere vragen over statistiek, onderzoek, de geneeskunde en het leven. 
Je stimuleerde mij om kritisch te denken. 
Lisette, telkens weer kwam ik jou lastig vallen met kleine problemen en tel-
kens weer nam jij de tijd om mij uit de brand te helpen. Jouw punctualiteit en 
taalgevoel maken elk artikel af. Ook ben ik je erg dankbaar voor een bepaald 
gesprek dat we ooit hadden.  
Dan, bedankt voor alle hulp bij het verzamelen van de data. Jouw goede pa-
tiëntcontacten hebben zeker bijgedragen aan onze hoge participatie ratio’s.  
Leden van de leescommissie, bedankt voor het beoordelen en goedkeuren 
van mijn proefschrift. 
Desiree, bedankt voor alle administratieve hulp bij mijn promotie. 
De mensen van Datawyse, bedankt voor de hulp bij de omslag, de lay-out en 
het drukken van dit proefschrift.  
Mijn moeder, mam, ik kan altijd op je rekenen. Je bent de meest zorgzame, 
geduldige, flexibele, warme en oprechte persoon die ik ken. Zowel pap als ik 
moeten regelmatig ons (tegenstrijdige) verhaal bij jou kwijt en jij weet dit tel-
kens weer in goede banen te lijden. Jouw kookkunsten maken elke dag weer 
goed. 
David, mijn broertje, zo vaak hielp jij mij uit de problemen als mijn compu-
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